

CITATION REPORT

List of articles citing

Epidermal growth factor-related peptides and their receptors in human malignancies

DOI: 10.1016/1040-8428(94)00144-i
Critical Reviews in Oncology/Hematology, 1995, 19, 183-232.

Source: <https://exaly.com/paper-pdf/25973008/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2281	Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. 1994 , 20, 373		
2280	Type 1 growth factor receptors: an overview of recent developments. 1995 , 4, 11-18		21
2279	c-erbB3 protein expression in ovarian cancer. 1996 , 49, M199-202		26
2278	ErbB2 activation and signal transduction in normal and malignant mammary cells. 1996 , 1, 199-206		15
2277	Differences between phosphotyrosine accumulation and Neu/ErbB-2 receptor expression in astrocytic proliferative processes. Implications for glial oncogenesis. 1996 , 78, 1272-83		22
2276	Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line. 1996 , 66, 538-43		18
2275	The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4. 1996 , 271, 20047-52		127
2274	Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 1996 , 88, 1770-6		101
2273	Sun Tzu and the Art of BusinessSun Tzu and the Art of Business By McNeillyMark R., Oxford: Oxford University Press, 1996, 225 pages, hard, cover, \$25.00. 1997 , 11, 129-130		1
2272	Characterization of chimeric proteins constructed from human epidermal growth factor (EGF) and the Drosophila EGF-receptor antagonist argos. 1997 , 10, 677-82		
2271	Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain. 1997 , 16, 259-71		13
2270	c-erbB-3 protein expression in ductal carcinoma in situ of the breast. 1997 , 33, 1846-50		27
2269	The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. 1997 , 410, 83-6		537
2268	Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. 1997 , 16, 5608-17		89
2267	ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. 1997 , 16, 1647-55		1158
2266	ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. 1997 , 2, 97-107		88
2265	[Tyrosine kinase inhibitors. An approach to pathogenesis-oriented tumor therapy]. 1997 , 38, 1074-82		

2264	Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. 1997 , 73, 277-82	30
2263	Growth factor receptors: structure, mechanism, and drug discovery. 1997 , 43, 339-66	58
2262	Cytotoxic Peptides: Naphthoquinonyl Derivatives of Luteinizing Hormone-Releasing Hormone. 1998 , 5, 421-427	
2261	Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. 1998 , 17, 3385-97	286
2260	Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. 1998 , 17, 5948-63	102
2259	A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera. 1998 , 219, 23-43	20
2258	The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. 1998 , 1377, M25-37	72
2257	Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours. 1998 , 75, 310-6	30
2256	Specificity within the EGF family/ErbB receptor family signaling network. 1998 , 20, 41-8	595
2255	The immunohistochemical detection of cripto-1 in benign and malignant human bladder. 1998 , 185, 108-11	9
2254	Heregulin-dependent autocrine loop regulates growth of K-ras but not erbB-2 transformed rat thyroid epithelial cells. 1998 , 176, 383-91	12
2253	Cytotoxic peptides: Naphthoquinonyl derivatives of luteinizing hormone-releasing hormone. 1998 , 5, 421-427	4
2252	Increased serum levels of transforming growth factor-alpha in patients with colorectal cancer. 1998 , 41, 219-24	12
2251	Suppression of tumour development by substances derived from the diet--mechanisms and clinical implications. 1998 , 45, 1-12	71
2250	Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression. 1998 , 247, 294-301	83
2249	Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. 1998 , 90, 1087-94	62
2248	Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. 1998 , 90, 1080-7	119
2247	Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. 1998 , 273, 10496-505	118

2246	Systemic administration of epidermal growth factor reduces fat mass in rats: effects on the hormone-sensitive-lipase, lipoprotein lipase and leptin. 1998 , 50, 292-6	6
2245	Structure-based minimization of transforming growth factor-alpha (TGF-alpha) through NMR analysis of the receptor-bound ligand. Design, solution structure, and activity of TGF-alpha 8-50. 1998 , 273, 27357-63	12
2244	ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. 1998 , 18, 5042-51	212
2243	EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. 1998 , 13, 335-42	19
2242	Uterine and vaginal organ growth requires epidermal growth factor receptor signaling from stroma. 1998 , 139, 913-21	81
2241	ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 6809-14	11.5 91
2240	Integration of growth factor, extracellular matrix, and retinoid signals during bronchial epithelial cell differentiation. 1998 , 18, 6666-78	39
2239	ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. 1998 , 18, 6090-101	118
2238	Expression of transforming growth factor alpha and epidermal growth factor receptor in human bladder cancer. 1999 , 59, 267-77	32
2237	Constitutive expression of Heregulin induces apoptosis in an erbB-2 overexpressing breast cancer cell line SKBr-3. 1999 , 15, 883-92	7
2236	Expression of cripto and amphiregulin in colon mucosa from high risk colon cancer families. 1999 , 14, 437-40	3
2235	Receptor tyrosine kinase and p16/CDKN2 expression in a case of tripe palms associated with non-small-cell lung cancer. 1999 , 199, 290-5	1
2234	Dominance of ErbB-1 heterodimers in lung epithelial cells overexpressing ErbB-2. Both ErbB-1 and ErbB-2 contribute significantly to tumorigenicity. 1999 , 21, 701-9	12
2233	Ca ²⁺ /calmodulin-dependent kinase II phosphorylates the epidermal growth factor receptor on multiple sites in the cytoplasmic tail and serine 744 within the kinase domain to regulate signal generation. 1999 , 274, 16168-73	58
2232	Growth factor receptors as targets for drug development: monoclonals beat kinase inhibitors to market, but are they better drugs?. 1999 , 9, 487-489	
2231	ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. 1999 , 274, 17209-18	279
2230	Pharmacological effects of epidermal growth factor (EGF) with focus on the urinary and gastrointestinal tracts. 1999 , 107, 5-42	8
2229	A role for intracellular immunization in chemosensitization of tumor cells?. 1999 , 6, 1202-9	6

2228	A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. 1999 , 18, 2579-88	106
2227	Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. 1999 , 18, 3481-90	103
2226	NDF/hereregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways. 1999 , 18, 3440-51	84
2225	Involvement of Notch1 in the development of mouse mammary tumors. 1999 , 18, 5973-81	176
2224	Antisense oligonucleotides to the epidermal growth factor receptor. 1999 , 53, 41-50	25
2223	Role of an anti-epidermal growth factor receptor in treating cancer. 1999 , 18, 427-36	89
2222	Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. 1999 , 17, 259-69	178
2221	The epidermal growth factor receptor and its inhibition in cancer therapy. 1999 , 82, 241-50	678
2220	Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. 1999 , 82, 207-18	91
2219	Selective changes in EGF receptor expression and function during the proliferation, differentiation and apoptosis of mammary epithelial cells. 1999 , 78, 511-23	18
2218	Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. 1999 , 27, 885-94	70
2217	Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. 1999 , 21, 61-70	57
2216	Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors. 1999 , 25-79	367
2215	Production of epidermal growth factor related ligands in tumorigenic and benign human lung epithelial cells. 1999 , 142, 55-63	21
2214	In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. 1999 , 65, 165-74	43
2213	The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 4995-5000	11.5 351
2212	Biochemistry of HER2 oncogenesis in breast cancer. 2000 , 11, 31-48	12
2211	Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells. 2000 , 48, 63-80	40

2210	EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. 2000 , 11, 319-25	25
2209	Targeting of epidermal growth factor receptor and protein kinase A: molecular basis and therapeutic applications. 2000 , 11, 777-83	21
2208	Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. 2000 , 85, 710-5	26
2207	Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells. 2000 , 86, 617-25	24
2206	ErbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. 2000 , 86, 644-51	25
2205	Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. 2000 , 144, 221-8	27
2204	Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. 2000 , 19, 4574-81	75
2203	Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. 2000 , 19, 5863-71	80
2202	The EGF receptor family as targets for cancer therapy. 2000 , 19, 6550-65	1132
2201	Quantitation of the mRNA expression of the epidermal growth factor system: selective induction of heparin-binding epidermal growth factor-like growth factor and amphiregulin expression by growth factor stimulation of prostate stromal cells. 2000 , 136, 209-17	13
2200	Protein kinases as therapeutic targets. 2000 , 17, 1345-53	58
2199	Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. 2000 , 43, 1205-23	173
2198	The ErbB signaling network: receptor heterodimerization in development and cancer. 2000 , 19, 3159-67	1806
2197	A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. 2000 , 275, 8641-9	129
2196	Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. 2000 , 18, 904-14	629
2195	Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. 2000 , 105, 1233-41	132
2194	Induction of the angiogenic modulator fibroblast growth factor-binding protein by epidermal growth factor is mediated through both MEK/ERK and p38 signal transduction pathways. 2000 , 275, 10802-11	71
2193	NMR study of the differential contributions of residues of transforming growth factor alpha to association with its receptor. 2000 , 13, 143-7	16

2192	Cell-cell and cell-extracellular matrix adhesion molecules communicate with growth factor receptors: an interactive signaling Web. 2000 , 18, 591-3		1
2191	Antisense and therapeutic oligonucleotides: toward a gene-targeting cancer clinic. 2000 , 10, 1711-1724		8
2190	Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells. 2000 , 92, 987-94		24
2189	Cripto-1-induced increase in vimentin expression is associated with enhanced migration of human Caski cervical carcinoma cells. 2000 , 257, 223-9		47
2188	Colon cancer cells adhesion and spreading on autocrine laminin-10 is mediated by multiple integrin receptors and modulated by EGF receptor stimulation. 2000 , 261, 360-71		44
2187	Quantitative imaging of lateral ErbB1 receptor signal propagation in the plasma membrane. 2000 , 290, 1567-70		287
2186	Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. 2000 , 2, 176-83		107
2185	Tyrosine kinase signalling in breast cancer. 2000 , 2, 154-7		57
2184	Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. 2000 , 60 Suppl 1, 25-32; discussion 41-2		124
2183	ZD1839 ('Iressa') as an anticancer agent. 2000 , 60 Suppl 1, 33-40; discussion 41-2		215
2182	Time-dependent changes in the luminal surface and mass of the rat colon during prolonged systemic treatment with epidermal growth factor. 2000 , 35, 300-5		2
2181	Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor. 2000 , 18, 11-29		59
2180	Kinase inhibitors in cancer therapy: a look ahead. 2000 , 59, 435-76		65
2179	4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. <i>Journal of Medicinal Chemistry</i> , 2000 , 43, 3244-56	8.3	175
2178	37th annual meeting of the American Society of Clinical Oncology. San Francisco, CA, May 12-15, 2001. 2001 , 1, 76-81		
2177	Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. 2001 , 84, 1322-9		65
2176	Comparative QSAR study of tyrosine kinase inhibitors. 2001 , 101, 2573-600		37
2175	Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. 2001 , 229, 163-75		174

2174	An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway. 2001 , 267, 81-7	46
2173	Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. 2001 , 37, 251-9	69
2172	EGFR and cancer prognosis. 2001 , 37 Suppl 4, S9-15	1473
2171	Introduction. EGFR in tumour growth: biological role and clinical implications. 2001 , 37 Suppl 4, S1-2	
2170	The EGFR as a target for anticancer therapy--focus on cetuximab. 2001 , 37 Suppl 4, S16-22	379
2169	The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. 2001 , 37, 2169-77	46
2168	Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. 2001 , 490, 142-52	256
2167	Growth factors and their receptors: new targets for prostate cancer therapy. 2001 , 58, 114-22	94
2166	Chromosome 7 Aneusomy. A Marker for Metastatic Melanoma?. 2001 , 3, 245-254	54
2165	Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer. 2001 , 18, 709-27	40
2164	IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. 2001 , 1, 719-32	82
2163	Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium. 2001 , 22, 299-309	10
2162	The role of EGF-related peptides in tumor growth. 2001 , 6, D685-707	107
2161	Clinical Significance of Epidermal Growth Factor Receptor Content in Gastric Cancer. 2001 , 16, 183-188	10
2160	The role of EGF-related peptides in tumor growth. 2001 , 6, d685-707	85
2159	Epidermal growth factor receptor biology (IMC-C225). 2001 , 13, 506-13	191
2158	Tyrosine kinase inhibitors-ZD1839 (Iressa). 2001 , 13, 491-8	127
2157	The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. 2001 , 12, 745-60	184

2156	Chapter 11. Growth factor receptor kinases in cancer. 2001 , 36, 109-118	6
2155	Renal cell cultures for the study of growth factor interactions underlying kidney organogenesis. 2001 , 37, 251-8	7
2154	Ganglioside modulates ligand binding to the epidermal growth factor receptor. 2001 , 116, 69-76	43
2153	Mechanisms of action of flavopiridol. <i>Critical Reviews in Oncology/Hematology</i> , 2001 , 38, 139-70	7 181
2152	Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2001 , 38, 17-23	7 381
2151	Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways. 2001 , 49, 38-47	11
2150	Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. 2001 , 93, 172-8	79
2149	ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. 2001 , 94, 774-82	159
2148	Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase. 2001 , 6, 141-50	29
2147	Identification of Cripto-1 in human milk. 2001 , 66, 1-7	26
2146	Roles of Akt/PKB and IKK complex in constitutive induction of NF-kappaB in hepatocellular carcinomas of transforming growth factor alpha/c-myc transgenic mice. 2001 , 34, 32-41	54
2145	Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. 2001 , 51, 775-84	38
2144	Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. 2001 , 8, 555-65	59
2143	Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. 2001 , 20, 2101-11	49
2142	Untangling the ErbB signalling network. 2001 , 2, 127-37	5216
2141	Small molecule inhibitors of the epidermal growth factor receptor in patients with non-small-cell lung cancer: an update of clinical data from the 2001 American Society of Clinical Oncology meeting. 2001 , 2, 258-60	
2140	ZD1839 (Iressa) in non-small-cell lung cancer. 2001 , 3, 27-32	13
2139	RENAL CELL CULTURES FOR THE STUDY OF GROWTH FACTOR INTERACTIONS UNDERLYING KIDNEY ORGANOGENESIS. 2001 , 37, 251	2

2138	Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. 2001 , 19, 571-7	7
2137	Genetically engineered rodent models of mammary gland carcinogenesis: an overview. 2001 , 29, 105-16	19
2136	Selected novel anticancer treatments targeting cell signaling proteins. 2001 , 6, 517-37	58
2135	Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. 2001 , 21, 4016-31	280
2134	The protein tyrosine phosphatase-PEST is implicated in the negative regulation of epidermal growth factor on PRL signaling in mammary epithelial cells. 2001 , 15, 2182-96	12
2133	Novel pharmacological agents in clinical development for solid tumours. 2001 , 10, 2059-88	12
2132	Generation and characterization of polyclonal antibodies specific for human p110 sEGFR. 2002 , 21, 183-9	8
2131	Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors. 2002 , 277, 1576-85	61
2130	ZD1839: targeting the epidermal growth factor receptor in cancer therapy. 2002 , 11, 837-49	50
2129	ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. 2002 , 86, 1157-61	160
2128	Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. 2002 , 86, 819-27	92
2127	Epidermal growth factor receptor dependence in human tumors: more than just expression?. 2002 , 7 Suppl 4, 31-9	379
2126	A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. 2002 , 13, 1225-35	31
2125	ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. 2002 , 20, 2240-50	666
2124	Anti-epidermal growth factor receptor drugs in cancer therapy. 2002 , 11, 755-68	75
2123	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. 2002 , 20, 3815-25	504
2122	Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing. 2002 , 13, 8-9	28
2121	Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition. 2002 , 20, 110-124	226

2120	Transforming growth factor β amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. 2002 , 21, 941	4
2119	Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. 2002 , 277, 27643-50	156
2118	Herstatin, an autoinhibitor of the human epidermal growth factor receptor 2 tyrosine kinase, modulates epidermal growth factor signaling pathways resulting in growth arrest. 2002 , 277, 20618-24	33
2117	Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. 2002 , 13, 65-72	197
2116	Recent and ongoing clinical trials for treating colorectal cancer. 2002 , 11, 871-80	4
2115	ZD1839 (IRESSA): a selective EGFR-TK inhibitor. 2002 , 2, 161-8	38
2114	EGF/ErbB receptor family in ovarian cancer. 2002 , 107, 247-58	89
2113	Novel targets for lung cancer therapy: part I. 2002 , 20, 2881-94	108
2112	Why the epidermal growth factor receptor? The rationale for cancer therapy. 2002 , 7 Suppl 4, 2-8	346
2111	Therapeutics targeting signal transduction for patients with colorectal carcinoma. 2002 , 64, 227-54	40
2110	GROWTH FACTOR AND SIGNAL TRANSDUCTION TARGETS FOR CANCER THERAPY. 2002 , 31-53	
2109	Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. 2002 , 13, 4029-44	114
2108	ZD1839 (Iressa): for more than just non-small cell lung cancer. 2002 , 7 Suppl 4, 16-24	73
2107	An update of new targets for cancer treatment: receptor-mediated signals. 2002 , 13 Suppl 4, 29-38	13
2106	New Directions in the Treatment of Cancer: Inhibition of Signal Transduction. 2002 , 15, 5-16	1
2105	Perspectives on anti-HER monoclonal antibodies. 2002 , 63 Suppl 1, 17-24	57
2104	Novel therapeutics for head and neck cancer. 2002 , 14, 334-42	45
2103	Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody C225 against Glioblastoma Multiforme. 2002 , 51, 1005-1014	13

2102	Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. 2002 , 13, 949-56	22
2101	Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. 2002 , 51, 1005-13; discussion 1013-4	89
2100	Role of Epidermal Growth Factor Receptor in Breast Carcinoma. 2002 , 1, 415-424	2
2099	Erlotinib Hydrochloride. 2002 , 27, 923	11
2098	Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity. 2002 , 275, 9-16	10
2097	Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002. 2002 , 2, 140-5	
2096	The 2001 European Cancer Conference. Lisbon, Portugal. October 21-25, 2001. 2002 , 1, 203-7	
2095	Molecular insights into gastrointestinal neuroendocrine tumours: importance and recent advances. 2002 , 34, 668-80	34
2094	Gefitinib. 2002 , 62, 2237-48; discussion 2249-50	39
2093	HER-targeted tyrosine-kinase inhibitors. 2002 , 63 Suppl 1, 6-16	44
2092	Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. 2002 , 20, 4292-302	717
2091	Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. 2002 , 295, 515-8	54
2090	Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225. 2002 , 18, 30-5	11
2089	The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma. 2002 , 18, 20-9	10
2088	The role of growth factors in malignancy: a focus on the epidermal growth factor receptor. 2002 , 18, 13-9	7
2087	Receptor tyrosine kinases as targets for anticancer drugs. 2002 , 8, 17-23	196
2086	The ErbB receptor family: a therapeutic target for cancer. 2002 , 8, S19-26	145
2085	[Principal therapeutic uses of monoclonal antibodies in oncology]. 2002 , 6 Suppl 1, 24s-28s	3

2084	Activation of the PI3K/Akt pathway and chemotherapeutic resistance. 2002 , 5, 234-48	446
2083	The role of new agents in the treatment of non-small cell lung cancer. 2002 , 38, 2347-61	26
2082	Epithelial growth factor receptor interacting agents. 2002 , 16, 1041-63	35
2081	Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues. 2002 , 4, 141-50	28
2080	Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. 2002 , 20, 2217-9	64
2079	ErbB receptor tyrosine kinase inhibitors as therapeutic agents. 2002 , 7, d1926	9
2078	Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. 2002 , 20, 110-24	405
2077	The future of targeted therapy: combining novel agents. 2002 , 63 Suppl 1, 47-56	21
2076	Searching for a standard. 2002 , 20, 359-61	2
2075	Molecular targets in cancer therapy and their impact on cancer management. 2002 , 63 Suppl 1, 1-5	8
2074	Zd1839 (Iressa) Preclinical Studies and Pharmacology. 2002 , 88, S155-S157	3
2073	Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells. 2002 , 2, 14	24
2072	Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. 2002 , 29, 15-26	28
2071	Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. 2002 , 29, 27-36	167
2070	Epidermal growth factor receptor-targeted therapy in colorectal cancer. 2002 , 29, 10-17	6
2069	Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. 2002 , 29, 11-21	13
2068	Lack of toxicity of EGFR antisense gene therapy. 2002 , 2, 174-86	10
2067	Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. 2002 , 12, 1386-94	27

2066	Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. 2002 , 24, 632-6	94
2065	Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. 2002 , 98, 357-61	109
2064	ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. 2002 , 98, 463-9	76
2063	Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. 2002 , 99, 538-48	211
2062	Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. 2002 , 101, 567-75	117
2061	Combined modality radioimmunotherapy. Promise and peril. 2002 , 94, 1320-31	34
2060	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. 2002 , 94, 1593-611	391
2059	Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. 2002 , 95, 301-8	36
2058	Detection and localization of Cripto-1 binding in mouse mammary epithelial cells and in the mouse mammary gland using an immunoglobulin-cripto-1 fusion protein. 2002 , 190, 74-82	19
2057	Targeting epidermal growth factor receptor in lung cancer. 2002 , 4, 317-24	42
2056	An update on epidermal growth factor receptor inhibitors. 2002 , 4, 47-55	21
2055	Deranged expression of the E-cadherin/beta-catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomas. 2002 , 31, 450-7	75
2054	Novel approaches to the treatment of non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 41, 57-77	7 29
2053	Clinical impact of novel treatment strategies. 2002 , 21, 6970-81	39
2052	Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. 2002 , 21, 6255-63	576
2051	Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). 2002 , 86, 1518-23	131
2050	Protein kinase A as target for novel integrated strategies of cancer therapy. 2002 , 968, 139-47	88
2049	The epidermal growth factor receptor: a new target for anticancer therapy. 2002 , 26, 109-64	50

2048	NF-kappaB in pancreatic cancer. 2003 , 33, 15-26	44
2047	3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. 2003 , 17, 475-93	45
2046	Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. 2003 , 10, 234-41	136
2045	Morphological properties of zero-stress state in rat large intestine during systemic EGF treatment. 2003 , 48, 442-8	7
2044	Targeted therapy for lung cancer. 2003 , 5, 326-33	1
2043	The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. 2003 , 52, 442-8	61
2042	Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF. 2003 , 30, 1348-56	23
2041	Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors. 2003 , 443, 28-31	24
2040	Elevated serum epidermal growth factor receptor level is correlated with lymph node metastasis in lung cancer. 2003 , 8, 79-82	29
2039	Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. 2003 , 13, 454-68	35
2038	27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002. 2003 , 4, 205-9	
2037	Erlotinib (OSI-774, Tarceva), a selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with chemotherapy for advanced non-small-cell lung cancer. 2003 , 4, 336-8	11
2036	39th Annual Meeting of the American Society of Clinical Oncology: Chicago, Illinois, May 30 to June 3, 2003. 2003 , 5, 13-7	
2035	Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. 2003 , 4, 499-515	556
2034	New oxaliplatin-based combinations in the treatment of colorectal cancer. 2003 , 5 Suppl 3, 1-9	1
2033	CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. 2003 , 30, 65-78	85
2032	Epidermal growth factor receptor expression in ameloblastoma. 2003 , 39, 138-43	25
2031	The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. 2003 , 30, 3-11	134

2030	Phase I studies of ZD1839 in patients with common solid tumors. 2003 , 30, 21-9	63
2029	Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. 2003 , 30, 30-8	35
2028	New directions for ZD1839 in the treatment of solid tumors. 2003 , 30, 49-55	104
2027	Dermatologic side effects associated with gefitinib therapy: clinical experience and management. 2003 , 4, 366-9	91
2026	The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer. 2003 , 5 Suppl 1, S5-S10	2
2025	Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. 2003 , 66, 551-63	38
2024	Detection of epidermal growth factor receptor mRNA in peripheral blood of cervical cancer patients. 2003 , 89, 480-5	13
2023	Targeting HER1/EGFR: A molecular approach to cancer therapy. 2003 , 30, 3-14	170
2022	Development of ZD1839 in colorectal cancer. 2003 , 30, 17-22	11
2021	Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRVIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. 2003 , 105, 273-80	46
2020	Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. 2003 , 106, 699-705	63
2019	Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?. 2003 , 194, 13-9	108
2018	Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. 2003 , 196, 370-7	92
2017	EGF- and cell-cycle-regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer. 2003 , 38, 188-200	54
2016	Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. 2003 , 796, 181-8	43
2015	Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases. 2003 , 11, 5155-70	42
2014	EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. 2003 , 55, 713-23	91
2013	Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 46 Suppl, S85-104	7 98

2012	Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. 2003 , 7, 37-43; discussion 43		48
2011	Growth regulatory factors and signalling proteins in testicular germ cell tumours. 2003 , 111, 212-24; discussion 224		30
2010	ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. 2003 , 56, 142-9		34
2009	Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis. 2003 , 89, 681-6		78
2008	Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells. 2003 , 22, 4488-97		45
2007	Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis. 2003 , 22, 6679-89		10
2006	Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. 2003 , 22, 6629-38		80
2005	Pharmacogenomics: road to anticancer therapeutics nirvana?. 2003 , 22, 6621-8		48
2004	Gefitinib. 2003 , 3, 556-557		8
2003	Gefitinib. 2003 , 2, 515-6		82
2002	[Transitional bladder carcinoma TaG1: role of the EGFR tyrosin kinase activation in the cellular proliferation]. 2003 , 121, 641-4		
2001	Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). <i>Journal of Medicinal Chemistry</i> , 2003 , 46, 19-33	8.3	234
2000	The molecular basis of lung cancer: molecular abnormalities and therapeutic implications. 2003 , 4, 12		46
1999	Epidermal growth factor receptor as a therapeutic target in colorectal cancer. 2003 , 2, 246-51		85
1998	Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives. 2003 , 3, 19-33		28
1997	Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. 2003 , 2, 50-7		49
1996	Highlights from: 39th Annual Meeting of the American Society of Clinical Oncology: Chicago, Illinois. May 31 to June 3, 2003. 2003 , 3, 78-84		1
1995	Highlights from: XII European Cancer Conference, Copenhagen, Denmark, September 21-25, 2003. 2003 , 3, 142-6		

1994	14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2003 , 3, 10-4	3
1993	Modification of Radiation Response. 2003 ,	5
1992	Application of a molecularly imprinted polymer for the effective recognition of different anti-epidermal growth factor receptor inhibitors. 2003 , 75, 6381-7	44
1991	Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. 2003 , 21, 2237-46	2543
1990	E-Cadherin Binding Modulates EGF Receptor Activation. 2003 , 10, 105-118	66
1989	Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. 2003 , 21, 2787-99	1051
1988	ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. 2003 , 40, 301-7	30
1987	Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer. 2003 , 42 Suppl 1, S65-9	2
1986	Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. 2003 , 285, 39-49	83
1985	[Epidermal growth factor inhibitors]. 2003 , 24, 372-83	2
1984	An overview of targeted treatments in cancer. 2003 , 25, 2121-37	75
1983	Nonsmall-cell lung cancer: chemoprevention studies. 2003 , 15, 405-20	5
1982	What's new in the treatment of advanced prostate cancer?. 2003 , 39, 136-46	19
1981	Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. 2003 , 39, 1348-54	192
1980	The ErbB receptors and their role in cancer progression. 2003 , 103-114	1
1979	[Clinical significance of tumor content of epidermal growth factor receptor in breast cancer]. 2003 , 22, 386-94	
1978	Erlotinib: a new therapeutic approach for non-small cell lung cancer. 2003 , 12, 1395-401	64
1977	Frontal affinity chromatography combined on-line with mass spectrometry: a tool for the binding study of different epidermal growth factor receptor inhibitors. 2003 , 75, 6388-93	33

1976	The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma. <i>Annals of Medicine</i> , 2003 , 35, 450-7	1.5	3
1975	The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 8933-8	11.5	749
1974	Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. 2003 , 278, 35781-90		142
1973	Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. 2003 , 532, 253-68		149
1972	Gefitinib (ZD1839, Iressa [®]): a selective epidermal growth factor receptor-tyrosine kinase inhibitor. 2003 , 9, 151-160		4
1971	Developing inhibitors of the epidermal growth factor receptor for cancer treatment. 2003 , 95, 851-67		306
1970	Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. 2003 , 8, 576-86		58
1969	Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus. 2003 , 23, 579-93		21
1968	Activation of tyrosine kinases in cancer. 2003 , 8, 531-8		152
1967	Molecular dynamics simulations of the transmembrane domain of the oncogenic ErbB2 receptor dimer in a DMPC bilayer. 2003 , 21, 179-200		12
1966	The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy. 2003 , 12, 577-92		1
1965	Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. 2003 , 14, 1346-63		78
1964	Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. 2003 , 3, 269-79		41
1963	Signal transduction--directed cancer treatments. 2003 , 43, 199-231		76
1962	Lung cancer. 4: chemotherapy for non-small cell lung cancer: the end of the beginning. 2003 , 58, 352-6		10
1961	ADP-ribosylation factor 4 small GTPase mediates epidermal growth factor receptor-dependent phospholipase D2 activation. 2003 , 278, 2661-8		49
1960	A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. 2003 , 14, 656-8		33
1959	Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. 2003 , 159, 439-52		129

1958	Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. 2003 , 14, 873-80	48
1957	Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. 2003 , 14, 922-30	231
1956	Retinoid Targets in Cancer Therapy and Chemoprevention. 2003 , 2, 149-155	30
1955	Inhibition of signal transduction in EGF-dependent epithelial cell lines. 2003 , 12, 673-7	3
1954	The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. 2003 , 23, 1179-86	20
1953	Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. 2003 , 144, 1032-44	449
1952	. 2003 , 26, S75-S80	5
1951	Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas. 2003 , 26, S75-80	13
1950	Neural stem cell biology may be well suited for improving brain tumor therapies. 2003 , 9, 189-204	51
1949	Mitogenic signaling cascades in glial tumors. 2003 , 52, 1425-34; discussion 1434-5	52
1948	Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. 2003 , 8, 501-14	25
1947	EGFR tyrosine kinase inhibitor "gefitinib (Iressa)" for cancer therapy. 2003 , 122, 491-7	12
1946	Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. 2003 , 10, 388-95	33
1945	Overview of targeted therapies for cancer. 2003 , 60, S4-10	22
1944	ErbB-targeted therapeutic approaches in human cancer. 2003 , 127-135	
1943	Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas. 2003 , 8, e1-13	19
1942	Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. 2004 , 84, 23-6	73
1941	The deaf and the dumb. 2003 , 57-68	1

1940	Epidermal Growth Factor Receptor and c-erbB-2 Contents in Unresectable (UICC R1 or R2) Gastric Cancer. 2003 , 18, 200-206	7
1939	ErbBs in mammary development. 2003 , 93-102	2
1938	Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer. 2004 , 61, 889-98	5
1937	Neoadjuvant Therapy of Rectal Cancer New Treatment Perspectives. 2004 , 90, 373-378	8
1936	Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. 2004 , 44, 52-8	21
1935	The role of growth factor signaling in malignancy. 2003 , 115, 19-72	13
1934	Membranous Levels of C-ErbB-2 Oncoprotein in Gastric Cancer: Their Relationship with Clinicopathological Parameters and Their Prognostic Significance. 2004 , 19, 268-274	4
1933	Her-2/Neu Receptor in Prostate Cancer Development and Progression to Androgen Independence. 2004 , 90, 163-170	35
1932	Wnt-Independent β -catenin Transactivation in Tumor Development. 2004 , 3, 569-571	26
1931	Epidermal growth factor receptor inhibitors in lung cancer therapy. 2004 , 25 Suppl 1, 17-27	7
1930	Molecular biological design of novel antineoplastic therapies. 2004 , 13, 577-607	4
1929	Novel targeted agents in the treatment of lung cancer. 2004 , 13, 609-29	2
1928	Gefitinib (Iressa): a novel treatment for non-small cell lung cancer. 2004 , 4, 5-17	37
1927	Signaling multiplex of the epidermal growth factor receptor. 2004 , 4, 1145-56	2
1926	Epidermal growth factor receptor as a therapeutic target in lung cancer. 2004 , 25 Suppl 1, 11-6	6
1925	Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. 2004 , 64, 5720-7	143
1924	Principles of Molecular Oncology. 2004 ,	6
1923	Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn?. 2004 , 16 Suppl 4, 44-8	14

1922	Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells. 2004 , 279, 3543-52		151
1921	Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. <i>Clinical Cancer Research</i> , 2004 , 10, 691-700	12.9	78
1920	Caspase-8-dependent HER-2 cleavage in response to tumor necrosis factor alpha stimulation is counteracted by nuclear factor kappaB through c-FLIP-L expression. 2004 , 64, 2684-91		33
1919	HER1/EGFR targeting: refining the strategy. 2004 , 9, 58-67		91
1918	Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. 2004 , 64, 7977-84		74
1917	Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. <i>Clinical Cancer Research</i> , 2004 , 10, 7311-7	12.9	61
1916	SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. 2004 , 64, 6166-73		136
1915	EGF gene polymorphism and the risk of incident primary melanoma. 2004 , 64, 2668-72		46
1914	Relationship between antiapoptotic molecules and metastatic potency and the involvement of DNA-dependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade. 2004 , 311, 1062-70		34
1913	Effects of growth factors and receptor blockade on gastrointestinal cancer. 2004 , 53, 1059-63		2
1912	Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). <i>Clinical Cancer Research</i> , 2004 , 10, 6476-86	12.9	73
1911	Treatment of metastatic head and neck cancer: chemotherapy and novel agents. 2003 , 114, 295-314		19
1910	Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. 2004 , 15, 786-92		47
1909	Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. <i>Clinical Cancer Research</i> , 2004 , 10, 784-93	12.9	309
1908	The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. 2004 , 22, 1926-33		313
1907	Epidermal growth factor regulates ubiquitination, internalization and proteasome-dependent degradation of connexin43. 2004 , 117, 1211-20		141
1906	The phosphoprotein StarD10 is overexpressed in breast cancer and cooperates with ErbB receptors in cellular transformation. 2004 , 64, 3538-44		32
1905	Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 4383-8	12.9	71

1904	Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage. 2004 , 24, 8907-16		82
1903	Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. 2004 , 15, 831-8		42
1902	Recent results in understanding molecular pathways in the medical treatment of esophageal and gastric cancer. 2004 , 27, 17-21		13
1901	Molecular analysis of the erbB gene family calmodulin-binding and calmodulin-like domains in astrocytic gliomas. 2004 , 25, 1489		
1900	Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. 2004 , 15, 33-7		30
1899	In vitro toxicity of A-431 carcinoma cells with antibodies to epidermal growth factor receptor and epithelial glycoprotein-1 conjugated to radionuclides emitting low-energy electrons. <i>Clinical Cancer Research</i> , 2004 , 10, 5957-66	12.9	19
1898	The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. 2004 , 1, 27-34		4
1897	Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. 2004 , 173, 4699-707		129
1896	Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. <i>Clinical Cancer Research</i> , 2004 , 10, 3885-96	12.9	142
1895	Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. 2004 , 52, 893-901		286
1894	Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 4874-84	12.9	66
1893	Targeting the epidermal growth factor receptor. 2004 , 91, 418-24		126
1892	Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. 2004 , 91, 208-12		180
1891	Heparin-binding epidermal growth factor cleavage mediates zinc-induced epidermal growth factor receptor phosphorylation. 2004 , 30, 540-7		35
1890	Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor. 2004 , 84, 308-9		28
1889	Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. 2004 , 34, 901-15		36
1888	Targeting protein kinases in cancer therapy: a success?. 2004 , 4, 1113-24		41
1887	Cetuximab (Erbiximab)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. 2004 , 58, 970-6		27

1886	Cancer. 2004 , 3, S6-S10	1
1885	Cetuximab. 2004 , 3, 549-50	104
1884	Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. 2004 , 23, 646-53	209
1883	Disruption of STAT3 signaling leads to tumor cell invasion through alterations of homotypic cell-cell adhesion complexes. 2004 , 23, 3317-27	35
1882	Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). 2004 , 90, 82-6	46
1881	Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients. 2004 , 90, 1563-71	17
1880	Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. 2004 , 17, 772-80	50
1879	Argos inhibits epidermal growth factor receptor signalling by ligand sequestration. 2004 , 430, 1040-4	114
1878	Effects of tea polyphenols on signal transduction pathways related to cancer chemoprevention. 2004 , 555, 3-19	116
1877	Development and validation of ELISA for herceptin detection in human serum. 2004 , 295, 169-82	48
1876	Oncogenic growth factor receptors: implications for signal transduction therapy. 2004 , 14, 262-70	110
1875	Focus on head and neck cancer. 2004 , 5, 311-6	299
1874	Cetuximab in cancers of the lung and head & neck. 2004 , 31, 61-7	22
1873	Gefitinib: phase II and III results in advanced non-small cell lung cancer. 2004 , 31, 93-9	18
1872	Targeting the HER-kinase axis in cancer. 2004 , 31, 9-20	53
1871	Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. 2004 , 31, 3-8	33
1870	Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. 2004 , 31, 23-30	16
1869	Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer. 2004 , 94, 705-12	16

1868	Epidermal growth factor receptor as a target to improve treatment of lung cancer. 2004 , 5, 340-52	7
1867	Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. 2004 , 6 Suppl 1, S7-S19	29
1866	Enhancement of peripheral benzodiazepine receptor ligand-induced apoptosis and cell cycle arrest of esophageal cancer cells by simultaneous inhibition of MAPK/ERK kinase. 2004 , 67, 1701-10	24
1865	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). 2004 , 68, 135-44	48
1864	Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. 2004 , 68, 1453-64	80
1863	Induction of Cdc25B expression by epidermal growth factor and transforming growth factor-alpha. 2004 , 68, 2221-7	5
1862	Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cells. 2004 , 16, 1249-61	27
1861	Differential phosphoproteomes of EGF and EGFR kinase inhibitor-treated human tumor cells and mouse xenografts. 2004 , 1, 69-80	23
1860	Roles of the transcription factors snail and slug during mammary morphogenesis and breast carcinoma progression. 2004 , 9, 183-93	72
1859	Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. 2004 , 1030, 69-77	38
1858	Palliative Systemtherapie beim metastasierten Ösophaguskarzinom. 2004 , 10, 1202-1214	1
1857	The role of new targeted therapies in small-cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 51, 45-53	7 14
1856	Review of epidermal growth factor receptor biology. 2004 , 59, 21-6	859
1855	Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. 2004 , 59, 27-38	42
1854	A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells. 2004 , 53, 497-509	30
1853	Antiangiogenic strategies, compounds, and early clinical results in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 49, 91-107	7 33
1852	Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer. 2004 , 203, 672-80	65
1851	Review article: chemoprevention of colorectal cancer. 2004 , 19, 1-24	35

1850	Cellular localization of activated N-WASP using a conformation-sensitive antibody. 2004 , 59, 141-52	22
1849	Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. 2004 , 198, 31-9	55
1848	Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. 2004 , 198, 259-68	91
1847	Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. 2004 , 201, 97-105	45
1846	Signal transduction and oncogenesis by ErbB/HER receptors. 2004 , 58, 903-13	300
1845	Targeting the EGFR in neoplasia--more questions than answers. 2004 , 58, 899-902	2
1844	Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. 2004 , 58, 984-90	198
1843	Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. 2004 , 59, 11-20	176
1842	Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. 2004 , 12, 3421-9	53
1841	The role of targeted therapy in non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 51, 29-44	7 21
1840	Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles. 2004 , 14, 1411-6	23
1839	Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. 2004 , 22, 3238-47	922
1838	The expanding role of systemic therapy in head and neck cancer. 2004 , 22, 1743-52	176
1837	Oncogenic growth factor receptors: implications for signal transduction therapy. 2004 ,	
1836	Dans les cancers bronchiques non ^petites cellules de stade III et IV, le gfitinib oral permet d'obtenir 10 ^ 20 % de rponses mme aprs chec d'une, voire de deux lignes de chimiothrapie incluant du cisplatine. 2004 , 21, 60-61	
1835	Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients*1. 2004 ,	
1834	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa[ZD1839]). 2004 , 68, 135-135	
1833	Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors. 2004 , 6, 705-12	20

1832	Targeted therapies for cancer [from tamoxifen to gefitinib ("Iressa")] 2004 , 1, 411-416	2
1831	Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. 2004 , 44, 221-30	185
1830	The biology of non-small-cell lung cancer: identifying new targets for rational therapy. 2004 , 46, 135-48	31
1829	Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. 2004 , 46, 247-54	50
1828	Signal transduction pathways as novel therapy targets in lung cancer. 2004 , 45 Suppl 2, S177-86	4
1827	Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer. 2004 , 4, 51-62	13
1826	Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer. 2004 , 4, 107-23	4
1825	Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. 2004 , 6 Suppl 1, S20-3	73
1824	Bronchoalveolar carcinoma: current treatment and future trends. 2004 , 6 Suppl 2, S75-9	3
1823	Cetuximab as a single agent or in combination with chemotherapy in lung cancer. 2004 , 6 Suppl 2, S80-4	9
1822	Development of ligand-targeted liposomes for cancer therapy. 2004 , 8, 335-53	128
1821	Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma. 2004 , 171, 897-902	35
1820	[The pathologist and EGFR in 2004: I like you, nor do it]. 2004 , 24, 416-26	1
1819	ErbB receptors: directing key signaling networks throughout life. 2004 , 44, 195-217	486
1818	Androgen receptor in prostate cancer. 2004 , 25, 276-308	1256
1817	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. 2004 , 351, 337-45	4112
1816	Epidermal growth factor receptor: a promising target in solid tumours. 2004 , 30, 1-17	212
1815	Targeting of epidermal growth factor receptor by cyclopentenone prostaglandin 15-Deoxy-Delta ^{12,14} -prostaglandin J ₂ in human oral squamous carcinoma cells. 2004 , 211, 97-103	6

1814	Monoclonal antibodies in the treatment of colorectal cancer. 2004 , 40, 1292-301	65
1813	Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients. 2004 , 40, 1776-86	15
1812	The ErbB/HER receptor protein-tyrosine kinases and cancer. 2004 , 319, 1-11	309
1811	Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors. 2004 , 31, 469-76	62
1810	7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies. 2004 , 23, 168-75	21
1809	Epidermal growth factor receptor in tumor angiogenesis. 2004 , 18, 1007-21, viii	130
1808	Growth factor receptors as targets for lung cancer therapy. 2004 , 16, 3-12	15
1807	Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. 2004 , 15, 503-12	118
1806	Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib (Iressa) ZD1839. 2004 , 12, 1053	4
1805	The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. 2004 , 29, e1-8	188
1804	The role of EGFR inhibitors in nonsmall cell lung cancer. 2004 , 16, 130-5	76
1803	Erlotinib (Tarceva) inhibits oral cavity carcinoma and synergizes with cisplatin and ionizing radiation in vitro. 2004 , 1, 67-74	2
1802	Targeted therapies in the treatment of colorectal cancers. 2005 , 12, 105-10	30
1801	Antiepidermal Growth Factor Receptor Antibody: Immunohistochemistry. 2005 , 3, 79-92	
1800	Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. 2005 , 128, 3975-84	88
1799	Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities. 2005 , 28, 467-70	
1798	Clinical value of epidermal growth factor receptor expression in primary breast cancer. 2005 , 12, 271-3	33
1797	Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. 2005 , 433-450	0

1796	Development of Precise Pharmacodiagnostic (PharmDx) Tests for Molecular Targeted Therapies. 2005 , 38, 209-216	1
1795	Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. 2005 , 28, 481-6	25
1794	Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. 2005 , 16, 483-94	41
1793	Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. 2005 , 814, 143-7	39
1792	Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. 2005 , 62, 309-17	116
1791	A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. 2005 , 17, 418-24	133
1790	Targeting ligand cleavage to inhibit the ErbB pathway in cancer. 2005 , 1059, 56-60	3
1789	2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. 2005 , 104, 2701-8	64
1788	Diagnostic challenges in pathology. 2005 , 15, 403-405	
1787	CpG Island methylation patterns in various histotypes of endometrial cancer. 2005 , 15, 405-405	
1786	Novel strategies for the management of uterine malignant mixed mullerian tumors. 2005 , 15, 405-405	0
1785	What is the correct management of stage i UPSC?. 2005 , 15, 405-406	2
1784	Advances in the management of advanced and recurrent uterine papillary serous carcinoma. 2005 , 15, 406-406	1
1783	Is lymphadenectomy required for all patients with endometrial cancer?. 2005 , 15, 406-407	2
1782	Laparoscopically assisted surgical staging for endometrial cancer. 2005 , 15, 407-407	12
1781	Updates in chemotherapy in the treatment of advanced and recurrent endometrial cancer. 2005 , 15, 407-408	1
1780	The role of radiation treatment in intermediate risk endometrial cancer-pro. 2005 , 15, 408-409	
1779	Role of radiation treatment in intermediate risk endometrial cancer-con. 2005 , 15, 409-409	1

1778	Future challenges in clinical and translational research for endometrial cancer. 2005 , 15, 398-399	4
1777	Tyrosine kinase inhibitors in endometrial cancer. 2005 , 15, 409-411	15
1776	Novel biologic therapies for the treatment of endometrial cancer. 2005 , 15, 411-411	17
1775	Role of gene expression profiling in distinguishing biologically and clinically distinct subclasses of endometrial carcinoma. 2005 , 15, 403-403	
1774	Early molecular changes in endometrial cancer. 2005 , 15, 399-400	4
1773	Loss of cables is associated with development of endometrial hyperplasia and cancer. 2005 , 15, 400-400	
1772	Endometrial cancer in women with HNPCC. 2005 , 15, 400-401	7
1771	Atypical endometrial hyperplasia: A tough call. 2005 , 15, 401-401	7
1770	Controversies in the management of atypical hyperplasia: Conservative management vs. simple hysterectomy. 2005 , 15, 401-402	
1769	Predictors of poor prognosis in endometrial cancer. 2005 , 15, 402-402	
1768	MSI in endometrial cancer: Prevalence and clinical applications. 2005 , 15, 402-403	2
1767	Gefitinib in advanced non-small cell lung cancer. 2005 , 35, 77-82	
1766	Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations. 2005 , 31, 384-94	35
1765	Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. 2005 , 92, 125-30	24
1764	Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). 2005 , 92, 1711-9	122
1763	A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. 2005 , 92, 1846-9	47
1762	ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. 2005 , 92 Suppl 1, S6-13	133
1761	ERBB receptors and cancer: the complexity of targeted inhibitors. 2005 , 5, 341-54	2593

1760	Erlotinib hydrochloride. 2005 , 4, 13-4	142
1759	Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. 2005 , 24, 5173-90	58
1758	Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. 2005 , 7, 301-11	794
1757	The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. 2005 , 8, 287-97	348
1756	Autocrine, paracrine and juxtacrine signaling by EGFR ligands. 2005 , 17, 1183-93	290
1755	Updated data from the Iressa survival in lung cancer trial. 2005 , 6, 340-2	2
1754	Combined modality treatment for rectal cancer. 2005 , 32, 103-12	10
1753	Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective. 2005 , 32, S27-35	19
1752	Redefining bronchioloalveolar carcinoma. 2005 , 32, 329-35	20
1751	The role of cetuximab in the therapy of previously treated advanced colorectal cancer. 2005 , 32, S55-8	6
1750	Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. 2005 , 32, S59-62	27
1749	Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. 2005 , 32, S9-15	69
1748	N-methyl-N'-nitro-N-nitrosoguanidine interferes with the epidermal growth factor receptor-mediated signaling pathway. 2005 , 570, 175-84	15
1747	Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2005 , 205, 355-63	26
1746	Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. 2005 , 117, 883-8	133
1745	Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. 2005 , 103, 1881-90	61
1744	Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. 2005 , 103, 2435-46	69
1743	Transient transfection of epidermal growth factor receptor gene into MCF7 breast ductal carcinoma cell line. 2005 , 23, 157-61	2

1742	Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. 2005 , 83, 917-26		85
1741	Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. 2005 , 371, 141-51		16
1740	[EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer]. 2005 , 100, 785-93		2
1739	Blockade of epidermal growth factor receptor (EGFR) activity. <i>Critical Reviews in Oncology/Hematology</i> , 2005 , 53, 179-92	7	17
1738	Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?. <i>Critical Reviews in Oncology/Hematology</i> , 2005 , 55, 67-81	7	24
1737	Novel therapeutics in colorectal cancer. 2005 , 48, 1632-50		14
1736	Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. 2005 , 7, 116-22		4
1735	Expression of epidermal growth factor receptor in different salivary adenoid cystic carcinoma cell lines. 2005 , 17, 213-216		1
1734	HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. 2005 , 74, 77-86		60
1733	Molecularly targeted therapy for pediatric brain tumors. 2005 , 75, 335-43		8
1732	Molecular therapy of head and neck cancer. 2005 , 24, 129-46		33
1731	Monoclonal Antibody Strategies for Targeting HER2. 2005 , 627-645		
1730	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. 2005 , 10, 2611-7		18
1729	Therapeutic Monoclonal Antibodies in Oncology. 2005 , 98, 146-152		20
1728	Targeting of the EGFR As a Modulator of Cancer Chemotherapy. 2005 , 1-26		2
1727	CpG ISLAND METHYLATION PATTERNS IN VARIOUS HISTOTYPES OF ENDOMETRIAL CANCER: 0011. 2005 , 15, 405.1-405		
1726	TYROSINE KINASE INHIBITORS IN ENDOMETRIAL CANCER: 0020. 2005 , 15, 409.2-411		
1725	DIAGNOSTIC CHALLENGES IN PATHOLOGY: 0010. 2005 , 15, 403.2-405		

1724	EARLY MOLECULAR CHANGES IN ENDOMETRIAL CANCER: 0001. 2005 , 15, 399-400	4
1723	ENDOMETRIAL CANCER IN WOMEN WITH HNPCC: 0003. 2005 , 15, 400.2-401	
1722	ROLE OF RADIATION TREATMENT IN INTERMEDIATE RISK ENDOMETRIAL CANCER: 0019. 2005 , 15, 409.1-409	
1721	Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. 2005 , 65, 3273-80	72
1720	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. 2005 , 65, 1459-70	249
1719	Cetuximab: adverse event profile and recommendations for toxicity management. 2005 , 9, 332-8	34
1718	Molecular determinants of cetuximab efficacy. 2005 , 23, 3536-44	205
1717	Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. 2005 , 16, 1867-73	19
1716	Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. 2005 , 65, 9176-84	157
1715	DNA drug design for cancer therapy. 2005 , 11, 2811-23	10
1714	Sulindac metabolites inhibit epidermal growth factor receptor activation and expression. 2005 , 4, 16	15
1713	Cetuximab. 2005 , Suppl, S10-1	57
1712	Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. 2005 , 16 Suppl 4, iv61-68	91
1711	Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. 2005 , 65, 10524-35	71
1710	Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). 2005 , 65, 1770-7	197
1709	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. <i>Clinical Cancer Research</i> , 2005 , 11, 5539-48	12.9 234
1708	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. 2005 , 23, 3227-34	343
1707	HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. 2005 , 16, 538-48	39

1706	Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. <i>Clinical Cancer Research</i> , 2005 , 11, 5300-9	12.9	87
1705	In Reply:. 2005 , 23, 3866-3867		1
1704	Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 4783-92	12.9	124
1703	Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. 2005 , 23, 5560-7		213
1702	Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. 2005 , 23, 1791-3		37
1701	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. 2005 , 23, 5323-33		286
1700	Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification. 2005 , 19, 2078-90		58
1699	Matrix metalloproteinase/epidermal growth factor receptor/mitogen-activated protein kinase signaling regulate fra-1 induction by cigarette smoke in lung epithelial cells. 2005 , 32, 72-81		54
1698	Folsūre in der Prūvention des kolorektalen Karzinoms. 2005 , 30, 1-12		1
1697	Epidermal growth factor receptor inhibitors in cancer treatment. 2005 , 1, 221-34		49
1696	Cetuximab in the treatment of colorectal cancer. 2005 , 1, 173-81		13
1695	Erlotinib hydrochloride. 2005 , 4, S14-S15		18
1694	Chemoprevention of lung cancer: concepts and strategies. 2005 , 5, 549-65		4
1693	Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. 2005 , 23, 5578-87		337
1692	Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. 2005 , 23, 5568-77		418
1691	Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. 2005 , 10, 602-12		48
1690	Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. 2005 , 92, 1737-45		46
1689	The epidermal growth factor receptor family. 2005 , 12 Suppl 1, S17-27		162

1688	Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. 2005 , 280, 8503-12		71
1687	Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. 2005 , 280, 42694-700		85
1686	Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. 2005 , 280, 22473-81		251
1685	Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. <i>Clinical Cancer Research</i> , 2005 , 11, 7080s-7086s	12.9	61
1684	Epidermal growth factor receptor inhibitors: a moving target?. <i>Clinical Cancer Research</i> , 2005 , 11, 7203-5	12.9	16
1683	Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. 2005 , 23, 2502-12		302
1682	15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. 2005 , 280, 3217-23		219
1681	Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. 2005 , 23, 6172-80		92
1680	Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. <i>Clinical Cancer Research</i> , 2005 , 11, 7480-9	12.9	82
1679	Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. 2005 , 25, 7734-42		216
1678	Impact of EGFR expression on colorectal cancer patient prognosis and survival. 2005 , 16, 102-8		279
1677	Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. <i>Clinical Cancer Research</i> , 2005 , 11, 8686-98	12.9	451
1676	Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. 2005 , 23, 6838-45		513
1675	Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. 2005 , 10, 855-74		8
1674	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. 2005 , 97, 880-7		402
1673	Predicting the future from trials of the past: epidermal growth factor receptor expression and outcome of fractionated radiation therapy trials. 2005 , 23, 5437-9		1
1672	Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology. 2005 , 25, 9082-91		17
1671	Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidylinositol-3-kinase in human ovarian surface epithelial cells. 2005 , 12, 407-21		60

1670	Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. 2005 , 12 Suppl 1, S159-71	76
1669	Therapeutic targeting of receptor tyrosine kinases in lung cancer. 2005 , 9, 533-59	20
1668	Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer. 2005 , 1, 51-61	1
1667	Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. 2005 , 65, 6371-9	74
1666	Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues. 2005 , 280, 27826-31	24
1665	Therapy of breast cancer with molecular targeting agents. 2005 , 16 Suppl 4, iv28-36	35
1664	Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. 2005 , 68, 502-10	92
1663	Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis. 2005 , 65, 5848-56	39
1662	Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. 2005 , 97, 1663-70	70
1661	Folic acid and colorectal cancer prevention: Molecular mechanisms and epidemiological evidence (Review). 2005 , 26, 1449	2
1660	Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. 2005 , 15, 305	3
1659	[Basic principles of signal transduction]. 2005 , 28 Suppl 4, 14-7	2
1658	Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. 2005 , 68, 538-47	37
1657	From XenoMouse [®] Technology to Panitumumab (ABX-EGF). 2005 , 647-657	3
1656	Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 6650-6	12.9 132
1655	Therapeutic monoclonal antibodies in oncology. 2005 , 98, 146-52	18
1654	Biomarkers to predict response to epidermal growth factor receptor inhibitors. 2005 , 4, 1369-72	63
1653	Chaperoning antigen presentation by MHC class II molecules and their role in oncogenesis. 2005 , 93, 129-58	11

1652	Growth of intestinal epithelium in organ culture is dependent on EGF signalling. 2005 , 303, 252-62	67
1651	Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors. 2005 , 2, 492-496	9
1650	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. 2005 , 97, 643-55	1367
1649	Treatment of elderly cancer patients with chemotherapy. 2005 , 23, 537-47	9
1648	State of the art in therapy for non-small cell lung cancer. 2005 , 23, 427-42	58
1647	Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. 2005 , 19, 1978-85	287
1646	Receptor-targeted cancer therapy. 2005 , 24, 271-82	27
1645	Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. 2005 , 97, 1516-24	123
1644	Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. 2005 , 288, G447-56	109
1643	The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. 2005 , 53, 291-302	38
1642	The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice. 2005 , 129, 251-9	26
1641	SRL172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients. 2005 , 64, 248-51	3
1640	ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter. 2005 , 326, 455-65	27
1639	Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. 2005 , 27, 684-94	175
1638	Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?. 2005 , 41, 1383-92	91
1637	Growth factors and their relationship to neoplastic and paraneoplastic disease. 2005 , 16, 83-94	3
1636	The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors. 2005 , 217, 73-86	46
1635	Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. 2005 , 230, 33-46	32

1634	Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma. 2005 , 226, 123-31	16
1633	Single-dose clinical pharmacokinetic studies of gefitinib. 2005 , 44, 1165-77	112
1632	Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. 2005 , 5, 124-31	54
1631	Epidermal Growth Factor Receptor as a Target for Chemotherapy. 2005 , 5, S19-S27	47
1630	Detection of disseminated tumor cells in peripheral blood. 2005 , 42, 155-96	218
1629	ADAM proteases, ErbB pathways and cancer. 2005 , 14, 591-606	20
1628	Amphiregulin: an early trigger of liver regeneration in mice. 2005 , 128, 424-32	143
1627	Targeted therapy in colorectal cancer: do we know enough?. 2006 , 38, 71-7	5
1626	Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. 2005 , 49, 337-43	150
1625	Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells. 2005 , 50, 19-24	26
1624	Mechanisms of drug resistance in cancer chemotherapy. 2005 , 14 Suppl 1, 35-48	411
1623	Inhibitors of Protein Kinases and Protein Phosphates. 2005 ,	1
1622	Erlotinib. 2005 , 4, 247-252	3
1621	Recent Advances in the Systemic Therapy of Metastatic Colorectal Cancer. 2005 , 4, 15-34	3
1620	Redox properties of tea polyphenols and related biological activities. 2005 , 7, 1704-14	93
1619	Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. 2005 , 45, 357-84	107
1618	Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. 2005 , 92, 1069-77	39
1617	High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 5337-48	8.3 69

1616	Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. 2005 , 50, 393-9		15
1615	Erlotinib in previously treated non-small-cell lung cancer. 2005 , 353, 123-32		4590
1614	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. 2005 , 7, R570-9		94
1613	Protein Tyrosine Kinases. 2006 ,		4
1612	Biomarkers in Breast Cancer. 2006 ,		3
1611	The place of targeted therapies in the management of non-small cell bronchial carcinoma. 2006 , 23, 137-147	2	
1610	Cancer Drug Resistance. 2006 ,		17
1609	Influence of antibiotic treatment on breast carcinoma development in proto-neu transgenic mice. 2006 , 66, 6219-24		32
1608	The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. 2006 , 11, 665-83		1
1607	Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. <i>Annals of Medicine</i> , 2006 , 38, 545-51	1.5	47
1606	Pharmacoproteomics study of cetuximab in nasopharyngeal carcinoma. 2006 , 5, 3260-7		18
1605	Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma. 2006 , 168, 1686-96		18
1604	Epidermal growth factor receptor and hedgehog signaling pathways are active in esophageal cancer cells from rat reflux model. 2006 , 134, 1-9		29
1603	Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway. 2006 , 25, 3277-85		7
1602	Novel targeted therapies for non-small cell lung cancer. 2006 , 16, 353-66		1
1601	Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. 2006 , 176, 787-92		29
1600	Highlights from: 42nd Annual Meeting of the American Society of Clinical Oncology. 2006 , 6, 184-8		
1599	Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. 2006 , 66, 1441-63		11

1598	Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. 2006 , 6, 59-65	9
1597	Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. 2006 , 6, 214-8	18
1596	[Expression of epidermal growth factor receptor (EGFR) in hormone-independent breast cancers]. 2006 , 25, 15-9	1
1595	Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?. 2006 , 4, 92	4
1594	Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. 2006 , 23, 74-9	96
1593	Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. 2006 , 54, 387-98	88
1592	Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. 2006 , 3, 726-36	28
1591	Targeting angiogenesis with integrative cancer therapies. 2006 , 5, 9-29	80
1590	Epidermal growth factor-conjugated poly(ethylene glycol)-block- poly(delta-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics. 2006 , 17, 399-409	99
1589	Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. 2006 , 66, 2173-80	180
1588	Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. 2006 , 10, 306-15	34
1587	[Targeted therapies in pediatric oncology: a new therapeutic approach?]. 2006 , 13, 189-94	
1586	Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors. 2006 , 12, 68-74	5
1585	Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. 2006 , 349, 372-82	20
1584	Epidermal growth factor receptor (EGFR) signaling in cancer. 2006 , 366, 2-16	1421
1583	Effects of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) on endometrial cancer (HHUA) cell apoptosis and EGF stimulated cell proliferation in vitro. 2006 , 16, 202-10	11
1582	Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. 2006 , 32, 74-89	137
1581	Key cancer cell signal transduction pathways as therapeutic targets. 2006 , 42, 290-4	118

1580	Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. 2006 , 62, 155-62	95
1579	Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. 2006 , 24, 121-36	111
1578	Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. 2006 , 37, 1324-32	51
1577	Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. 2006 , 55, 349-53	44
1576	Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro. 2006 , 88, 114-22	18
1575	[Epidermal growth factor receptor inhibitors side effects]. 2006 , 97, 296-310	21
1574	Targeted therapies: a nursing perspective. 2006 , 22, 1-4	6
1573	Antibody Therapy for Solid Tumors. 2006 , 433-444	
1572	Oncogenes. 2006 ,	
1571	Protein Tyrosine Kinases as Targets for Cancer and Other Indications. 2006 , 1-29	3
1570	The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer. 2006 , 177-191	
1569	Autocrine Growth Factor Signaling in Motility. 2006 , 89-109	1
1568	Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis. 2006 , 1, 147-167	8
1567	Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. 2006 , 12, 229-36	39
1566	Recent new approaches to the treatment of head and neck cancer. 2006 , 17, 365-75	20
1565	Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies. 2006 , 18, 609-14	3
1564	Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. 2006 , 16, 475-83	90
1563	Effect of gefitinib on brain metastases from non-small cell lung cancer. 2006 , 46, 504-7	8

1562	QSAR and 3D QSAR of inhibitors of the epidermal growth factor receptor. 2006 , 106, 1432-1444	7
1561	HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. 2006 , 19, 224-31	46
1560	EGFR transactivation in the regulation of SMC function. 2001 , 947, 42-54; discussion 54-5	71
1559	Epidermal growth factor receptor expression in feline oral squamous cell carcinomas. 2006 , 4, 33-40	26
1558	Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib. 2006 , 97, 155-62	57
1557	Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. 2006 , 97, 1115-24	59
1556	Impact of genetic diagnostics on drug development strategy. 2006 , 5, 459-62	10
1555	Panitumumab. 2006 , 5, 987-8	54
1554	Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. 2006 , 94, 792-7	94
1553	Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. 2006 , 94, 1136-43	114
1552	Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. 2006 , 94, 1604-9	70
1551	Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa. 2006 , 95, 1525-8	14
1550	Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. 2006 , 19, 788-96	47
1549	Selective proapoptotic activity of a secreted recombinant antibody/AIF fusion protein in carcinomas overexpressing HER2. 2006 , 13, 313-20	31
1548	Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. 2006 , 25, 278-87	219
1547	Clinical experience with gefitinib: an update. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 58, 31-45	7 46
1546	Cetuximab in advanced non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 59, 139-49	7 16
1545	Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 60, 99-111	7 30

1544	Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket. 2006 , 16, 1633-7	37
1543	Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation. 2006 , 65, 705-12	34
1542	Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. 2006 , 66, 195-200	71
1541	The enlargement of the hormone immune deprivation concept to the blocking of TGFalpha-autocrine loop: EGFR signaling inhibition. 2006 , 55, 628-38	5
1540	Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. 2006 , 57, 693-702	40
1539	In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. 2006 , 57, 709-18	81
1538	Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. 2006 , 58, 577-84	38
1537	An integrated agent-mathematical model of the effect of intercellular signalling via the epidermal growth factor receptor on cell proliferation. 2006 , 242, 774-89	42
1536	Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab. 2006 , 1, 2-12	2
1535	Targeted therapies in colorectal cancer: Complications and management. 2006 , 2, 125-133	2
1534	Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. 2006 , 7, 16-22	9
1533	Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas. 2006 , 12, 87-91	49
1532	Flow cytometry: a new approach for the molecular profiling of breast cancer. 2006 , 80, 46-53	37
1531	EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. 2006 , 100, 101-6	78
1530	Relevant molecular markers and targets. 2006 , 103, S6-S13	15
1529	Catalase reverses tumorigenicity in a malignant cell line by an epidermal growth factor receptor pathway. 2006 , 40, 863-75	24
1528	Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. 2006 , 41, 1521-33	167
1527	PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. 2006 , 41, 1449-58	47

1526	Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. 2006 , 10, 39-50	311
1525	The complexity of targeting EGFR signalling in cancer: from expression to turnover. 2006 , 1766, 120-39	106
1524	Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. 2006 , 1766, 217-29	27
1523	A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. 2006 , 114, 277-87	191
1522	Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. 2006 , 6, 277	46
1521	Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. 2006 , 6, 46	58
1520	Pathways of dysregulation in renal cell carcinoma: rational approaches to development of novel treatment. 2006 , 5 Suppl 1, S7-S18	1
1519	Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. 2006 , 8 Suppl 1, S15-22	12
1518	Development of antibody-based therapeutics for oncology indications. 2006 , 67, 699-728	2
1517	Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. 2006 , 97, 724-34	56
1516	Cell cycle control in breast cancer cells. 2006 , 97, 261-74	156
1515	Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. 2006 , 208, 344-53	54
1514	Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. 2006 , 106, 1857-62	31
1513	Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. 2006 , 106, 1917-24	34
1512	Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. 2006 , 107, 1207-18	153
1511	Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. 2006 , 107, 2337-45	30
1510	New insights on the anticancer properties of dietary polyphenols. 2006 , 26, 747-66	414
1509	Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. 2006 , 26, 569-94	101

1508	Targeted photodynamic therapy. 2006 , 38, 522-31		123
1507	Fluorine-18 labeling of ML04 [presently the most promising irreversible inhibitor candidate for visualization of EGFR in cancer. 2006 , 49, 533-543		17
1506	Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis. 2006 , 18, 532-7		16
1505	Tissue microarray analysis of EGFR gene amplification and gain in Bulgarian patients with colorectal cancer. 2006 , 29, 198-200		2
1504	EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. 2006 , 66, 3197-204		229
1503	Biological agents versus chemotherapy in the treatment of colorectal cancer. 2006 , 7, 1251-71		2
1502	Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. 2006 , 17, 981-5		101
1501	Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice. 2006 , 10, 281-7		3
1500	A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 3381-8	12.9	101
1499	Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. 2006 , 17 Suppl 7, vii109-14		83
1498	Signalling pathways implicated in early mammary gland morphogenesis and breast cancer. 2006 , 2, e112		55
1497	Targeted therapy for renal cell carcinoma: a new therapeutic paradigm. 2006 , 24, 640-56		7
1496	Joint effect of asthma/atopy and an IL-6 gene polymorphism on lung cancer risk among lifetime non-smoking Chinese women. 2006 , 27, 1240-4		40
1495	Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. 2006 , 24, 2659-65		131
1494	Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. 2006 , 26, 6283-98		187
1493	Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 1154-65	6.1	79
1492	Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2006 , 12, 7406-13	12.9	17
1491	Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. 2007 , 44, 166-72		37

1490	Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells. <i>Clinical Cancer Research</i> , 2006 , 12, 4989-99	12.9	26
1489	Label-free and real-time cell-based kinase assay for screening selective and potent receptor tyrosine kinase inhibitors using microelectronic sensor array. 2006 , 11, 634-43		56
1488	Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 209-18	6.1	87
1487	Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. <i>Clinical Cancer Research</i> , 2006 , 12, 1680-5	12.9	136
1486	Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastatic colorectal cancer. 2006 , 24, 1892-7		81
1485	Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. <i>Clinical Cancer Research</i> , 2006 , 12, 1647-53	12.9	356
1484	Erlotinib-induced breast cancer regression. 2006 , 40, 2043-7		13
1483	Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. 2006 , 66, 11279-86		70
1482	Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. 2006 , 2, 47-51		6
1481	PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells. <i>Clinical Cancer Research</i> , 2006 , 12, 4192-9	12.9	33
1480	Inhibitors of signal transduction protein kinases as targets for cancer therapy. 2006 , 12, 153-223		17
1479	Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. <i>Clinical Cancer Research</i> , 2006 , 12, 6186-93	12.9	71
1478	Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. 2006 , 17 Suppl 2, ii46-48		20
1477	Expression of Epidermal Growth Factor Receptor in Primary Colorectal Adenocarcinoma Predicts Expression in Recurrent Disease. 2006 , 125, 229-233		15
1476	Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. 2006 , 5, 657-64		139
1475	Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. 2006 , 8, 67-78		177
1474	Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. <i>Clinical Cancer Research</i> , 2006 , 12, 7252-60	12.9	89
1473	Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. 2006 , 66, 3802-12		51

1472	Epidermal growth factor receptor inhibition and non-small cell lung cancer. 2006 , 43, 291-323		14
1471	Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. 2006 , 24, 4309-16		118
1470	Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. 2006 , 281, 626-37		94
1469	Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. 2006 , 24, 4922-7		269
1468	Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. <i>Clinical Cancer Research</i> , 2006 , 12, 4036-42	12.9	53
1467	Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. 2006 , 66, 404-11		84
1466	Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 1883-94	6.1	37
1465	Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. 2006 , 24, 1612-9		181
1464	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. 2007 , 7, 821-36		9
1463	Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. 2007 , 72, 248-58		62
1462	Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice. 2007 , 97, 183-93		27
1461	Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. 2007 , 7, 503-18		27
1460	Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines. 2007 , 8, 2979-90		2
1459	Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. 2007 , 20, 189-99		88
1458	Current concepts for the combined treatment modality of ionizing radiation with anticancer agents. 2007 , 13, 519-35		23
1457	The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib. <i>Clinical Cancer Research</i> , 2007 , 13, 5170-5	12.9	28
1456	Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy. 2007 , 13, 3368-3377		59
1455	Advances in the treatment of patients with gastric adenocarcinoma. 2007 , 46, 277-85		42

1454	Tyrosine kinase inhibitors: a potential approach to the treatment of hepatocellular carcinoma. 2007 , 13, 3301-4		11
1453	Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 523-31	12.9	19
1452	Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. 2007 , 12, 211-20		43
1451	Targeted therapy of breast cancer. 2007 , 13, 497-517		24
1450	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 2007 , 2, 335-48		3
1449	Emerging drugs for targeted therapy of bladder cancer. 2007 , 12, 435-48		5
1448	Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. 2007 , 11, 1287-98		23
1447	New target agents in the treatment of colorectal cancer patients. 2007 , 2, 861-71		1
1446	Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. 2007 , 8, 319-27		33
1445	Erlotinib in cancer treatment. 2007 , 18 Suppl 6, vi35-41		72
1444	Panitumumab a novel drug in cancer treatment. 2007 , 18 Suppl 6, vi16-21		24
1443	Biological therapy update in colorectal cancer. 2007 , 7, 509-19		8
1442	A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. 2007 , 23, 2117-23		11
1441	Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. 2007 , 7, 309-19		33
1440	Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 5377-84	12.9	21
1439	Cetuximab: clinical results in colorectal cancer. 2007 , 18 Suppl 6, vi8-10		12
1438	Association between functional EGF+61 polymorphism and glioma risk. <i>Clinical Cancer Research</i> , 2007 , 13, 2621-6	12.9	74
1437	Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. <i>Clinical Cancer Research</i> , 2007 , 13, 3597-604	12.9	57

1436	Biology of interactions: antiepidermal growth factor receptor agents. 2007 , 25, 4057-65		184
1435	CETUXIMAB (ERBITUX [®]), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER. 2007 , 43-67		
1434	Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 1414-24	6.1	69
1433	Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. 2007 , 25, 2171-7		762
1432	A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. 2007 , 67, 665-73		43
1431	Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney. <i>Clinical Cancer Research</i> , 2007 , 13, 4360-4	12.9	31
1430	Breast Cancer. 2007 ,		
1429	Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. 2007 , 18, 730-7		28
1428	Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. 2007 , 3, 236-241		
1427	Erlotinib in pancreatic cancer: are tumor cells the (only) target?. 2007 , 25, 5836-7		4
1426	Editorial [The Role of Epidermal Growth Factor Receptor (EGFR) Targeting Drugs in the Treatment of Cancer Guest Editor: Fortunato Ciardiello]. 2007 , 3, 223-225		
1425	Regression of early and intermediate stages of colon cancer by targeting multiple members of the EGFR family with EGFR-related protein. 2007 , 67, 5389-96		18
1424	Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 1892-902	12.9	114
1423	In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. <i>Clinical Cancer Research</i> , 2007 , 13, 6639-48	12.9	98
1422	EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. 2007 , 282, 26656-26665		89
1421	Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. 2007 , 2, S125-7		5
1420	Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. 2007 , 30, 1019		1
1419	An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. 2007 , 30, 355-60		19

1418	Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. 2007 ,	5
1417	Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges. 2007 , 22, 10-23	3
1416	Models for Tumour Growth and Differentiation. 2007 ,	1
1415	A novel breast cancer cell line initially established from pleural effusion: Evolution towards a more aggressive phenotype. 2007 ,	
1414	Immunohistochemical evaluation of H-R3 a novel humanized monoclonal antibody that neutralizes the EGF-receptor. 2007 , 15, 213-9	5
1413	Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma. 2007 , 15, 441-5	6
1412	Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. 2007 , 30, S17-26	21
1411	An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). 2007 ,	9
1410	Molecular targets in gynaecological cancers. 2007 , 39, 26-45	12
1409	LRIG inhibitors of growth factor signalling - double-edged swords in human cancer?. 2007 , 43, 676-82	75
1408	Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses. 2007 , 33, 230-83	39
1407	Rational bases for the development of EGFR inhibitors for cancer treatment. 2007 , 39, 1416-31	95
1406	Expression of single-chain antibody-barstar fusion in plants. 2007 , 89, 31-8	29
1405	Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma. 2007 , 248, 32-40	26
1404	Selective downregulation of EGF receptor and downstream MAPK pathway in human cancer cell lines by active components partially purified from the seeds of <i>Livistona chinensis</i> R. Brown. 2007 , 248, 137-46	22
1403	Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. 2007 , 248, 269-79	42
1402	Cellular responses to EGFR inhibitors and their relevance to cancer therapy. 2007 , 254, 165-77	121
1401	Expression of ErbB-1 and 2 in vestibular schwannomas. 2007 , 14, 1199-206	14

1400	Epidermal growth factor can induce apoptosis in neuroblastoma. 2007 , 42, 482-8	8
1399	Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. 2007 , 56, 500-5	51
1398	Current Treatment in Advanced Renal Cell Carcinoma (RCC): Impact of Targeted Therapies in the Management of RCC. 2007 , 6, 484-491	8
1397	Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 13092-7	11.5 203
1396	Apoptosis, Senescence, and Cancer. 2007 ,	6
1395	Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. 2007 , 9, R63	160
1394	Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. 2007 , 9, R50	40
1393	The Role of EGFR Inhibition in Colorectal Cancer. 2007 , 99-118	1
1392	Colorectal Cancer. 2007 ,	1
1391	Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer—a review of the literature. 2007 , 12, 201-10	69
1390	The developing trend of monoclonal antibodies in the treatment of colorectal cancer. 2007 , 7, 871-83	6
1389	Cancer Prevention. 2007 ,	3
1388	Tyrosine kinase inhibitors in pediatric malignancies. 2007 , 25, 606-12	7
1387	Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. 2007 , 178, 7467-72	169
1386	Apoptotic epidermal growth factor (EGF)-conjugated block copolymer micelles as a nanotechnology platform for targeted combination therapy. 2007 , 4, 769-81	55
1385	Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. 2007 , 12, 610-21	277
1384	Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. 2007 , 25, 1545-52	777
1383	Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. 2007 , 18, 1185-9	59

1382	[Biologic therapy: current and future applications in oncology]. 2007 , 129, 184-93	3
1381	Pharmacotherapy for oesophagogastric cancer. 2007 , 67, 2539-56	4
1380	Combining targeted therapies to enhance the effectiveness of chemotherapy in patients with treatment-refractory colorectal cancer. 2007 , 6 Suppl 2, S53-9	1
1379	Development and Clinical Indications of Cetuximab. 2007 , 22, 40-46	10
1378	The Rationale for the Combination of Selective EGFR Inhibitors with Cytotoxic Drugs and Radiotherapy. 2007 , 22, 47-52	10
1377	Targeted Therapeutics in Cancer Treatment. 2007 , 117-148	
1376	EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB. 2007 , 155-178	
1375	Metal-binding properties of a dicysteine-containing motif in protein tyrosine kinases. 2007 , 8, 1592-605	4
1374	Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231). 2007 , 120, 181-8	39
1373	Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. 2007 , 121, 2095-104	32
1372	Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. 2008 , 122, 1530-8	49
1371	Targeting cell signaling pathways for drug discovery: an old lock needs a new key. 2007 , 102, 580-92	107
1370	Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. 2007 , 109, 1836-44	61
1369	Improved biochemical strategies for targeted delivery of taxoids. 2007 , 15, 3597-623	48
1368	Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis. 2007 , 1, 1651-9	51
1367	Targeting death-inducing receptors in cancer therapy. 2007 , 26, 3745-57	166
1366	Current role of antibody therapy in patients with metastatic colorectal cancer. 2007 , 26, 3661-78	44
1365	Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. 2007 , 26, 3654-60	116

1364	A robustness-based approach to systems-oriented drug design. 2007 , 6, 202-10	411
1363	Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. 2007 , 75, 788-99	65
1362	The epidermal growth factor receptor: from development to tumorigenesis. 2007 , 75, 770-87	246
1361	Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis. 2007 , 99, 196-201	5
1360	+61A>G polymorphism in the EGF gene does not increase the risk of lung cancer. 2007 , 12, 902-5	26
1359	Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. 2007 , 98, 629-35	199
1358	Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. 2007 , 98, 1275-80	198
1357	Application of EGFP-EGF fusions to explore mechanism of endocytosis of epidermal growth factor. 2007 , 28, 111-7	5
1356	Molecular mechanisms of ZD1839 (Iressa)-induced apoptosis in human leukemic U937 cells. 2007 , 28, 1205-14	8
1355	Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells. 2007 , 28, 1224-30	38
1354	Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. 2007 , 28, 1476-93	38
1353	EGFR associated expression profiles vary with breast tumor subtype. 2007 , 8, 258	208
1352	Targeted agents and esophageal cancer--the next step?. 2007 , 17, 62-9	21
1351	Future strategies for targeted therapies and tailored patient management in pancreatic cancer. 2007 , 34, 354-64	8
1350	[Treatment with cetuximab in metastatic colorectal cancer patients who do not express the epidermal growth factor receptor]. 2007 , 31, 264-9	3
1349	Increased cyclooxygenase-2 expression associated with inflammatory cellular infiltration in elderly patients with vulvar cancer. 2007 , 1095, 143-53	11
1348	Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. 2007 , 14, 942-53	112
1347	PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment?. 2007 , 34, 1510-1	3

1346	T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. 2007 , 56, 1701-10		35
1345	Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. 2007 , 60, 295-303		42
1344	Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. 2007 , 60, 661-70		15
1343	Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. 2007 , 25, 351-5		7
1342	Cell motility and cytoskeletal regulation in invasion and metastasis. 2007 , 12, 143-52		148
1341	Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. 2007 , 101, 355-65		115
1340	Epithelial molecular markers in the peripheral blood of patients with colorectal cancer. 2007 , 50, 1188-203		36
1339	Interaktionen von EGFR- und VEGFR-Inhibitoren mit Chirurgie und Strahlentherapie. 2007 , 13, 67-72		1
1338	Co-expression of EGF receptor, TGFalpha and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis. 2007 , 450, 321-8		13
1337	Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. 2007 , 133, 169-76		13
1336	Carcinoma ex pleomorphic adenoma of the salivary gland: an immunohistochemical study. 2007 , 264, 789-95		26
1335	Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?. 2007 , 9, 255-64		17
1334	Update in the management of ovarian and cervical carcinoma. <i>Clinical and Translational Oncology</i> , 2007 , 9, 443-51	3.6	15
1333	Mechanisms of resistance to EGFR inhibitors. 2007 , 2, 31-37		5
1332	Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 2008 , 110, 127-34		16
1331	Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. 2008 , 111, 79-91		68
1330	EGF promoter SNPs, plasma EGF levels and risk of breast cancer in Chinese women. 2008 , 111, 321-7		19
1329	Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. 2008 , 112, 25-33		34

1328	Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. 2008 , 112 Suppl 1, 53-66	40
1327	Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. 2008 , 27, 387-402	26
1326	Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. 2008 , 25, 477-89	33
1325	Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. 2008 , 25, 1318-26	40
1324	Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor. 2008 , 10, 99-106	38
1323	Amphiregulin as a novel target for breast cancer therapy. 2008 , 13, 171-9	39
1322	Modulation of key signal transduction molecules by a novel peptide combination effective for the treatment of gastrointestinal carcinomas. 2008 , 26, 505-16	4
1321	The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. 2008 , 64, 31-41	96
1320	Insight into the recognition patterns of the ErbB receptor family transmembrane domains: heterodimerization models through molecular dynamics search. 2008 , 37, 851-64	12
1319	The relative bioavailability of gefitinib administered by granular formulation. 2008 , 62, 203-8	8
1318	[Cellular mechanisms of tumor response: clinical demands]. 2008 , 48, 820-31	2
1317	A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer. 2008 , 70, 1707-29	18
1316	Molekulardiagnostik von Mutationen des epidermalen Wachstumsfaktor-Rezeptors und Aktivierung nachgeschalteter Signalwege in nichtkleinzelligen Lungenkarzinomen. 2008 , 1, 101-108	
1315	EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines. 2008 , 14, 39-43	34
1314	Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. 2008 , 129, 563-78	149
1313	KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. 2008 , 453, 417-31	241
1312	COMMENTS. 2008 , 111, 212-224	
1311	Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. 2008 , 8, 4383-401	86

1310	Metabolite identification of a new antitumor agent icotinib in rats using liquid chromatography/tandem mass spectrometry. 2008 , 22, 2176-84		8
1309	EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. 2008 , 69, 359-372		34
1308	Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. 2008 , 122, 267-73		158
1307	Inhibition of epidermal growth factor receptor signaling pathway by delphinidin, an anthocyanidin in pigmented fruits and vegetables. 2008 , 123, 1508-15		45
1306	MMTV-EGF receptor transgene promotes preneoplastic conversion of multiple steroid hormone-responsive tissues. 2008 , 103, 2010-8		10
1305	The role of the EGFR signaling in tumor microenvironment. 2008 , 214, 559-67		280
1304	Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. 2008 , 216, 698-707		29
1303	Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. 2008 , 30, 667-74		45
1302	The development of HKI-272 and related compounds for the treatment of cancer. 2008 , 341, 465-77		123
1301	Vascular changes in hepatocellular carcinoma. 2008 , 291, 721-34		138
1300	The use of xenograft models for the selection of cancer treatments with the EGFR as an example. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 65, 200-11	7	50
1299	New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 67, 103-12	7	58
1298	The biological properties of cetuximab. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 68, 93-106	7	96
1297	Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases. 2008 , 18, 3495-9		44
1296	Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2. 2008 , 32, 814-26		17
1295	4-Amino-6-aryl-amino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors. 2008 , 18, 4615-9		55
1294	Novel human antibody therapeutics: the age of the Umabs. 2008 , 3, 1157-71		38
1293	Establishment and characterization of a cell line (IGSK-3) secreting human chorionic gonadotropin, adrenocorticotrophic hormone and parathyroid hormone-related protein derived from primary poorly differentiated adenocarcinoma of the stomach. 2008 , 21, 88-94		1

1292	Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. 2008 , 27, 339-46	108
1291	Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. 2008 , 99, 214-20	174
1290	Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer. 2008 , 99, 2455-60	29
1289	The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer. 2008 , 314, 1881-91	11
1288	The status and role of ErbB receptors in human cancer. 2008 , 84, 79-89	68
1287	A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. 2008 , 110, 140-5	72
1286	Epidermal growth factor receptor structural alterations in gastric cancer. 2008 , 8, 10	40
1285	Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. 2008 , 8, 337	47
1284	Dissecting lipid raft facilitated cell signaling pathways in cancer. 2008 , 1785, 182-206	146
1283	Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. 2008 , 1785, 232-65	113
1282	Gain of the EGFR gene located on 7p12 is a frequent and early event in squamous cell carcinoma of the lung. 2008 , 184, 31-7	13
1281	No association between epidermal growth factor and epidermal growth factor receptor polymorphisms and nasopharyngeal carcinoma. 2008 , 185, 69-73	15
1280	Bioinformatics approach to mRNA markers discovery for detection of circulating tumor cells in patients with gastrointestinal cancer. 2008 , 32, 236-50	26
1279	ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. 2008 , 20, 2145-55	71
1278	Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. 2008 , 81, 344-53	25
1277	Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice. 2008 , 228, 315-25	26
1276	Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. 2008 , 93, 2057-62	122
1275	Mutational status of EGFR and KIT in thymoma and thymic carcinoma. 2008 , 62, 316-20	82

1274	Locally advanced and metastatic gastric cancer: current management and new treatment developments. 2008 , 68, 299-317	31
1273	Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. 2008 , 7, 33-43	46
1272	Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation. 2008 , 7, 48-54	37
1271	First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents. 2008 , 7 Suppl 2, S47-51	5
1270	NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols. 2008 , 6, 9	40
1269	Dendrimer-epidermal growth factor conjugate displays superagonist activity. 2008 , 9, 603-9	79
1268	Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. 2008 , 2, 167-78	39
1267	Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. 2008 , 10, R80	103
1266	Ovarian Cancer. 2008 ,	2
1265	EGFR Signaling Networks in Cancer Therapy. 2008 ,	7
1264	Targeted Radionuclide Tumor Therapy. 2008 ,	9
1263	Molecular Biomethods Handbook. 2008 ,	10
1262	Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy. 2008 ,	2
1261	Targeted Cancer Therapy. 2008 ,	6
1260	Genetic susceptibility of epidermal growth factor +61A>G and transforming growth factor beta1 -509C>T gene polymorphisms with gallbladder cancer. 2008 , 69, 360-7	36
1259	Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. 2008 , 376, 1388-402	118
1258	Clinical utility of type 1 growth factor receptor expression in colon cancer. 2008 , 195, 604-10	16
1257	Anti-EGFR activation, anti-proliferative and pro-apoptotic effects of polyclonal antibodies induced by EGFR-based cancer vaccine. 2008 , 26, 4918-26	16

1256	EGFR antagonists in cancer treatment. 2008 , 358, 1160-74	1570
1255	Reactive oxygen species in tumor metastasis. 2008 , 266, 53-9	276
1254	Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. 2008 , 44, 419-26	32
1253	Validation of HB-EGF and amphiregulin as targets for human cancer therapy. 2008 , 365, 555-61	102
1252	Molecular-targeted therapies: lessons from years of clinical development. 2008 , 34, 61-80	41
1251	Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. 2008 , 34, 103-21	50
1250	Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. 2008 , 60 Suppl 2, S10-8	16
1249	Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. <i>Clinical Cancer Research</i> , 2008 , 14, 731-41 ^{12.9}	160
1248	Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor. 2008 , 20, 217-23	9
1247	Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?. 2008 , 180, 1146-53	4
1246	Targeted therapy for solid tumors: current status. 2008 , 17, 279-301, vii-viii	10
1245	The tyrphostin B42 inhibits cell proliferation and HER-2 autophosphorylation in cervical carcinoma cell lines. 2008 , 26, 136-44	7
1244	Implications of EGFR PharmDx kit for cetuximab eligibility. 2008 , 8, 141-8	15
1243	Anti-epidermal growth factor receptor strategies for advanced breast cancer. 2008 , 26, 757-68	7
1242	Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. 2008 , 23, 619-31	60
1241	Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. 2008 , 29, 217-33	396
1240	Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. 2008 , 13, 1166-76	39
1239	New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. 2008 , 13, 289-98	73

1238	Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?. 2008 , 13, 933-44		35
1237	RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. 2008 , 68, 4183-91		76
1236	A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 4484-90	12.9	60
1235	Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 590-8	6.1	30
1234	EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. 2008 , 19, 310-20		55
1233	Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 972-9	6.1	21
1232	Differential sensitivity of A549 non-small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors. 2008 , 7, 557-68		23
1231	Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. 2008 , 3, 258-64		48
1230	Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). 2008 , 31, 237-41		7
1229	Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial. 2008 , 74, 223-8		19
1228	Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?. 2008 , 23, 383-97		6
1227	EGF receptor variant III as a target antigen for tumor immunotherapy. 2008 , 7, 977-85		57
1226	Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract. 2008 , 13, 39-50		26
1225	Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development. 2008 , 98, 900-6		20
1224	Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. <i>Clinical Cancer Research</i> , 2008 , 14, 4943-50	12.9	55
1223	Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. 2008 , 29, 1448-58		55
1222	Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 3632-41	6.1	34
1221	Correlating EGFR expression with receptor-binding properties and internalization of ⁶⁴ Cu-DOTA-cetuximab in 5 cervical cancer cell lines. 2008 , 49, 1472-9		81

1220	EGFR-targeting agents in oncology. 2008 , 18, 889-901		16
1219	Principles of Molecular Oncology. 2008 ,		1
1218	Epidermal growth factor receptor-targeted therapy. 2008 , 81 Spec No 1, S36-44		21
1217	Modeling cancer progression via pathway dependencies. 2008 , 4, e28		54
1216	The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. 2008 , 9, 252-62		16
1215	Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2008 , 14, 502-8	12.9	101
1214	Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. <i>Clinical Cancer Research</i> , 2008 , 14, 4326-35	12.9	26
1213	Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. <i>Clinical Cancer Research</i> , 2008 , 14, 840-6	12.9	85
1212	Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. 2008 , 68, 7083-9		83
1211	Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. 2008 , 13 Suppl 1, 1-4		18
1210	Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. 2008 , 283, 1156-66		67
1209	Overview of gefitinib in non-small cell lung cancer: an Asian perspective. 2009 , 39, 137-50		50
1208	Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. <i>Clinical Cancer Research</i> , 2008 , 14, 2543-50	12.9	62
1207	Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3. 2008 , 82, 5486-93		64
1206	Polyethylene glycol-mediated colorectal cancer chemoprevention: roles of epidermal growth factor receptor and Snail. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 3103-11	6.1	21
1205	Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. 2008 , 74, 793-806		46
1204	Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. 2008 , 74, 807-22		51
1203	Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. <i>Clinical Cancer Research</i> , 2008 , 14, 7884-95	12.9	102

1202	NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. 2008 , 7, 81-8	45
1201	Targeting important pathways in head and neck cancer: from the bench to the clinic. 2008 , 8, 1819-35	0
1200	The potential role of mTOR inhibitors in non-small cell lung cancer. 2008 , 13, 139-47	98
1199	Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. 2008 , 3, 1446-53	86
1198	EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor fate. 2008 , 410, 585-94	51
1197	Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. 2008 , 3, 664-73	31
1196	Expression and clinical significance of epidermal growth factor receptor and type 1 insulin-like growth factor receptor in nasopharyngeal carcinoma. 2008 , 117, 192-200	27
1195	Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: analysis of its long-term prognostic value. 2008 , 4, 83-91	11
1194	Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer. 2008 ,	5
1193	Cetuximab: its use in combination with radiation therapy and chemo-therapy in the multimodality treatment of head and neck cancer. 2008 , 3, 76-83	6
1192	Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. 2008 , 14, 2983-98	68
1191	Medical Management of Colorectal Liver Metastasis. 222-242	1
1190	New directions in the management of advanced pancreatic cancer: a review. 2008 , 19, 435-46	32
1189	Advances in the Treatment of Metastatic Non-Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. 2008 , 15, 352-358	
1188	Expression of epiregulin, a novel epidermal growth factor ligand associated with prognosis in human oral squamous cell carcinomas. 2008 ,	1
1187	Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. 2008 , 5, 209-17	57
1186	Tumor-associated EGFR over-expression specifically activates Stat3 and Smad7 resulting in desensitization of TGF- β signaling. 2008 ,	1
1185	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. 2009 , 215	

1184	Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. 2009 , 16, 16-26	101
1183	Expression of the Epidermal Growth Factor Receptor Family in Correlation to the Estrogen Receptor Expression in Peritoneal and Ovarian Endometriosis. 2009 , 1, 122-130	
1182	Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. 2009 , 2009, 567486	85
1181	Association study of an epidermal growth factor gene functional polymorphism with the risk and prognosis of gliomas in Brazil. 2009 , 24, 277-281	9
1180	EGFR genomic alterations in cancer: prognostic and predictive values. 2009 , E3, 879	3
1179	Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. 2009 , 14, 601-11	29
1178	Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. 2009 , 27, 3908-15	131
1177	Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. 2009 , 18, 1735-51	52
1176	Erlotinib: applications in therapy and current status of research. 2009 , 2, 15-36	1
1175	Epidermal growth factor-activated aryl hydrocarbon receptor nuclear translocator/HIF-1{beta} signal pathway up-regulates cyclooxygenase-2 gene expression associated with squamous cell carcinoma. 2009 , 284, 9908-16	22
1174	Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. 2009 , 14, 399-411	76
1173	Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells. 2009 , 150, 14-23	126
1172	Mig-6 is required for appropriate lung development and to ensure normal adult lung homeostasis. 2009 , 136, 3347-56	31
1171	Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?. <i>Molecular Cancer Research</i> , 2009 , 7, 1000-12	6.6 93
1170	Renal Cell Carcinoma. 2009 ,	3
1169	Role of Src family kinases in acquired resistance to EGFR therapies in cancer. 2009 , 8, 704-6	9
1168	Epidermal growth factor-induced GnRH-II synthesis contributes to ovarian cancer cell invasion. 2009 , 23, 1646-56	14
1167	Novel investigational drugs for gastric cancer. 2009 , 18, 945-55	15

1166	Novel Preparation of gefitinib. 2009 , 2009, 388-390		1
1165	New Agents [Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing. 2009 , 5, 1-19		
1164	A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. <i>Clinical Cancer Research</i> , 2009 , 15, 6702-8	12.9	74
1163	PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. 2009 , 50, 1116-23		93
1162	Epidermal growth factor receptor is involved in enterocyte anoikis through the dismantling of E-cadherin-mediated junctions. 2009 , 296, G235-44		34
1161	The development, optimization and validation of an ELISA bioanalytical method for the determination of Cetuximab in human serum. 2009 , 1, 144-148		8
1160	Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells. <i>Molecular Cancer Research</i> , 2009 , 7, 1378-89	6.6	42
1159	Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. 2009 , 69, 1383-91		120
1158	Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer. 2009 , 5, 272-6		11
1157	Acetylcholine-induced activation of M3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells. 2009 , 296, G755-63		56
1156	Gene expression profiling of ErbB receptors and ligands in human meningiomas. 2009 , 27, 691-8		16
1155	Ovarian cancer and genetic susceptibility: association of A61G polymorphism in the EGF gene. 2009 , 234, 241-5		19
1154	An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. 2009 , 69, 7811-8		29
1153	Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen. <i>Molecular Cancer Research</i> , 2009 , 7, 809-20	6.6	29
1152	Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. 2009 , 20, 213-26		31
1151	Transient receptor potential type vanilloid 1 suppresses skin carcinogenesis. 2009 , 69, 905-13		78
1150	Target-based therapies in breast cancer: current status and future perspectives. 2009 , 16, 675-702		47
1149	Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 1885-92	6.1	48

1148	Erlotinib and bevacizumab have synergistic activity against melanoma. <i>Clinical Cancer Research</i> , 2009 , 15, 3495-502	12.9	62
1147	Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. 2009 , 9, 119		93
1146	Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. 2009 , 9, 237		59
1145	HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. 2009 , 9, 433		141
1144	Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature. 2009 , 29, 858-66		10
1143	Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation. 2009 , 315, 2658-72		23
1142	Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. 2009 , 113, 384-90		28
1141	Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. 2009 , 31 Pt 2, 2332-48		79
1140	EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts. 2009 , 625, 23-30		24
1139	Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women. 2009 , 36, 572-80		41
1138	Dendritic cells pulsed with GST-EGFR fusion protein: effect in antitumor immunity against head and neck squamous cell carcinoma. 2010 , 32, 626-35		4
1137	A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. 2009 , 124, 2589-96		42
1136	Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers. 2009 , 125, 2029-35		35
1135	EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. 2009 , 125, 2479-82		83
1134	Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. 2009 , 106, 1113-22		90
1133	Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. 2009 , 108, 1356-63		18
1132	Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. 2009 , 135, 467-76		9
1131	EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. 2009 , 135, 771-82		34

1130	Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. 2009 , 135, 1377-86		21
1129	A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). 2009 , 92, 99-105		144
1128	Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2009 , 11, 737-747	3.6	7
1127	Strahlenbiologie: Hypofraktionierung und kombinierte Therapien. 2009 , 42, 434-440		
1126	Do tumor cavitation and sex in resected stage I non-small-cell lung cancer correlate with prognosis?. 2009 , 33, 497-504		9
1125	The EGF receptor-sox2-EGF receptor feedback loop positively regulates the self-renewal of neural precursor cells. 2010 , 28, 279-86		65
1124	Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands. 2009 , 100, 654-62		26
1123	Genetic prognostic and predictive markers in colorectal cancer. 2009 , 9, 489-99		517
1122	Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. 2009 , 28 Suppl 1, S32-7		202
1121	The emerging role of the RAB25 small GTPase in cancer. 2009 , 10, 1561-8		68
1120	Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer. 2009 , 10, 247-57		14
1119	Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. 2009 , 157, 1541-8		26
1118	Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. 2009 , 158, 610-20		75
1117	Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors. 2009 , 19, 817-20		67
1116	Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. 2009 , 2, ra31		291
1115	Pharmacogenomics and -genetics in colorectal cancer. 2009 , 61, 375-80		14
1114	The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells. 2009 , 70, 116-28		4
1113	HER-family gene amplification and expression in resected pancreatic cancer. 2009 , 35, 1098-104		21

1112	Heregulin-beta1 promotes metastasis of breast cancer cell line SKBR3 through upregulation of Snail and induction of epithelial-mesenchymal transition. 2009 , 280, 50-60	16
1111	The roles of phospholipase D in EGFR signaling. 2009 , 1791, 862-8	41
1110	Epidermal growth factor genetic variation, breast cancer risk, and waiting time to onset of disease. 2009 , 28, 265-9	18
1109	Ligand-based targeted therapy for cancer tissue. 2009 , 6, 285-304	154
1108	Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer. 2009 , 64, 121-3	3
1107	The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells. 2009 , 65, 290-8	9
1106	Impact of EGFR immunoexpression on STAT3 activation and association with proinflammatory/regulatory cytokine pattern in laryngeal squamous cell carcinoma. 2009 ,	
1105	Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR. 2009 , 2, 24	20
1104	Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. 2009 , 2, 45	177
1103	Targeting the EGF receptor ectodomain in the context of cancer. 2009 , 13, 1347-61	1
1102	Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. 2009 , 23, 1396-404	107
1101	A pan-HER approach for cancer therapy: background, current status and future development. 2009 , 9, 97-110	37
1100	Receptor tyrosine kinase signaling: a view from quantitative proteomics. 2009 , 5, 1112-21	54
1099	Breast Cancer in the Post-Genomic Era. 2009 ,	3
1098	Targeting Transduction Pathways for Research and Medical Intervention. 2009 , 735-761	
1097	Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. 2009 , 14, 909-20	33
1096	Curcumin synergizes with resveratrol to inhibit colon cancer. 2009 , 61, 544-53	137
1095	EGFR signaling and drug discovery. 2009 , 77, 400-10	324

1094	Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. 2009 , 2, 321-8	184
1093	Enediye lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells. 2009 , 20, 41-9	6
1092	Editorial. 2009 , 20 Spec No 1, S1-3	86
1091	NonSmall Cell Lung Carcinoma. 2009 , 14, 199-205	2
1090	Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. 2009 , 4, 684-8	59
1089	Determination of EGFR status in gliomas: usefulness of immunohistochemistry and fluorescent in situ hybridization. 2009 , 17, 220-6	16
1088	Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. 2009 , 20, 856-66	43
1087	Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findings. 2009 , 21, 289-93	9
1086	EGFR(s) in aging and carcinogenesis of the gastrointestinal tract. 2010 , 11, 436-50	9
1085	Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. 2010 , 11, 851-64	40
1084	KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. 2010 , 36, 1137-44	11
1083	Detection of HER-2 and EGFR gene amplification using chromogenic in-situ hybridization technique in ovarian tumors. 2010 , 18, 69-74	7
1082	Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. 2010 , 251, 857-64	32
1081	Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways. 2010 , 10, 626-39	14
1080	Association between +61G polymorphism of the EGF gene and glioma risk in different ethnicities: a meta-analysis. 2010 , 222, 229-35	13
1079	Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model. 2010 , 37, 767-72	3
1078	Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. 2010 , 36, 757-63	25
1077	Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?. 2010 , 8, 822-32	31

1076	Synergistic anti-neoplastic effect of AG1478 in combination with cisplatin or paclitaxel on human endometrial and ovarian cancer cells. 2010 , 3, 479-84		6
1075	Molekulardiagnostik des Lungenkarzinoms zur Therapiestratifizierung. 2010 , 3, 87-93		
1074	Involvement of Lipid Rafts in Growth Factor Receptors-Mediated Signaling for Cancer Metastasis. 2010 , 209-224		
1073	Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. 2010 , 59, 47-62		42
1072	[Molecular diagnostics in lung carcinoma for therapy stratification]. 2010 , 31, 22-8		3
1071	Involvement of aryl hydrocarbon receptor nuclear translocator in EGF-induced c-Jun/Sp1-mediated gene expression. 2010 , 67, 3523-33		9
1070	[Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects]. 2010 , 61, 654-61		9
1069	Temperature-induced unfolding of epidermal growth factor (EGF): insight from molecular dynamics simulation. 2010 , 29, 2-12		20
1068	Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations. 2010 , 25, 713-21		22
1067	In silico QSAR studies of anilinoquinolines as EGFR inhibitors. <i>Journal of Molecular Modeling</i> , 2010 , 16, 263-77	2	17
1066	Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues. 2010 , 136, 587-94		16
1065	EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. 2010 , 5, 245-55		50
1064	Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. 2010 , 27, 91-7		15
1063	Association between EGF promoter polymorphisms and cancer risk: a meta-analysis. 2010 , 27, 1389-97		20
1062	Biomarkers in bronchopulmonary cancer. <i>Clinical and Translational Oncology</i> , 2010 , 12, 92-9	3.6	3
1061	Evolving treatment of advanced colorectal cancer. 2010 , 12, 153-9		14
1060	Overexpression and activation of epidermal growth factor receptor in hemangioblastomas. 2010 , 99, 195-200		13
1059	Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. 2010 , 12, 616-25		16

1058	In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels. 2010 , 27, 2343-55	106
1057	Association between epidermal growth factor polymorphism and esophageal squamous cell carcinoma susceptibility. 2010 , 55, 40-5	11
1056	The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. 2010 , 10, 255	103
1055	Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. 2010 , 10, 376	48
1054	Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. 2010 , 10, 631	128
1053	Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol. 2010 , 10, 651	6
1052	Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. 2010 , 80, 613-23	69
1051	Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). 2010 , 116, 157-62	43
1050	A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). 2010 , 118, 308-12	50
1049	Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. 2010 , 14, 51-69	110
1048	Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy. 2010 , 14, 805-17	2
1047	Cell type-dependent biomarker expression in adenoid cystic carcinoma: biologic and therapeutic implications. 2010 , 116, 5749-56	47
1046	Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. 2010 , 127, 1931-40	24
1045	Promising tumor-associated antigens for future prostate cancer therapy. 2010 , 30, 67-101	23
1044	A combined A431 cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening compounds from total alkaloid of Radix Caulophylli acting on the human EGFR. 2010 , 878, 2712-8	37
1043	Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery. 2010 , 22, 272-80	38
1042	Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation. 2010 , 18, 6634-45	44
1041	Genetic polymorphism of epidermal growth factor 61A>G and cancer risk: a meta-analysis. 2010 , 34, 150-6	33

1040	Integration of panitumumab into the treatment of colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 74, 16-26	7	20
1039	Human TGFalpha-derived peptide TGFalphaL3 fused with superantigen for immunotherapy of EGFR-expressing tumours. 2010 , 10, 91		13
1038	Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. 2010 , 5, 46		27
1037	Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. 2010 , 101, 167-72		56
1036	RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. 2010 , 17, 352-9		35
1035	MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo. 2010 , 17, 409-19		25
1034	Targeting non-malignant disorders with tyrosine kinase inhibitors. 2010 , 9, 956-70		102
1033	Development of an ErbB-overexpressing A-431 optical reporting tumor xenograft model to assess targeted photodynamic therapy regimens. 2010 , 86, 1379-89		2
1032	Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. 2010 , 17 Suppl 1, S18-30		60
1031	EGFR overexpression in squamous cell carcinoma of the penis. 2010 , 17, 4-6		27
1030	PRINCIPLES OF ADJUVANT THERAPY IN CHILDHOOD CANCER. 2010 , 837-852		
1029	EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment. 2010 , 3, 2238-2247		27
1028	Molecular Oncogenesis of Prostate Adenocarcinoma: Role of the Human Epidermal Growth Factor Receptor 2 (HER-2/neu). 2010 , 96, 645-649		16
1027	Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2011 , 2, 1-9	2.9	1
1026	Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer. 2010 , 2, 143-56		19
1025	Drug resistance in lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2010 , 23	2.9	5
1024	Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. 2010 , 333, 373-81		29
1023	Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 3378-89	12.9	77

1022	Mechanisms of Oncogenesis. 2010 ,		3
1021	ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 1503-14	6.1	15
1020	Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation. <i>Clinical Cancer Research</i> , 2010 , 16, 2709-14	12.9	27
1019	Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2010 , 16, 2095-105	12.9	81
1018	The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. 2010 , 19, 186-96		28
1017	Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. 2010 , 28, 1351-7		347
1016	The Scientific Basis of Urology. 2010 ,		9
1015	Sulindac metabolites induce proteosomal and lysosomal degradation of the epidermal growth factor receptor. 2010 , 3, 560-72		9
1014	Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin. 2010 , 56, 268-74		4
1013	ETS-1 oncogenic activity mediated by transforming growth factor alpha. 2010 , 70, 730-40		17
1012	Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. 2010 , 285, 24775-82		98
1011	Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. 2010 , 28, 3330-5		99
1010	Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. 2010 , 15, 216-35		39
1009	Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. 2010 , 28, 911-7		368
1008	New and potential clinical applications of KRAS as a cancer biomarker. 2010 , 4, 383-95		5
1007	Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. 2010 , 38, 9-21		39
1006	Colorectal cancer in review: the role of the EGFR pathway. 2010 , 19, 357-69		42
1005	A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2010 , 16, 1915-23	12.9	64

1004	Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. <i>Clinical Cancer Research</i> , 2010 , 16, 4990-5001	12.9	70
1003	Association between epidermal growth factor +61 G/A polymorphism and glioma risk in a Chinese Han population. 2010 , 38, 1645-52		8
1002	Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. 2010 , 15, 1002-8		28
1001	Epidermal growth factor increases lysophosphatidic acid production in human ovarian cancer cells: roles for phospholipase D2 and receptor transactivation. 2010 , 298, C163-70		32
1000	Biomarkers for ovarian cancer detection and therapy. 2010 , 9, 668-77		28
999	Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer. 2010 , 5, 142-51		2
998	Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes. 2010 , 1, 125-41		20
997	Target cell-restricted apoptosis induction by 528scFv-TRAIL fusion protein specific for human EGFR and expressed in Escherichia coli. 2010 , 36, 1229-34		1
996	[Cutaneous side effects of EGFR inhibitors--appearance and management]. 2010 , 135, 149-54		24
995	p21-activated kinases in Erbb2-positive breast cancer: A new therapeutic target?. 2010 , 1, 124-128		22
994	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. 2010 , 11, 2363-89		18
993	Microglia and central nervous system immunity. 2010 , 21, 43-51		42
992	The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas. 2010 , 21, 87-93		24
991	Emerging profile of cetuximab in non-small cell lung cancer. 2010 , 68, 332-7		10
990	Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer. 2010 , 69, 259-64		16
989	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?. 2010 , 7, 401-14		205
988	Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated. 2010 , 9, 222		33
987	Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. 2010 , 49, 729-40		53

986	In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. 2010 , 138, 435-46	176
985	Fluorescence lifetime cross correlation spectroscopy resolves EGFR and antagonist interaction in live cells. 2010 , 82, 6415-21	51
984	A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. 2010 , 41, 94-102	71
983	The molecular therapy of colorectal cancer. 2010 , 31, 171-8	42
982	Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. 2010 , 36, 492-500	153
981	Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. 2010 , 46, 901-11	45
980	A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors. 2010 , 8, 202-8	7
979	Adenocarcinoma of the Esophagogastric Junction. 2010 ,	3
978	Ovarian Cancer. 2010 ,	1
977	Nanotechnology for early cancer detection. 2010 , 10, 428-55	212
976	The role of estrogen receptors, erbB receptors, vascular endothelial growth factor and its receptors, and vascular endothelial growth inhibitor in the development of the rat mammary gland. 2010 , 28, 379-93	8
975	Epidermal growth factor induces cell death in the absence of overexpressed epidermal growth factor receptor and ErbB2 in various human cancer cell lines. 2010 , 28, 505-14	13
974	Epidermal growth factor receptor signaling in nonsmall cell lung cancer. 2010 , 28, 515-25	15
973	First-line treatment of advanced ovarian cancer: current research and perspectives. 2010 , 10, 47-60	67
972	Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. 2010 , 335, 830-40	55
971	Cetuximab in the treatment of patients with colorectal cancer. 2011 , 11, 937-49	38
970	Non-small-cell lung carcinoma vaccines in clinical trials. 2011 , 10, 887-97	5
969	Prognostic biomarkers in ovarian cancer. 2010 , 8, 231-51	25

968	Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. 2011 , 4, 65-75	92
967	ARAP1 association with CIN85 affects epidermal growth factor receptor endocytic trafficking. 2011 , 103, 171-84	13
966	Treatment of non-small-cell lung cancer with erlotinib or gefitinib. 2011 , 364, 947-55	309
965	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. 2011 , 71, 249-57	92
964	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. 2011 , 72, 3-8	35
963	HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. 2011 , 1, 472-4	27
962	Resveratrol modulates MED28 (Magacin/EG-1) expression and inhibits epidermal growth factor (EGF)-induced migration in MDA-MB-231 human breast cancer cells. 2011 , 59, 11853-61	35
961	Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. 2011 , 5, 9480-93	115
960	Liposomal nanomedicine for breast cancer therapy. 2011 , 6, 1085-100	42
959	Design and Synthesis of Drug Conjugates of Vitamins and Growth Factors. 2011 , 1283-1322	
958	Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). 2011 , 38, 1197-217	45
957	Systemic Therapy for Colon Cancer. 2011 , 167-183	
956	Clinical development of 2NME-based oncology treatment regimens. 2011 , 32, 856-63	
955	Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. 2011 , 37, 533-42	28
954	[Targeted therapies and radiation therapy in non-small cell lung cancer]. 2011 , 15, 527-35	4
953	A novel hybrid peptide targeting EGFR-expressing cancers. 2011 , 47, 773-83	59
952	Co-expression of erythropoietin receptor with human epidermal growth factor 2 may counteract trastuzumab inhibition in gastric cancer. 2011 , 77, 948-52	1
951	Drug eruptions in dermatology. 2011 , 6, 273-286	8

950	Reactivation of Epithelial-Mesenchymal Transition in Invasive and Metastatic Cancer. 2011 , 13-69	0
949	Selective growth inhibition of human breast cancer cells by graviola fruit extract in vitro and in vivo involving downregulation of EGFR expression. 2011 , 63, 795-801	59
948	Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. 2011 , 99, 323-30	66
947	Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer. 2011 , 101, 152-7	6
946	A mathematical model for the effects of HER2 over-expression on cell cycle progression in breast cancer. 2011 , 73, 2865-87	4
945	Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy. 2011 , 16, 1714-32	5
944	Intraoperative imaging in ovarian cancer: fact or fiction?. 2011 , 10, 248-57	15
943	Molecular imaging metrics to evaluate response to preclinical therapeutic regimens. 2011 , 16, 393-410	2
942	Successful treatment of epidermal growth factor receptor inhibitor-induced periungual inflammation with adapalene. 2011 , 3, 130-6	10
941	EGFR pathway in advanced non-small cell lung cancer. 2011 , 3, 501-17	14
940	Effects of Growth Hormone (GH) Overexpression in Signaling Cascades Involved in Promotion of Cell Proliferation and Survival. 2011 ,	
939	The Molecular Basis of Resistance to the Antiproliferative Effect of EGFR Inhibition in Human Glioblastoma Multiforme Cell Lines. 2011 ,	
938	Basic cancer biology and immunology. 35-48	
937	Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma. 2011 , 7, 65-77	2
936	EGFR genomic alterations in cancer: prognostic and predictive values. 2011 , 3, 879-87	23
935	Epidermal Growth Factor Receptor (EGFR) Phosphorylation, Signaling and Trafficking in Prostate Cancer. 2011 ,	4
934	Signal Transduction Pathways in Breast Cancer [Drug Targets and Challenges. 2011 ,	
933	Irreversible EGFR inhibitor EKB-569 targets low-LET [radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma. 2011 , 6, e29705	13

932	In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody. 2011 , 26, 949-55	13
931	Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy. 2011 , 34, 395-400	20
930	Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy. 2011 , 23, 24-30	25
929	Clinicopathologic implications of the epidermal growth factor receptor, cyclooxygenase 2 expression, and human papillomavirus status in squamous cell carcinoma of the uterine cervix in the elderly. 2011 , 21, 337-48	5
928	NO donor and MEK inhibitor synergistically inhibit proliferation and invasion of cancer cells. 2012 , 40, 807-15	8
927	Molecular detection of epidermal growth factor receptor in colorectal cancer: does it still make sense?. 2011 , 13, 542-8	3
926	Rab5A is associated with axillary lymph node metastasis in breast cancer patients. 2011 , 102, 2172-8	45
925	Epidermal growth factor receptor as a therapeutic target in veterinary oncology. 2011 , 9, 81-94	13
924	Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. 2011 , 9, 195-203	18
923	Mammalian EGF receptor activation by the rhomboid protease RHBDL2. 2011 , 12, 421-7	89
922	Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand. 2011 , 15, 2525-38	16
921	Positron emission tomography imaging of cancer biology: current status and future prospects. 2011 , 38, 70-86	81
920	Biomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment. 2011 , 12, 360-8	22
919	Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer. 2011 , 12, 350-9	14
918	Combinational RNAi gene therapy of hepatocellular carcinoma by targeting human EGFR and TERT. 2011 , 42, 387-91	11
917	The multiple roles of amphiregulin in human cancer. 2011 , 1816, 119-31	118
916	Anti-tumor effects of B-2, a novel 2,3-disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazoline derivative, on the human lung adenocarcinoma A549 cell line in vitro and in vivo. 2011 , 189, 90-9	15
915	Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. 2011 , 20, 158-72	128

914	The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma. 2011 , 41, 818-23	4
913	EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy. 2011 , 18, 2952-60	43
912	Molecular imaging of epidermal growth factor receptor kinase activity. 2011 , 417, 57-64	11
911	A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. 2011 , 29, 167-74	28
910	Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression. 2011 , 101, 199-206	22
909	Helianthin induces antiproliferative effect on human glioblastoma cells in vitro. 2011 , 102, 9-18	5
908	The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells. 2011 , 102, 353-66	28
907	A monoclonal antibody targeted against epidermal growth factor receptor variant III enhances cisplatin efficiency. 2011 , 137, 1455-61	1
906	Pathophysiologie und Molekulardiagnostik beim nichtkleinzelligen Lungenkarzinom. 2011 , 17, 670-678	
905	[Molecular diagnostics of lung cancer for treatment stratification]. 2011 , 52, 146, 148-50, 152-4	3
904	[New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin]. 2011 , 52, 1359-64	6
903	Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). 2011 , 67, 579-86	14
902	Label free gravimetric detection of epidermal growth factor receptor by antibody immobilization on quartz crystal microbalance. 2011 , 46, 543-550	30
901	Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. 2011 , 28, 1048-53	12
900	Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. 2011 , 6, 171-80	9
899	EGFR inhibitor enhances cisplatin sensitivity of human glioma cells. 2011 , 31, 773-778	10
898	Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells. 2011 , 15, 942-57	20
897	BEYOND KRAS: Other markers and potential treatment strategies for KRAS mutant and wild-type patients. 2011 , 12, 126-35	2

896	Effects of n-3 PUFAs on breast cancer cells through their incorporation in plasma membrane. 2011 , 10, 73	83
895	Addressing brain tumors with targeted gold nanoparticles: a new gold standard for hydrophobic drug delivery?. 2011 , 7, 2301-6	93
894	Chrysophanic acid blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway. 2011 , 25, 833-7	40
893	Labeling approaches for the GE11 peptide, an epidermal growth factor receptor biomarker. 2011 , 54, 693-701	18
892	Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. 2011 , 100, 3731-50	91
891	Knock-down of amphiregulin inhibits cellular invasion in inflammatory breast cancer. 2011 , 226, 2691-701	28
890	Genetic modeling of gliomas in mice: new tools to tackle old problems. 2011 , 59, 1155-68	79
889	New Synthetic Route of Two Active Isomeric Metabolites of Erlotinib and Their Bioactivity Studies against Several Tumor Cell Lines. 2011 , 29, 1709-1714	0
888	Discovery of 4-benzylamino-substituted β -arbolines as a novel class of receptor tyrosine kinase inhibitors. 2011 , 6, 63-72	11
887	Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells. 2011 , 117, 2408-18	19
886	Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. 2011 , 128, 951-61	83
885	Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases. 2011 , 21, 781-5	18
884	Synthesis of nanocarriers with remote magnetic drug release control and enhanced drug delivery for intracellular targeting of cancer cells. 2011 , 7, 2873-82	22
883	Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells. 2011 , 7, 454-63	60
882	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer. 2011 , 12, 922-33	24
881	Development of targeted therapy for squamous cell carcinomas of the head and neck. 2011 , 11, 373-86	9
880	Chemotherapy for non-small-cell lung carcinoma: from a blanket approach to individual therapy. 2011 , 32, 78-93	8
879	Häufige Haut-Nebenwirkungen von neuen onkologischen Medikamenten. 2011 , 37, 451-457	1

878	Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases. 2011 , 436, 241-51		26
877	How do cyclin D1, EGFR, and COX-2 attribute to colorectal carcinoma prognosis? An immunohistochemical study on tissue microarray. 2011 , 31, 6-12		1
876	The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model. 2011 , 16, 10556-69		40
875	Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. 2011 , 29, 3419-26		299
874	Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. <i>Clinical Cancer Research</i> , 2011 , 17, 5901-12	12.9	32
873	Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. 2011 , 2011, 352182		68
872	EGF and TGF- β Effects on Thyroid Function. 2011 , 2011, 431718		18
871	Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. 2011 , 11, 50-7		40
870	Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells. 2011 , 301, G347-55		24
869	Deregulated expression of sprouty2 and microRNA-21 in human colon cancer: Correlation with the clinical stage of the disease. 2011 , 11, 111-21		59
868	An in vitro chemoresponse assay defines a subset of colorectal and lung carcinomas responsive to cetuximab. 2011 , 11, 196-203		3
867	Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. 2011 , 3, 67-75		10
866	A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. 2011 , 3, 38-48		58
865	Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. 2011 , 48, 47-54		22
864	The role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer. <i>Cancers</i> , 2011 , 3, 2667-78	6.6	5
863	Targeted Therapy and Molecular Genetics. 2012 , 539-560.e6		1
862	Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. <i>International Journal of Molecular Sciences</i> , 2012 , 13, 12268-86	6.3	33
861	The role of molecular pathology in non-small-cell lung carcinoma-now and in the future. 2012 , 19, S24-32		25

860	A phase I/II trial of vandetanib for patients with recurrent malignant glioma. 2012 , 14, 1519-26		66
859	Supportive care treatments for toxicities of anti-egfr and other targeted agents. 2012 , 19, S59-63		30
858	MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012 , 13, 255-60	1.7	95
857	Epidermal growth factor genetic variation associated with advanced cervical cancer in younger women. 2012 , 35, 247-50		7
856	Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1467-76	6.1	45
855	Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapy. 2012 , 12, 788-803		4
854	Emerging role of cetuximab in the treatment of colorectal cancer. 2012 , 7, 233-47		8
853	A functional polymorphism in the epidermal growth factor gene is associated with risk for glioma in a Chinese population. 2012 , 16, 449-52		9
852	Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. 2012 , 106, 666-72		28
851	Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. 2012 , 106, 883-8		7
850	A human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 594-603	6.1	28
849	Microbubble therapy enhances anti-tumor properties of cisplatin and cetuximab in vitro and in vivo. 2012 , 146, 938-45		56
848	Mechanisms of resistance to endocrine therapies for breast cancer. 2012 , 9, 165-71		
847	Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab. 2012 , 5, 674-89		12
846	The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer. 2012 , 6, 137-47		3
845	Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. 2012 , 5, 439-47		31
844	Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor. 2012 , 225, 135-40		17
843	Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer. 2012 , 7, e48532		32

842	Obatoclox and lapatinib interact to induce toxic autophagy through NOXA. 2012 , 81, 527-40	50
841	The role of molecular diagnostics in cancer diagnosis and treatment. 2012 , 35 Suppl 1, 8-12	6
840	Grb2, a double-edged sword of receptor tyrosine kinase signaling. 2012 , 5, pe49	51
839	Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. 2012 , 7, 272-80	35
838	The pattern of epidermal growth factor receptor variation with disease progression and aggressiveness in colorectal cancer depends on tumor location. 2012 , 3, 1129-1135	14
837	Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment. 2012 , 7, 3-13	
836	Effects of curcumin on global gene expression profiles in the highly invasive human breast carcinoma cell line MDA-MB 231: A gene network-based microarray analysis. 2013 , 5, 23-27	13
835	A pilot characterization of human lung NSCLC by protein pathway activation mapping. 2012 , 7, 1755-1766	19
834	Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. 2012 , 41, 1128-38	43
833	Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors. 2012 , 22, 5870-5	30
832	Morphologic and molecular analysis of 39 spontaneous feline pulmonary carcinomas. 2012 , 49, 971-8	33
831	Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies. 2012 , 8, 273-92	32
830	Molecular markers for cancer prognosis and treatment: have we struck gold?. 2012 , 327, 142-52	31
829	Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. 2012 , 30, 2352-63	52
828	In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores. 2012 , 14, R61	51
827	Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT. 2012 , 23, 237-46, viii	20
826	Autophosphorylation activation and inhibition by curcumin of the epidermal growth factor receptor reconstituted in liposomes. 2012 , 25, 623-9	8
825	Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model. 2012 , 101, 4100-6	2

824	Role of epidermal growth factor receptor in breast cancer. 2012 , 136, 331-45	371
823	Non-clinical immuno-toxicological evaluation of HER1 cancer vaccine in non-human primates: a 12-month study. 2012 , 31, 89-95	4
822	Epidermal growth factor receptor (EGFR) gene copy number in colorectal adenoma-carcinoma progression. 2012 , 205, 630-5	8
821	Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation. 2012 , 30, 220-9	9
820	Macroporous hydrogel micropillars for quantifying Met kinase activity in cancer cell lysates. 2012 , 137, 4052-61	7
819	Docking and molecular dynamics studies of new potential inhibitors of the human epidermal receptor 2. 2012 , 38, 1132-1142	6
818	Photodiagnosis and photodynamic therapy of peritoneal metastasis of ovarian cancer. 2012 , 9, 16-31	30
817	Role of Epidermal Growth Factor-Triggered PI3K/Akt Signaling in the Migration of Medulloblastoma-Derived Cells. 2012 , 5, 502-413	26
816	Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. 2012 , 422, 532-44	27
815	Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast cancer cells. 2012 , 314, 147-54	21
814	Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. 2012 , 11, 133-44	56
813	Nuclear translocation of the cytoplasmic domain of HB-EGF induces gastric cancer invasion. 2012 , 12, 205	14
812	Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer. 2012 , 36, 341-6	8
811	The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. 2012 , 36, 490-6	61
810	Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target. 2012 , 48, 991-996	27
809	Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. 2012 , 76, 177-82	99
808	Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood. 2012 , 76, 332-8	15
807	HER family receptor and ligand status in thymic carcinoma. 2012 , 77, 515-21	26

806	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. 2012 , 6, 15-26		62
805	Individualization of cancer treatment from radiotherapy perspective. 2012 , 6, 211-21		54
804	EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation. 2012 , 43, 2027-35		31
803	Novel targeted agents for the treatment of advanced breast cancer. 2012 , 4, 893-914		9
802	Prognostic and predictive roles of KRAS mutation in colorectal cancer. <i>International Journal of Molecular Sciences</i> , 2012 , 13, 12153-68	6.3	135
801	Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 2251-64	8.3	48
800	Cellular effects of HER3-specific affibody molecules. 2012 , 7, e40023		38
799	Differential effect of growth factors on invasion and proliferation of endocrine resistant breast cancer cells. 2012 , 7, e41847		23
798	Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway. 2012 , 27, e305-13		16
797	Potential anticancer properties of grape antioxidants. 2012 , 2012, 803294		80
796	Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence. <i>Frontiers in Oncology</i> , 2012 , 2, 31	5.3	22
795	Cutaneous side effects of new antitumor drugs: clinical features and management. 2012 , 109, 133-40		32
794	Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases. 2012 , 6, e6		1
793	Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma. 2012 , 3, 931-936		15
792	Aptamer-Nanoparticle Bioconjugates for Drug Delivery. 2012 ,		1
791	Cetuximab and biomarkers in non-small-cell lung carcinoma. 2012 , 6, 221-31		8
790	A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment. 2012 , 131, 956-69		29
789	Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. 2012 , 131, E822-9		98

788	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. 2012 , 483, 100-3	1417
787	Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. <i>Clinical Cancer Research</i> , 2012 , 18, 4942-53	12.9 128
786	Single domain antibodies: a new concept for epidermal growth factor receptor and EGFRvIII targeting. 2012 , 31, 1015-26	16
785	Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. 2012 , 30, 433-46	47
784	Suppression of the epidermal growth factor receptor inhibits epithelial-mesenchymal transition in human pancreatic cancer PANC-1 cells. 2012 , 57, 1181-9	26
783	Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women. 2012 , 29, 539-46	10
782	Effect of rs6983267 polymorphism in the 8q24 region and rs4444903 polymorphism in EGF gene on the risk of sporadic colorectal cancer in Iranian population. 2012 , 29, 1044-9	25
781	Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). 2012 , 69, 891-9	71
780	The current situation of Sunitinib in treating non-small cell lung cancer. 2012 , 11, 177-180	
779	Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). 2012 , 13, 252-66	95
778	Nuclear translocation of pro-amphiregulin induces chemoresistance in gastric cancer. 2012 , 103, 708-15	11
777	Liver-intestine cadherin induction by epidermal growth factor receptor is associated with intestinal differentiation of gastric cancer. 2012 , 103, 1744-50	29
776	Ascochlorin inhibits growth factor-induced HIF-1 α activation and tumor-angiogenesis through the suppression of EGFR/ERK/p70S6K signaling pathway in human cervical carcinoma cells. 2012 , 113, 1302-13	23
775	MicroRNA profiling differentiates colorectal cancer according to KRAS status. 2012 , 51, 1-9	89
774	ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. 2012 , 32, 166-215	65
773	Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice. 2012 , 69, 577-90	6
772	A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. 2012 , 69, 547-54	44
771	Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma. 2013 , 35, 809-18	5

770	Identification of a novel antagonist of the ErbB1 receptor capable of inhibiting migration of human glioblastoma cells. 2013 , 36, 201-11		2
769	Molecular mechanisms of hormone resistance of breast cancer. 2013 , 155, 384-95		13
768	Design of peptidomimetics for inhibition of HER2 receptor dimerization by a combination of virtual screening, MD simulations, and QSAR in silico methods. 2013 , 81, 455-62		5
767	Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors. 2013 , 23, 5385-8		19
766	Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model. 2013 , 9, 4221-36		90
765	3,4-dihydroxyphenyl acetic acid and (+)-epoxydon isolated from marine algae-derived microorganisms induce down regulation of epidermal growth factor activated mitogenic signaling cascade in Hela cells. <i>Cancer Cell International</i> , 2013 , 13, 49	6.4	10
764	Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy. 2013 , 20 Suppl 3, S599-606		8
763	Bioengineering strategies for designing targeted cancer therapies. 2013 , 118, 1-59		49
762	Electrochemical impedance immunosensor based on gold nanoparticles-protein G for the detection of cancer marker epidermal growth factor receptor in human plasma and brain tissue. 2013 , 50, 143-9		131
761	Reirradiation plus EGFR inhibition in locally recurrent and unresectable head and neck cancer: final results from a single institution. 2013 , 189, 842-8		8
760	Targeting the immune system in the treatment of non-small-cell lung cancer. 2013 , 14, 580-94		11
759	Application of 300nm enhanced fluorescence on a plasmonic chip modified with a bispecific antibody to a sensitive immunosensor. 2013 , 5, 8628-32		35
758	Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms. 2013 , 30, 329-61		10
757	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. 2013 , 39, 839-50		84
756	B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR). 2013 , 153, 33-40		8
755	Harnessing the immune system for the treatment of non-small-cell lung cancer. 2013 , 31, 1021-8		116
754	Epidermal growth factor receptor targeted nuclear delivery and high-resolution whole cell X-ray imaging of Fe ₃ O ₄ @TiO ₂ nanoparticles in cancer cells. 2013 , 7, 10502-17		96
753	Ovarian Neoplasm Imaging. 2013 ,		

752	Ambient temperature synthesis of citrate stabilized and biofunctionalized, fluorescent calcium fluoride nanocrystals for targeted labeling of cancer cells. 2013 , 1, 294-305	37
751	Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions. 2013 , 13, 2125-34	66
750	Development and validation of a sensitive LC-MS/MS assay for the simultaneous quantification of allitinib and its two metabolites in human plasma. 2013 , 86, 49-55	6
749	Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial. 2013 , 13, 345	7
748	Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. 2013 , 72, 1213-22	14
747	Multimerization of anti-(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers. 2013 , 280, 4816-26	9
746	Sensitive detection of KRAS mutations using enhanced-ice-COLD-PCR mutation enrichment and direct sequence identification. 2013 , 34, 1568-80	34
745	The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. 2013 , 280, 5350-70	193
744	Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma. 2013 , 169, 51-8	10
743	Rhomboid proteins: a role in keratinocyte proliferation and cancer. 2013 , 351, 301-7	21
742	Estrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer. 2013 , 137, 837-47	16
741	Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx. 2013 , 18, 454-63	15
740	GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. <i>Clinical Cancer Research</i> , 2013 , 19, 1126-38	12.9 89
739	Breast cancer biomarker measurements and standards. 2013 , 7, 17-29	30
738	Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells. 2013 , 82, 397-406	17
737	Construction and characterization of functional anti-epiregulin humanized monoclonal antibodies. 2013 , 441, 1011-7	10
736	Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. 2013 , 44, 380-9	54
735	Viral protein-coating of magnetic nanoparticles using simian virus 40 VP1. 2013 , 167, 8-15	19

734	Molecular markers for targeted neoadjuvant rectal cancer therapy. 2013 , 2, 321-331	1
733	In vivo molecular imaging of epidermal growth factor receptor in patients with colorectal neoplasia using confocal laser endomicroscopy. 2013 , 330, 200-7	47
732	A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. 2013 , 49, 3763-72	112
731	Modified silaffin R5 peptides enable encapsulation and release of cargo molecules from biomimetic silica particles. 2013 , 21, 3533-41	34
730	SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier. 2013 , 12, 199-210	17
729	In silico analysis of molecular mechanisms of legume lectin-induced apoptosis in cancer cells. 2013 , 46, 86-96	23
728	Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. 2013 , 22, 341-56	24
727	Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors. 2013 , 61, 84-94	40
726	Recent developments in optofluidic-assisted Raman spectroscopy. 2013 , 37, 1-50	21
725	Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway. 2013 , 98, 2502-12	15
724	Drugs for Cancer. 2013 , 270-285	
723	Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway. 2013 , 58, 1349-61	54
722	Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. <i>Clinical Cancer Research</i> , 2013 , 19, 4717-27	12.9 54
721	Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma. 2013 , 934, 22-5	8
720	Differential expression and activation of epidermal growth factor receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC). 2013 , 39, 387-98	4
719	An overview of phenylcyclopropylamine derivatives: biochemical and biological significance and recent developments. 2013 , 33, 873-910	25
718	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. 2013 , 32, 3846-56	87
717	Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model. 2013 , 34, 1427-36	11

716	Afatinib in advanced non-small-cell lung cancer. 2013 , 2, 493-504		
715	Efficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer. 2013 , 23, 1-6		0
714	Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis. <i>BioMed Research International</i> , 2013 , 2013, 654354	3	32
713	Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy?. <i>Clinical Cancer Research</i> , 2013 , 19, 958-60	12.9	2
712	Induction of apoptosis and the regulation of ErbB signaling by laminarin in HT-29 human colon cancer cells. 2013 , 32, 291-5		60
711	Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. 2013 , 9, 271-81		16
710	Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1783-95	6.1	47
709	Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. 2013 , 18, 460-6		34
708	Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis. 2013 , 6, 448-54		8
707	The Prognostic and Predictive Value of Expression of P-AKT in Patients with FIGO IIB Locally Advanced Cervical Cancer under Chemotherapy.. 2013 , 23, 153-159		1
706	Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor. 2013 , 56, 280-8		6
705	Targeting Stat3 and Smad7 to restore TGF- β cytostatic regulation of tumor cells in vitro and in vivo. 2013 , 32, 2433-41		57
704	A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. 2013 , 24, 1392-400		30
703	Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. 2013 , 26, 1197-203		18
702	Challenges in clinical trial design for recurrent glioblastoma. 2013 , 3, 835-848		1
701	miR-152 controls migration and invasive potential by targeting TGF β n prostate cancer cell lines. 2013 , 73, 1082-9		69
700	The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors. 2013 , 19, 907-917		21
699	Different therapeutic effects of distinct KISS1 fragments on breast cancer in vitro and in vivo. 2013 , 43, 1219-27		6

- 698 Asperolide A, a marine-derived tetranorditerpenoid, induces G2/M arrest in human NCI-H460 lung carcinoma cells, is mediated by p53-p21 stabilization and modulated by Ras/Raf/MEK/ERK signaling pathway. **2013**, 11, 316-31 22
- 697 Combining molecular targeted agents with radiation therapy for malignant gliomas. **2013**, 6, 1079-95 15
- 696 Sex disparities in the association of lung adenocarcinoma with colorectal cancer. **2013**, 4, 691-6 1
- 695 Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma. **2013**, 6, 427-35 12
- 694 Epidermal growth factor receptor down-regulation triggers human myoblast differentiation. **2013**, 8, e71770 28
- 693 Genomic interaction profiles in breast cancer reveal altered chromatin architecture. **2013**, 8, e73974 30
- 692 Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors. **2013**, 8, e81393 8
- 691 Erlotinib resistance in lung cancer: current progress and future perspectives. **2013**, 4, 15 37
- 690 Epidermal growth factor receptor is related to poor survival in glioblastomas: single-institution experience. **2013**, 54, 101-7 5
- 689 In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features. **2013**, 7, 789-839 12
- 688 Tyrosine-kinase inhibitors in oncology. 872-883
- 687 Quantification and kinetic analysis of Grb2-EGFR interaction on micro-patterned surfaces for the characterization of EGFR-modulating substances. **2014**, 9, e92151 29
- 686 Association between the epidermal growth factor +61 G/A polymorphism and glioma risk: a meta-analysis. **2014**, 9, e95139 6
- 685 Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer. **2014**, 7, 841-52 10
- 684 Anticancer effects of different seaweeds on human colon and breast cancers. **2014**, 12, 4898-911 81
- 683 Erlotinib in Glioblastoma [A Current Clinical Perspective. **2014**, 0
- 682 The influence of adnectin binding on the extracellular domain of epidermal growth factor receptor. **2014**, 25, 2093-102 17
- 681 EGFR activation and signaling in cancer cells are enhanced by the membrane-bound metalloprotease MT4-MMP. **2014**, 74, 6758-70 23

680	Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. 2014 , 15, 623-32		25
679	Development of 90Y-DOTA-nimotuzumab Fab fragment for radioimmunotherapy. 2014 , 302, 49-56		3
678	EGF +61A/G polymorphism contributes to increased gastric cancer risk: evidence from a meta-analysis. <i>Cancer Cell International</i> , 2014 , 14, 134	6.4	4
677	Inhibition of EGFR autophosphorylation plays an important role in the anti-breast cancer efficacy of the dithiocarbamate derivative TM208. 2014 , 35, 239-47		4
676	Assessment of expression of epidermal growth factor receptor and p53 in meningiomas. 2014 , 62, 37-41		8
675	Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas. <i>Frontiers in Oncology</i> , 2014 , 4, 67	5.3	22
674	Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2014 , 10, 931-8		18
673	Receptor-targeted drug delivery: current perspective and challenges. 2014 , 5, 1007-24		36
672	First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era. 2014 , 10, 1081-93		5
671	Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role. 2014 , 10, 17-20		2
670	New Approaches in Immunotherapy for the Treatment of Lung Cancer. 2017 , 405, 1-31		6
669	Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. 2014 , 25, 2052-2058		46
668	EGFR-binding peptide: a patent evaluation of WO2014002836. 2014 , 24, 1409-11		
667	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. 2014 , 120, 2684-93		79
666	Synthesis of a new fluorine-18 glycosylated 'click' cyanoquinoline for the imaging of epidermal growth factor receptor. 2014 , 57, 92-6		8
665	Clinical effect of E-series of prostaglandin receptor 2 and epidermal growth factor receptor signal pathways in the development of esophageal squamous cell carcinoma. 2014 , 27, 388-95		3
664	Pharmacotherapy targeting the EGFR oncogene in NSCLC. 2014 , 15, 2293-305		16
663	Molecular Determinants of Head and Neck Cancer. 2014 ,		2

662	Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells. 2014 , 12, 367		9
661	Investigational therapies targeting the ErbB family in oesophagogastric cancer. 2014 , 23, 1349-63		3
660	Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2559-71	6.1	18
659	Erlotinib. 2014 , 201, 109-23		10
658	A microfluidic device to select for cells based on chemotactic phenotype. 2014 , 2, 101-105		7
657	Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective. <i>Frontiers in Oncology</i> , 2014 , 4, 182	5.3	14
656	Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy. 2014 , 7, 311-38		52
655	Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF- κ B-mediated antiapoptotic pathway. 2014 , 33, 2968-77		67
654	Modeling of liver metastatic disease with applied drug therapy. 2014 , 115, 162-70		8
653	Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. 2014 , 17, 76-86		31
652	Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells. 2014 , 88, 119-27		20
651	Quantitative assessment of the association between +61A>G polymorphism of epidermal growth factor gene and susceptibility to glioma. 2014 , 35, 369-77		6
650	Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. 2014 , 35, 2313-8		24
649	Genetics of Adrenal Tumors. 2014 , 313-321		
648	Frequency dependent impedimetric cytotoxic evaluation of anticancer drug on breast cancer cell. 2014 , 55, 44-50		20
647	Assessing Cytotoxic Effect of ZD6474 on MDA-MB-468 Cells Using Cell-Based Sensor. 2014 , 14, 1476-1481		11
646	Regulation of receptor tyrosine kinase ligand processing. 2014 , 6,		20
645	The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. 2014 , 66, 222-307		327

644	Electric cell-substrate impedance sensing technique to monitor cellular behaviours of cancer cells. 2014 , 4, 9432	15
643	Monitoring cellular activities of cancer cells using impedance sensing devices. 2014 , 193, 478-483	24
642	Over-expression of EGFR is closely correlated to poor prognosis in Tunisian patients with non-small cell lung adenocarcinoma. 2014 , 35, 256-68	9
641	Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. 2014 , 20, 11-28	48
640	Ablation of breast cancer cells using trastuzumab-functionalized multi-walled carbon nanotubes and trastuzumab-diphtheria toxin conjugate. 2014 , 83, 259-65	20
639	¹⁷⁷ Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model. 2014 , 11, 800-7	35
638	In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor. 2014 , 23, 5074-5085	40
637	Snail regulated by PKC/GSK-3 β pathway is crucial for EGF-induced epithelial-mesenchymal transition (EMT) of cancer cells. 2014 , 358, 491-502	49
636	Cetuximab (Erbix). 2014 , 1501-1520	
635	AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. 2014 , 33, 47	16
634	Associations between epidermal growth factor receptor gene mutation and serum tumor markers in advanced lung adenocarcinomas: a retrospective study. 2014 , 29, 156-61	1
633	Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma. 2014 , 210, 155-60	4
632	Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation. 2014 , 10, 1065-80	8
631	Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. 2014 , 25, 2047-2052	94
630	Cetuximab induces eme1-mediated DNA repair: a novel mechanism for cetuximab resistance. 2014 , 16, 207-20, 220.e1-4	10
629	Transcription factor SCL/TAL1 mediates the phosphorylation of MEK/ERK pathway in umbilical cord blood CD34+ stem cells during hematopoietic differentiation. 2014 , 53, 39-46	6
628	Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy. 2014 , 275, 232-43	23
627	Genetics and epigenetics of adrenocortical tumors. 2014 , 386, 67-84	67

626	Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. 2014 , 110, 362-9	45
625	Targeted anticancer therapy: overexpressed receptors and nanotechnology. 2014 , 436, 78-92	141
624	Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma. 2014 , 35, 7479-87	9
623	Confocal laser endomicroscopy for non-invasive head and neck cancer imaging: a comprehensive review. 2014 , 50, 711-6	22
622	The inhibitory effect of anthocyanins on Akt on invasion and epithelial-mesenchymal transition is not associated with the anti-EGFR effect of the anthocyanins. 2014 , 44, 1756-66	15
621	Fingolimod for the treatment of neurological diseases-state of play and future perspectives. 2014 , 8, 283	91
620	Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series. 2014 , 229, 97-101	15
619	Recent developments and current management of penile cancer. 2014 , 11, 169-181	1
618	Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells. 2014 , 32, 2230-6	22
617	Afatinib: rationale for use in non-small-cell lung cancer based on clinical trial data. 2014 , 4, 55-61	1
616	Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. 2014 ,	20
615	BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. 2014 , 21, 221-30	61
614	Personalized therapy for lung cancer. 2014 , 146, 1649-1657	41
613	Current outcome predictors in childhood primitive neuroectodermal tumors. 2015 , 01, 075-082	
612	C/EBP β promotes angiogenesis through secretion of IL-6, which is inhibited by genistein, in EGFRvIII-positive glioblastoma. 2015 , 136, 2524-34	19
611	EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. 2015 , 5, 13574	28
610	Lysine-specific demethylase 1 mediates epidermal growth factor signaling to promote cell migration in ovarian cancer cells. 2015 , 5, 15344	30
609	Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor. 2015 , 15, 957	13

608	Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan. 2015 , 10, 127	10
607	Signaling Pathway of GP88 (Progranulin) in Breast Cancer Cells: Upregulation and Phosphorylation of c-myc by GP88/Progranulin in Her2-Overexpressing Breast Cancer Cells. 2015 , 9, 71-7	5
606	HER family receptor expression and prognosis in pancreatic cancer. 2015 , 30, e327-32	8
605	Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. 2015 , 40, 661-71	9
604	Impact of epidermal growth factor receptor protein and gene alteration on Taiwanese hepatocellular carcinomas. 2015 , 30, 1397-404	3
603	Positional isomerization of a non-cleavable combi-molecule dramatically altered tumor cell response profile. 2015 , 85, 153-62	3
602	Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer. 2015 , 26, 995-1003	12
601	Role of HER family members in predicting prognoses in epithelial ovarian cancer: a meta-analysis. 2015 , 101, 595-602	5
600	Distinct Functions of Neutrophil in Cancer and Its Regulation. 2015 , 2015, 701067	98
599	Epidermal growth factor signaling in transformed cells. 2015 , 314, 1-41	66
598	Simultaneous topographic and recognition imaging of epidermal growth factor receptor (EGFR) on single human breast cancer cells. 2015 , 1848, 1988-95	15
597	Experience with erlotinib in the treatment of non-small cell lung cancer. 2015 , 9, 146-63	19
596	A phase I study of volasertib combined with afatinib, in advanced solid tumors. 2015 , 76, 843-51	14
595	Integrin β Suppresses the Phosphorylation of Epidermal Growth Factor Receptor and Its Cellular Signaling of Cell Proliferation via N-Glycosylation. 2015 , 290, 29345-60	24
594	S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial. 2015 , 94, e958	37
593	RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody. 2015 , 357, 374-383	3
592	IgE Antibodies: Generation and Function. 2015 ,	
591	Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells. 2015 , 334, 126-35	8

590	TGF- β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells. 2015 , 65, 34-42	50
589	Epidaurus: aggregation and integration analysis of prostate cancer epigenome. 2015 , 43, e7	9
588	Biomarkers for personalized oncology: recent advances and future challenges. 2015 , 64, S16-21	163
587	Tissue-specific selection of optimal reference genes for expression analysis of anti-cancer drug-related genes in tumor samples using quantitative real-time RT-PCR. 2015 , 98, 375-81	19
586	Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. 2015 , 200, 188-200	69
585	Systemic Chemotherapy. 2015 , 307-318	
584	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. 2015 , 18, 824-32	77
583	Lead compound bearing caffeic scaffold induces EGFR suppression in solid tumor cancer cells. 2015 , 13, 305-317	2
582	Nrdp1-mediated ErbB3 degradation inhibits glioma cell migration and invasion by reducing cytoplasmic localization of p27(Kip1). 2015 , 124, 357-64	15
581	Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting. 2015 , 127, 253-81	19
580	CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. 2015 , 5, 11483	189
579	Impact of EGFR and p53 expressions on survival and quality of life in locally advanced oral squamous cell carcinoma patients treated with chemoradiation. 2015 , 16, 1269-80	8
578	A historical overview of protein kinases and their targeted small molecule inhibitors. 2015 , 100, 1-23	288
577	A single nucleotide polymorphism in 3' untranslated region of epithelial growth factor receptor confers risk for pulmonary hypertension in chronic obstructive pulmonary disease. 2015 , 36, 166-78	25
576	Potential antitumor therapeutic application of Grimontia hollisae thermostable direct hemolysin mutants. 2015 , 106, 447-54	1
575	Oral Cancer. 2015 ,	2
574	Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer. 2015 , 15, 1327-36	9
573	Synthesis of (68)Ga-labeled NOTA-RGD-GE11 heterodimeric peptide for dual integrin and epidermal growth factor receptor-targeted tumor imaging. 2015 , 58, 299-303	11

572	A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype. 2015 , 24, 1864-72	10
571	The Nucleus-Localized Epidermal Growth Factor Receptor Is SUMOylated. 2015 , 54, 5157-66	7
570	Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer. 2015 , 90, 534-41	32
569	Emerging Therapeutic Targets for Male Germ Cell Tumors. 2015 , 17, 54	7
568	Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents. 2015 , 1, 33-41	34
567	Chemopreventive effect of leflunomide against Ehrlich's solid tumor grown in mice: Effect on EGF and EGFR expression and tumor proliferation. 2015 , 141, 193-201	21
566	Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib. 2015 , 33, 931-41	13
565	In vivo photoacoustic imaging of cancer using indocyanine green-labeled monoclonal antibody targeting the epidermal growth factor receptor. 2015 , 464, 820-5	24
564	Rhomboid domain containing 1 promotes colorectal cancer growth through activation of the EGFR signalling pathway. 2015 , 6, 8022	45
563	Ligand-Independent EGFR Signaling. 2015 , 75, 3436-41	116
562	Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer. 2015 , 11, 1907-24	11
561	Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects. 2015 , 35, 31-43	8
560	Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers?. 2015 , 33, 72-80	79
559	MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. 2015 , 36, 338-45	95
558	Dietary phytoestrogens present in soy dramatically increase cardiotoxicity in male mice receiving a chemotherapeutic tyrosine kinase inhibitor. 2015 , 399, 330-5	9
557	Hsp27 regulates EGF/ β -catenin mediated epithelial to mesenchymal transition in prostate cancer. 2015 , 136, E496-507	47
556	Pharmaceutical Biotechnology. 2016 ,	5
555	Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer. 2016 , 9, 929-35	10

554	GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy. 2016 , 11, 5125-5147		36
553	Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography. 2016 , 11, e0161427		2
552	Antibody Therapeutics in Oncology. 2016 , 02,		8
551	Dexamethasone-(C21-phosphoramidate)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549). 2016 , 10, 2575-97		2
550	HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	7
549	Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum. 2016 , 22, 7692-707		72
548	TGF- β and Hypoxia/Reoxygenation Promote Radioresistance of A549 Lung Cancer Cells through Activation of Nrf2 and EGFR. 2016 , 2016, 6823471		15
547	The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	14
546	The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family. 2016 , 4, 88		29
545	Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers. 2016 , 8,		32
544	Nanopreparations for skin cancer therapy. 2016 , 1-28		4
543	A Novel Technique to Detect EGFR Mutations in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	16
542	Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial. 2016 , 17, 459		2
541	Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model. 2016 , 7, 327		8
540	Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors. 2016 , 6, 118-30		28
539	Epidermal growth factor is a critical regulator of the cytokine IL-33 in intestinal epithelial cells. 2016 , 173, 2532-42		14
538	Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-life. 2016 , 6, 594-602		8
537	The epidermal growth factor receptor pathway in chronic kidney diseases. 2016 , 12, 496-506		47

536	Extracellular matrix gene expression profiling using microfluidics for colorectal carcinoma stratification. 2016 , 10, 054124		6
535	Regulation of Cancer Cell Behavior by the Small GTPase Rab13. 2016 , 291, 9929-37		27
534	Discovery of ERBB3 inhibitors for non-small cell lung cancer (NSCLC) via virtual screening. <i>Journal of Molecular Modeling</i> , 2016 , 22, 135	2	12
533	Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. 2016 , 27, 1573-9		53
532	MiR-374a suppresses lung adenocarcinoma cell proliferation and invasion by targeting TGFA gene expression. 2016 , 37, 567-75		32
531	Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR. 2016 , 8, 853-78		14
530	Synthesis and evaluation of novel non-covalent binding quinazoline glycoside derivatives targeting the L858R and T790M variants of EGFR. 2016 , 6, 36857-36862		7
529	Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model. 2016 , 17, 375-383.e2		10
528	Interplay between steroid hormone activation of the unfolded protein response and nuclear receptor action. 2016 , 114, 2-6		12
527	Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas. 2016 , 4, 467-471		13
526	Hepatitis B virus X protein reduces the stability of Nrdp1 to up-regulate ErbB3 in hepatocellular carcinoma cells. 2016 , 37, 10375-82		11
525	Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer - Proof of concept towards a systems pharmacology approach. 2016 , 94, 20-32		15
524	Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors. 2016 , 78, 271-80		2
523	Suppression of MicroRNA-7 (miR-7) Biogenesis by Nuclear Factor 90-Nuclear Factor 45 Complex (NF90-NF45) Controls Cell Proliferation in Hepatocellular Carcinoma. 2016 , 291, 21074-21084		55
522	Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake. 2016 , 6, 58		11
521	The safety of afatinib for the treatment of non-small cell lung cancer. 2016 , 15, 1563-1572		13
520	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator. 2016 , 49, 2285-2293		21
519	In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non-water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines. 2016 , 38, 1296-302		6

518	Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients. 2016 , 12, 2127-2132	11
517	Weak binding to E3 ubiquitin ligase c-Cbl increases EGFRvA protein stability. 2016 , 590, 1345-53	1
516	N-Cadherin and Fibroblast Growth Factor Receptors crosstalk in the control of developmental and cancer cell migrations. 2016 , 95, 415-426	25
515	Molecular Radio-Oncology. 2016 ,	1
514	Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors. 2016 , 198, 107-22	10
513	Current targeted therapies in the treatment of advanced colorectal cancer: a review. 2016 , 8, 276-93	65
512	Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies. 2016 , 1028, 100-110	10
511	Anticipatory UPR Activation: A Protective Pathway and Target in Cancer. 2016 , 27, 731-741	34
510	In vitro antiproliferative effect of trastuzumab (Herceptin(®)) combined with cetuximab (Erbix(®)) in a model of human non-small cell lung cancer expressing EGFR and HER2. 2016 , 16, 161-8	9
509	Neurological Complications of Systemic Cancer and Antineoplastic Therapy. 2016 ,	1
508	Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. 2016 , 34, 149-58	10
507	Anticipatory activation of the unfolded protein response by epidermal growth factor is required for immediate early gene expression and cell proliferation. 2016 , 422, 31-41	21
506	Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. 2016 , 34, 810-5	61
505	Epidermal growth factor: Porcine uterine luminal epithelial cell migratory signal during the peri-implantation period of pregnancy. 2016 , 420, 66-74	16
504	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. 2016 , 59, 468-79	160
503	Synthesis of Diagnostic Silicon Nanoparticles for Targeted Delivery of Thiourea to Epidermal Growth Factor Receptor-Expressing Cancer Cells. 2016 , 8, 8908-17	20
502	Fine-needle aspiration of small pulmonary nodules yields material for reliable molecular analysis of adenocarcinomas. 2016 , 5, 57-63	1
501	Cancer and Angiogenesis. 2016 , 39-54	

500	Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents. 2016 , 2, 9-19	31
499	Pharmacologic resistance in colorectal cancer: a review. 2016 , 8, 57-84	259
498	Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. 2016 , 5, e1119354	98
497	A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans. 2016 , 18, 228-38	25
496	Antiproliferative effects of Docetaxel are associated with lipid raft disruption in HER2-positive human breast cancer cells. 2016 , 27, 266-77	37
495	IGFBP2 potentiates nuclear EGFR-STAT3 signaling. 2016 , 35, 738-47	42
494	Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. 2016 , 35, 671-82	95
493	Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α particles or Auger electrons. 2017 , 109, 102-118	78
492	Transcriptional Regulation of Human Transforming Growth Factor- β in Astrocytes. 2017 , 54, 964-976	19
491	Feline Mammary Cancer. 2017 , 54, 32-43	18
490	Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing. 2017 , 102, 156-161	28
489	XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell. 2017 , 10, 6	23
488	Confocal laser endomicroscopy in head and neck malignancies using FITC-labelled EpCAM- and EGF-R-antibodies in cell lines and tumor biopsies. 2017 , 10, 1365-1376	8
487	The role of IL17B-IL17RB signaling pathway in breast cancer. 2017 , 88, 795-803	43
486	CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis. 2017 , 17, 5	35
485	Preparation and biological evaluation of Tc-HYNIC-(Ser)3-D4 peptide for targeting and imaging of non-small-cell lung cancer. 2017 , 13, 893-905	12
484	Photonic modulation of EGFR: 280nm low level light arrests cancer cell activation and migration. 2017 ,	
483	Cardio-oncology Related to Heart Failure: Epidermal Growth Factor Receptor Target-Based Therapy. 2017 , 13, 297-309	7

482	Non-melanoma skin cancer: new and future synthetic drug treatments. 2017 , 18, 689-699		15
481	Development of a human epidermal growth factor derivative with EGFR-blocking and depleted biological activities: A comparative in vitro study using EGFR-positive breast cancer cells. 2017 , 103, 275-285		8
480	Rhomboid proteases in human disease: Mechanisms and future prospects. 2017 , 1864, 2200-2209		41
479	Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells. 2017 , 357, 59-66		6
478	Precision Medicine for Heart Failure: Lessons From Oncology. 2017 , 10,		8
477	Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. 2017 , 81, 81-89		9
476	Development and Evaluation of F-IRS for Molecular Imaging Mutant EGF Receptors in NSCLC. 2017 , 7, 3121		16
475	Characterizing the detection threshold for optical imaging in surgical oncology. 2017 , 116, 898-906		14
474	The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1002-1009	6.1	33
473	Epidermal growth factor-induced pyruvate dehydrogenase kinase 1 expression enhances head and neck squamous cell carcinoma metastasis up-regulation of fibronectin. 2017 , 31, 4265-4276		11
472	Drug-biomarker co-development in oncology - 20 years and counting. 2017 , 30, 48-62		38
471	Hypoxic proliferation requires EGFR-mediated ERK activation in human pulmonary microvascular endothelial cells. 2017 , 312, L649-L656		7
470	Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc. 2017 , 46, 717-724		5
469	GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways. 2017 , 24, 1549-1564		55
468	Enhanced EGFR Targeting Activity of Plasmonic Nanostructures with Engineered GE11 Peptide. 2017 , 6, 1700596		32
467	A Conjugate of an Anti-Epidermal Growth Factor Receptor (EGFR) VHH and a Cell-Penetrating Peptide Drives Receptor Internalization and Blocks EGFR Activation. 2017 , 18, 2390-2394		16
466	PET-Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors. 2017 , 12, 407-421		8
465	Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861. 2017 , 11, 1527-1543		5

464	EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. 2017 , 75, 299-309		3
463	EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models. 2017 , 124, 496-503		15
462	Targeted Therapies. 2017 , 267-283		
461	Molecular Biology: Are We Getting Any Closer to Providing Clinically Useful Information?. 2017 , 30, 415-422		6
460	Resistance to Targeted Therapies in Breast Cancer. 2017 ,		
459	EGFR Resistance. 2017 , 103-116		
458	Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications. 2017 , 115-128		
457	Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. <i>The Cochrane Library</i> , 2017 , 6, CD007047	5.2	42
456	Sorafenib controls the epithelial-mesenchymal transition of ovarian cancer cells via EGF and the CD44-HA signaling pathway in a cell type-dependent manner. 2017 , 16, 1826-1836		13
455	Synthesis and biological evaluation of chalcone-linked pyrazolo[1,5]pyrimidines as potential anticancer agents. 2017 , 8, 1810-1816		29
454	Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice. 2017 , 36, 6		8
453	Tc-radiolabeled GE11-modified peptide for ovarian tumor targeting. 2017 , 25, 13		18
452	Simultaneous Fluorescent Markers for Perfusion, Protoporphyrin Metabolism, and EGFR Expression for Optically Guided Identification of Orthotopic Glioma. <i>Clinical Cancer Research</i> , 2017 , 23, 2203-2212	12.9	28
451	Tumor detection using magnetosome nanoparticles functionalized with a newly screened EGFR/HER2 targeting peptide. 2017 , 115, 53-64		42
450	Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549). 2017 , 89, 379-399		3
449	A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017 , 23, 1177-1185	12.9	18
448	Epidemiology of Lung Cancer. 2017 , 347-366		1
447	miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells. 2017 , 25, 125-131		22

446	Effects of epidermal growth factor receptor fusion protein on the cytotoxic activity of SOCS1-silenced dendritic cells in vitro. 2018 , 39, 1306-1312	1
445	Epithelial-mesenchymal transition in prostate cancer: an overview. 2017 , 8, 35376-35389	105
444	BIOMARKERS: AN IMPERATIVE ACCESSION FOR DIAGNOSIS OF A DISEASE AND DRUG DEVELOPMENT. 2017 , 10, 57	
443	Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. 2017 , 4, 39	17
442	The Role of Epidermal Growth Factor Receptor in the Management of Gastrointestinal Carcinomas: Present Status and Future Perspectives. 2017 , 23, 2314-2320	7
441	Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients. 2017 , 8, 227-239	15
440	Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists. 2017 , 18, 6-17	9
439	Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. 2017 , 12, e0178930	15
438	[25 years of the Association of Middle-German Otorhinolaryngologists (MDHNO)]. 2017 , 65, 789-792	
437	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence hybridization (FISH) to select the optimal patients for matched therapy?. 2017 , 8, 100863-100898	11
436	Structure-based virtual screening and molecular docking for the identification of potential multi-targeted inhibitors against breast cancer. 2017 , 9, 447-459	18
435	Expression and clinical value of EGFR in human meningiomas. 2017 , 5, e3140	10
434	Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study. 2018 , 109, 785-793	12
433	New Therapies in Head and Neck Cancer. 2018 , 4, 385-396	34
432	Affinity maturation of humanized anti-epidermal growth factor receptor antibody using a modified phage-based open sandwich selection method. 2018 , 8, 5414	3
431	Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography. 2018 , 31, e2701	5
430	Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis. 2018 , 293, 2850-2864	10
429	Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. 2018 , 118, 344-352	4

428	Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling. 2018 , 417, 152-160	55
427	EGF is highly expressed in hepatocellular carcinoma (HCC) and promotes motility of HCC cells via fibronectin. 2018 , 119, 4170-4183	18
426	Structure optimisation to improve the delivery efficiency and cell selectivity of a tumour-targeting cell-penetrating peptide. 2018 , 26, 777-792	8
425	Effect of psoriasis activity and topical treatment on plasma epidermal growth factor (EGF) and its soluble receptor (sEGFR). 2018 , 29, 135-139	5
424	Targeted Therapy and Molecular Genetics. 2018 , 470-492.e10	2
423	Peptide ligands for targeting the extracellular domain of EGFR: Comparison between linear and cyclic peptides. 2018 , 91, 605-619	10
422	In silico evaluation of the resistance of the T790M variant of epidermal growth factor receptor kinase to cancer drug Erlotinib. 2018 , 36, 4209-4219	10
421	Design, Synthesis, and Biological Evaluation of Polyaminocarboxylate Ligand-Based Theranostic Conjugates for Antibody-Targeted Cancer Therapy and Near-Infrared Optical Imaging. 2018 , 13, 2606-2617	4
420	Nonsmall cell lung cancer with rare exon 7 p.A289V mutation in the EGFR gene responds to Icotinib treatment: A case report. 2018 , 97, e13809	6
419	Deagalactotigonin, a Steroidal Glycoside from , Induces Apoptosis and Cell Cycle Arrest via Inhibiting the EGFR Signaling Pathways in Pancreatic Cancer Cells. <i>BioMed Research International</i> , 2018 , 2018, 3120972	8
418	ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC. 2018 , 9, 1312	14
417	Evaluation of EGFR-targeted gold/gold sulfide (GGS) nanoparticles as a theranostic agent in photothermal therapy. 2018 , 5, 125401	2
416	A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. 2018 , 104, 1-8	6
415	Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer. 2018 , 105, 1553-1572	21
414	Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC. 2018 , 26, 6135-6145	9
413	Astaxanthin enhances erlotinib-induced cytotoxicity by p38 MAPK mediated xeroderma pigmentosum complementation group C (XPC) down-regulation in human lung cancer cells. 2018 , 7, 1247-1256	7
412	The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy. 2018 , 8,	34
411	Treatments That Block Proteins Involved in Cell Communication. 2018 , 65-109	

410	Combined caveolin-1 and epidermal growth factor receptor expression as a prognostic marker for breast cancer. 2018 , 15, 9271-9282	9
409	High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors. 2018 , 13, e0199254	8
408	Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence. 2018 , 78, 5144-5154	89
407	Erlotinib. 2018 , 211, 1-17	12
406	Exploring pitfalls of Cu-labeled EGFR-targeting peptide GE11 as a potential PET tracer. 2018 , 50, 1415-1431	10
405	Modulation of Exposure to Static Magnetic Field Affects Targeted Therapy of Solid Tumors. 2018 , 38, 4549-4555	3
404	Delineating the underlying molecular mechanisms and key genes involved in metastasis of colorectal cancer via bioinformatics analysis. 2018 , 39, 2297-2305	5
403	Tumor-penetrating peptide fused EGFR single-domain antibody enhances radiation responses following EGFR inhibition in gastric cancer. 2018 , 40, 1583-1591	4
402	Colony-stimulating factor-1 receptor provides a growth advantage in epithelial cancer cell line A431 in the presence of epidermal growth factor receptor inhibitor gefitinib. 2018 , 51, 191-198	1
401	Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models. 2018 , 40, 1545-1553	2
400	Seaweeds and Cancer Prevention. 2018 , 269-290	8
399	Hallmarks of Cancer in the Reading Room: A Guide for Radiologists. 2018 , 211, 470-484	4
398	Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer. 2018 , 19, 14	2
397	Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics. 2018 , 371, 1-19	40
396	Highly efficient capture of cancer cells expressing EGFR by microfluidic methods based on antigen-antibody association. 2018 , 8, 12005	15
395	Discovery of 4,5-Dihydro-1-thieno[2',3':2,3]thiopyrro [4,5-c]pyrazole-3-carboxamide Derivatives as the Potential Epidermal Growth Factor Receptors for Tyrosine Kinase Inhibitors. 2018 , 23,	5
394	miR-202 Inhibits Cell Proliferation, Migration, and Invasion by Targeting Epidermal Growth Factor Receptor in Human Bladder Cancer. 2018 , 26, 949-957	25
393	Targeted Delivery of Cell Penetrating Peptide Virus-like Nanoparticles to Skin Cancer Cells. 2018 , 8, 8499	30

392	First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors. 2019 , 37, 147-158		4
391	The role of the EGFR signaling pathway in stem cell differentiation during planarian regeneration and homeostasis. 2019 , 87, 45-57		8
390	Severe first infusion reaction related to cetuximab in cancer patients in Arkansas. 2019 , 25, 1130-1134		1
389	Review of systemic agents in the treatment of advanced cutaneous squamous cell carcinoma. 2019 , 15, 3171-3184		5
388	Time-staggered delivery of erlotinib and doxorubicin by gold nanocages with two smart polymers for reprogrammable release and synergistic with photothermal therapy. 2019 , 217, 119327		33
387	Signal Transduction in Radiation Oncology. 2019 , 1-17		
386	Auger electrons for cancer therapy - a review. 2019 , 4, 27		100
385	Essentials of Bioinformatics, Volume II. 2019 ,		1
384	CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. 2019 , 10, 2683		83
383	Intron 1-Mediated Regulation of Expression in EGFR-Dependent Malignancies Is Mediated by AP-1 and BET Proteins. <i>Molecular Cancer Research</i> , 2019 , 17, 2208-2220	6.6	3
382	Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency. <i>Cancers</i> , 2019 , 11,	6.6	58
381	Real-Time Label-Free Targeting Assessment and in Vitro Characterization of Curcumin-Loaded Poly-lactic-glycolic Acid Nanoparticles for Oral Colon Targeting. 2019 , 4, 16878-16890		9
380	Preparation of injectable forms of immobilized protein drugs using UV-curable gelatin derivatives. 2019 , 80, 877-885		3
379	Acetylcholine receptors: Key players in cancer development. 2019 , 31, 46-53		28
378	Application of metasurface-enhanced infra-red spectroscopy to distinguish between normal and cancerous cell types. 2019 , 144, 1115-1127		12
377	Progress in the application of exosomes as therapeutic vectors in tumor-targeted therapy. 2019 , 21, 509-524		15
376	Analysis of Progress and Challenges of EGFR-Targeted Molecular Imaging in Cancer With a Focus on Affibody Molecules. 2019 , 18, 1536012118823473		11
375	A Look at Receptor-Ligand Pairs for Active-Targeting Drug Delivery from Crystallographic and Molecular Dynamics Perspectives. 2019 , 16, 3293-3321		8

374	Combination of Cetuximab and Oncolytic Virus Canerptaturev Synergistically Inhibits Human Colorectal Cancer Growth. 2019 , 13, 107-115	7
373	Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. 2019 , 10, 1031-1044	5
372	Spectroscopic exploration of binding of new imidazolium-based palladium(II) saldach complexes with CT-DNA as anticancer agents against HER2/neu overexpression. 2019 , 1191, 118-128	13
371	Capsaicin enhances erlotinib-induced cytotoxicity AKT inactivation and excision repair cross-complementary 1 (ERCC1) down-regulation in human lung cancer cells. 2019 , 8, 459-470	5
370	The Role of M3 Muscarinic Receptor Ligand-Induced Kinase Signaling in Colon Cancer Progression. <i>Cancers</i> , 2019 , 11,	6.6 17
369	Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study. 2019 , 2019, 9136249	3
368	Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain. 2019 , 163, 404-415	17
367	Phosphorylation of proliferating cell nuclear antigen promotes cancer progression by activating the ATM/Akt/GSK3 β /Snail signaling pathway. 2019 , 294, 7037-7045	13
366	2,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K. 2019 , 172, 36-47	11
365	The Role of Platelets in Tumor Growth, Metastasis, and Immune Evasion. 2019 , 547-561	5
364	The Role of Lipid Rafts in Mediating the Anticancer Effects of β -Tocotrienol. 2019 , 125-140	
363	Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer. 2019 , 14, e0215003	8
362	Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations. 2019 , 26, 396-426	32
361	Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. 2019 , 11, S2155-S2172	33
360	[Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data]. 2019 , 36, 649-663	2
359	The Evolving Landscape of Cancer Therapeutics. 2019 , 260, 43-79	5
358	Genetic Modification of CD8 T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies. 2019 , 10, 2990	9
357	The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma. 2019 , 16, 1199-1206	8

356	A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. 2019 , 37, 307-314	4	
355	Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. 2019 , 8, 408-417	41	
354	Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. 2019 , 19, e283-e296	15	
353	EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer. 2019 , 13, 725-737	14	
352	An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies. 2019 , 13, 246-263	16	
351	The redox mechanism investigation of non-small cell lung cancer drug: Erlotinib via theoretical and experimental techniques and its host guest detection by β -Cyclodextrin nanoparticles modified glassy carbon electrode. 2019 , 278, 172-180	9	
350	In silico studies of the interaction of the colon cancer receptor and RNA aptamer adsorbed on (1 0 1) facet of TiO ₂ nanoparticle investigated by molecular dynamics simulation. 2020 , 26, 941-954	1	
349	A Critical Review of Properties and Analytical/Bioanalytical Methods for Characterization of Cetuximab. 2020 , 50, 125-135	10	
348	A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer. 2020 , 38, 1077-1084	9	
347	Development of an LC-MS/MS method for quantifying two main metabolites of abivertinib in human plasma. 2020 , 34, e4704	3	
346	Identification of Two Kinase Inhibitors with Synergistic Toxicity with Low-Dose Hydrogen Peroxide in Colorectal Cancer Cells in vitro. <i>Cancers</i> , 2020 , 12,	6.6	9
345	Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. 2020 , 15, 67-73	1	
344	circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway. 2020 , 21, 885-899	13	
343	Cetuximab conjugated temozolomide-loaded poly (lactic-co-glycolic acid) nanoparticles for targeted nanomedicine in EGFR overexpressing cancer cells. 2020 , 60, 101928	13	
342	[Erlotinib plus Gemcitabine in metastatic pancreatic cancer: Results from a non-interventional trial]. 2020 , 58, 332-340		
341	Generation of a soluble and stable apoptin-EGF fusion protein, a targeted viral protein applicable for tumor therapy. 2020 , 175, 105687	2	
340	Phase 2 study of cetuximab (Erbix) in patients with progressive or recurrent endometrial cancer. 2020 , 30, 1733-1737	0	
339	EGFR-Binding Peptides: From Computational Design towards Tumor-Targeting of Adeno-Associated Virus Capsids. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6

338	Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). 2020 , 9, 1848058	3
337	Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells. 2020 , 75, 109741	7
336	Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. 2020 , 14, 565-576	5
335	Estimating breast tissue-specific DNA methylation age using next-generation sequencing data. 2020 , 12, 45	3
334	Dual Loading of Nanoparticles with Doxorubicin and Icotinib for the Synergistic Suppression of Non-Small Cell Lung Cancer. 2020 , 17, 390-402	4
333	Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule. 2020 , 9, 1762465	4
332	Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. 2020 , 147, 1-57	17
331	Single Nucleotide Variants Associated with Colorectal Cancer Among Iranian Patients: A Narrative Review. 2020 , 13, 167-180	2
330	Comprehensive pharmacogenomic characterization of gastric cancer. 2020 , 12, 17	8
329	Ampholine immobilized polymer microspheres for increasing coverage of human urinary proteome. 2020 , 215, 120931	2
328	A Feedback Loop Comprising EGF/TGF β 5 Sustains TFCP2-Mediated Breast Cancer Progression. 2020 , 80, 2217-2229	7
327	Feasibility of Surgical Resection After Induction Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for N2 Lung Adenocarcinomas. 2021 , 111, 290-295	1
326	Clinical development of CAR T cell therapy in China: 2020 update. 2021 , 18, 792-804	19
325	Development of an LC-MS/MS method for quantifying ASK120067, a novel mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) as well as its main metabolite in human plasma and its application in a pharmacokinetic study. 2021 , 1162, 122488	0
324	EGFR and anti-EGFR nanobodies: review and update. 2021 , 29, 387-402	7
323	Surface-decoration strategies in nanomedicine for cancer treatment. 2021 , 131-152	
322	Mechanisms of Cetuximab Resistance and How to Overcome It. 2021 , 21-51	
321	Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. 2021 , 13, 1758835920949418	1

320	Synthesis, potential antitumor activity, cell cycle analysis, and multitarget mechanisms of novel hydrazones incorporating a 4-methylsulfonylbenzene scaffold: a molecular docking study. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021 , 36, 1521-1539	5.6	5
319	Carbohydrate Systems in Targeted Drug Delivery: Expectation and Reality. 2021 , 47, 71-98		1
318	Design, synthesis, and analysis of antiproliferative and apoptosis-inducing activities of nitrile derivatives containing a benzofuran scaffold: EGFR inhibition assay and molecular modelling study. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021 , 36, 1488-1499	5.6	2
317	Proliferation of MDA-MB-231 can be suppressed by dimeric-epigallocatechin gallate through competitive inhibition of amphiregulin-epidermal growth factor receptor signaling. 2021 , 32, 647-656		1
316	Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. 2021 , 14, 1341-1366		7
315	Circular RNA circANKS1B acts as a sponge for miR-152-3p and promotes prostate cancer progression by upregulating TGF- β expression. 2021 , 81, 271-278		7
314	Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients. 2021 , 12,		6
313	Recent nanotheranostics applications for cancer therapy and diagnosis: A review. 2021 , 15, 247-256		2
312	EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy. 2021 , 16, 2443-2459		4
311	Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers. 2021 , 39, 1315-1323		1
310	Recent Progress of DNA Nanostructures on Amphiphilic Membranes. 2021 , 21, e2000440		3
309	Involvement of the A disintegrin and metalloproteinase 9 in oral cancer cell invasion. 2021 , 129, e12775		1
308	Magnetic Nanoparticle-Based Dianthin Targeting for Controlled Drug Release Using the Endosomal Escape Enhancer SO1861. 2021 , 11,		2
307	Precision oncology in metastatic colorectal cancer - from biology to medicine. 2021 , 18, 506-525		27
306	Oxidative Stress in Cancer Cell Metabolism. <i>Antioxidants</i> , 2021 , 10,	7.1	51
305	Novel circulating tumor cell-detection chip combining conventional podoplanin and EGFR antibodies for all histological malignant pleural mesothelioma. 2021 , 22, 522		1
304	Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?. 2021 , 14, 101056		5
303	Oxidative stress induces EGFR inhibition-related skin cell death. 2021 , 68, 235-242		3

302	Synthesis and Biological Evaluations of N-(4-Substituted Phenyl)-7-Hydroxy-4-Methyl-2-Oxoquinoline-1(2H)-Carbothioamides. 1-12		0
301	Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances. <i>Frontiers in Oncology</i> , 2021 , 11, 671548	5.3	0
300	Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. 2021 , 6, 201		103
299	Cell Plasticity and Prostate Cancer: The Role of Epithelial-Mesenchymal Transition in Tumor Progression, Invasion, Metastasis and Cancer Therapy Resistance. <i>Cancers</i> , 2021 , 13,	6.6	5
298	EGFR-IL-6 Signaling Axis Mediated the Inhibitory Effect of Methylseleninic Acid on Esophageal Squamous Cell Carcinoma. 2021 , 12, 719785		1
297	Cyclodextrin-based gefitinib nanobubbles for synergistic apoptosis in lung cancer. 1-12		2
296	Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance. <i>Cancers</i> , 2021 , 13,	6.6	17
295	Survival of gefitinib treated advanced non-small cell lung cancer patients harbouring EGFR mutations. 2021 , 9, 171-174		
294	Epidermal growth factor receptor (EGFR) mutation testing is useful for primary lung cancer diagnosis and appropriate surgical resection: A case series. 2021 ,		
293	Lung cancer epidermal growth factor receptor mutations and radiotherapy response: A multicentre clinical study. 2021 , 30, 15-18		0
292	Downregulation of p38 MAPK Activation and Radiation-Sensitive 52 Expression Enhances 5-Fluorouracil and Erlotinib-Induced Cytotoxicity in Human Lung Squamous Cells. 2021 , 106, 623-636		
291	Exploring the role of epidermal growth factor receptor variant III in meningeal tumors. 2021 , 16, e0255133		3
290	Magnitude of Ubiquitination Determines the Fate of Epidermal Growth Factor Receptor Upon Ligand Stimulation. 2021 , 433, 167240		1
289	GPCR-ErbB transactivation pathways and clinical implications. 2021 , 86, 110092		1
288	Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma. 2021 , 1876, 188598		2
287	Apoptosis modulating nanochemotherapeutics in the treatment of cancer: Recent progress and advances. 2021 , 153-207		
286	Triple Negative Breast Cancer. 2021 ,		
285	Pharmacokinetic properties and bioequivalence of gefitinib 250 mg in healthy Korean male subjects. 2021 , 29, 171-179		

284	Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. 2005 , 63, 93-114	9
283	Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?. 2008 , 610, 128-43	4
282	Genetic and Molecular Approaches to Imaging Breast Cancer. 2010 , 163-182	1
281	Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer. 2009 , 149, 189-202	8
280	Therapeutically Used Targeted Antigens in Radioimmunotherapy. 2008 , 13-23	2
279	A Time Travel Journey Through Cancer Therapies. 2013 , 3-35	1
278	The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP). 2002 , 107, 3-28	35
277	Adult High-Grade (Diffuse) Glioma. 2015 , 77-93	2
276	Epidermal Growth Factor-Related Peptides in Endocrine Neoplasias. 2000 , 137-191	1
275	Epidermal Growth Factor-Related Peptides and Their Cognate Receptors in Breast Cancer. 1999 , 31-57	1
274	Emerging Molecular Therapies. 2004 , 569-606	1
273	Expression and prognostic significance of the EGFR in solid tumors. 2008 , 210-223	1
272	Convergence of EGF Receptor and Src Family Signaling Networks in Cancer. 2008 , 112-130	1
271	Malignant Peripheral Nerve Sheath Tumors. 2008 , 43-81	3
270	Monoclonal Antibodies. 2008 , 547-561	3
269	Molecular-targeted therapy for cancer and nanotechnology. 2010 , 624, 11-23	6
268	IgE immunotherapy against cancer. 2015 , 388, 109-49	12
267	Targeting ERBB receptors in cancer. 2007 , 172, 45-57	7

266	Uncovering novel targets for cancer chemoprevention. 2007 , 174, 235-43	12
265	Molecular response prediction in multimodality treatment for adenocarcinoma of the esophagus and esophagogastric junction. 2010 , 182, 179-91	1
264	Targeted therapy of the epidermal growth factor receptor in the treatment of pancreatic cancer. 2008 , 177, 131-6	6
263	Erlotinib. 2010 , 184, 21-31	3
262	Targeted drug therapies and cancer. 2011 , 185, 159-71	11
261	Biological Treatments for Lung Cancer. 2004 , 333-350	1
260	Role of Signaling Pathway Modification. 2003 , 157-178	1
259	Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. 1996 , 213 (Pt 3), 113-28	3
258	EGF Family Receptors and Their Ligands in Human Cancer. 1998 , 113-165	8
257	Epidermal growth factor receptor pathway inhibitors. 2005 , 22, 205-23	11
256	An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. 2018 , 18, 35-45	38
255	Validation of Assays for the Bioanalysis of Novel Biomarkers. 2003 ,	7
254	Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC). 2013 , 13, 202-17	5
253	Tobacco Smoking and Lung Cancer: Perception-changing facts. 2013 , 13, 345-58	54
252	Hypoxia activated EGFR signaling induces epithelial to mesenchymal transition (EMT). 2012 , 7, e49766	55
251	Epidermal growth factor protects squamous cell carcinoma against cisplatin-induced cytotoxicity through increased interleukin-1 β expression. 2013 , 8, e55795	11
250	Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer. 2013 , 8, e75288	8
249	A real-time clinical endoscopic system for intraluminal, multiplexed imaging of surface-enhanced Raman scattering nanoparticles. 2015 , 10, e0123185	79

248	Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments. 2015 , 10, e0128360	13
247	Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. 2020 , 15, e0228909	24
246	EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery. 2016 , 3,	11
245	ErbB-2 signaling in advanced prostate cancer progression and potential therapy. 2019 , 26, R195-R209	7
244	Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis. 2015 , 20, 57-63	16
243	Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma. 2014 , 1, 40-45	10
242	Our experiences with erlotinib in second and third line treatment patients with advanced stage IIIB/IV non-small cell lung cancer. 2008 , 8, 386-90	2
241	Identification and validation of the angiogenic genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. 2020 , 12, 7848-7873	8
240	Polarization of macrophages in the tumor microenvironment is influenced by EGFR signaling within colon cancer cells. 2016 , 7, 75366-75378	28
239	Identification of the zinc finger 216 (ZNF216) in human carcinoma cells: a potential regulator of EGFR activity. 2016 , 7, 74947-74965	2
238	Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines. 2017 , 8, 11020-11029	7
237	RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer. 2017 , 8, 25251-25260	5
236	EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR. 2014 , 5, 1265-78	34
235	EGF receptor lysosomal degradation is delayed in the cells stimulated with EGF-Quantum dot bioconjugate but earlier key events of endocytic degradative pathway are similar to that of native EGF. 2017 , 8, 44335-44350	6
234	Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer. 2017 , 8, 72447-72456	11
233	Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems. 2017 , 8, 80804-80819	17
232	Phytosphingosine exhibits an anti-epithelial-mesenchymal transition function by the inhibition of EGFR signaling in human breast cancer cells. 2017 , 8, 77794-77808	7
231	Epidermal growth factor-induced cyclooxygenase-2 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation. 2015 , 6, 1723-39	23

230	Identification of epidermal growth factor receptor and its inhibitory microRNA141 as novel targets of Krüppel-like factor 8 in breast cancer. 2015 , 6, 21428-42		18
229	Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. 2016 , 7, 33391-407		14
228	Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. 2016 , 7, 41677-41690		30
227	Muscarinic receptor signaling and colon cancer progression. 2016 , 2, 195-200		6
226	Chemotherapy and molecular targeting therapy for recurrent cervical cancer. 2016 , 28, 241-53		26
225	First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. 2009 , 2, 73-82		3
224	Synthetic Peptide Libraries: From Random Mixtures to In Vivo Testing. 2020 , 27, 997-1016		5
223	Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2020 , 20, 815-834	3	64
222	Protein kinases and associated pathways in pluripotent state and lineage differentiation. 2014 , 9, 366-87		6
221	Carnosic Acid, Tangeretin, and Ginkgolide-B Anti-neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549). 2019 , 19, 802-819		4
220	The effect of tyrosine kinase inhibitors, tyrophostins: AG1024 and SU1498, on autocrine growth of prostate cancer cells (DU145). 2008 , 46, 185-91		14
219	Correlation of c-erbB-2, EGF and EGFR expression with postoperative survival of patients with advanced carcinoma of the stomach. 2009 , 47, 653-61		6
218	Promising Anticancer Effect of Aurisin A Against the Human Lung Cancer A549 Cell Line. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020 , 21, 49-54	1,7	1
217	Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch repair-deficient colorectal cancers. 2008 , 14, 1053-9		10
216	Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma. 2005 , 11, 1382-6		26
215	Emerging therapies in gastrointestinal cancers. 2006 , 12, 7440-50		18
214	Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma. 2006 , 12, 928-34		26
213	Rectal cancer treatment: improving the picture. 2007 , 13, 5805-12		6

212	Exploiting novel molecular targets in gastrointestinal cancers. 2007 , 13, 5845-56	16
211	Association between EGF +61A/G polymorphism and gastric cancer in Caucasians. 2011 , 17, 488-92	17
210	Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer. 2014 , 20, 2005-13	15
209	Clinical significance and usefulness of soluble heparin binding-epidermal growth factor in gastric cancer. 2015 , 21, 2080-8	7
208	High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. 2020 , 19, 1584-1592	2
207	Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). 2011 , 3, 57-64	15
206	Integrating anti-EGFR therapies in metastatic colorectal cancer. 2013 , 4, 285-98	17
205	Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. 2015 , 4, 584-97	45
204	A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia. 2017 , 54, 104-114	1
203	Panitumumab-induced acneiform rash in a patient with metastatic colon adenocarcinoma. 2013 , 58, 164	1
202	The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India. 2013 , 19, 48-53	4
201	Targeted therapies in development for non-small cell lung cancer. 2013 , 12, 22	58
200	Immunotherapy in Oral Cancer. 2019 , 11, S107-S111	15
199	Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features. 2015 , 7, 292-302	12
198	Lung cancer. 2005 , 25, 1-12	16
197	Targeting metastatic upper gastrointestinal adenocarcinomas. 2011 , 2, 135-49	2
196	Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. 2011 , 30, 5-12	86
195	Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014 , 15, 3185-9	1.7 4

- 194 Overexpression of EGFR protein in Bruneian lung cancer patients. *Asian Pacific Journal of Cancer Prevention*, **2015**, 16, 233-7 1.7 6
- 193 Cell Free EGFR mRNA Expression and Implications for Survival and Metastasis in Non-Small Cell Lung Cancer Cases. *Asian Pacific Journal of Cancer Prevention*, **2015**, 16, 6445-9 1.7 7
- 192 Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study. *Asian Pacific Journal of Cancer Prevention*, **2015**, 16, 7529-34 1.7 4
- 191 Insilco Design and Potential Cytotoxic agents EGFR Inhibitors of 4(3H) Quinazolinone Derivatives. **2021**, 4849-4855
- 190 Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress. *Bioorganic Chemistry*, **2021**, 116, 105393 5.1 6
- 189 Type I Family Growth Factor Receptors and Their Ligands in Prostate Cancer. **2000**, 277-291
- 188 Selected Targets and Rationally Designed Therapeutics for Patients with Colorectal Cancer. **2002**, 759-793
- 187 Signal Transduction Pathways Modulate Androgen Receptor Transcriptional Activity. **2002**, 57-90
- 186 Effect of Carotenoids on the Growth of HT-29 Human Colon Cancer Cells. **2003**, 32, 428-436
- 185 Investigational Approaches to the Treatment of Gynecologic Cancers. **2004**, 820-831
- 184 The Retinoids and Cancer Chemoprevention. **2004**, 277-288 3
- 183 Treatment with Monoclonal Antibodies. **2004**, 529-568
- 182 Signal transduction and apoptosis pathways as therapeutic targets. **2004**, 36, 307-23
- 181 The Potential of EGFR-Targeted Agents in Cancer Prevention. **2004**, 317-324 1
- 180 Erlotinib (TarcevaR) inhibits oral cavity carcinoma and synergizes with cisplatin and ionizing radiation in vitro. **2004**, 1, 67-74 1
- 179 Involvement of Receptor Tyrosine Kinases in Lung Cancer. **2004**,
- 178 Identification of Treatment Response Genes. **2006**, 1-19
- 177 Is There a Role for ErbB Dual Kinase Inhibition?. **2007**, 203-212

- 176 The Role of Targeted Therapy in the Treatment of Metastatic Colorectal Cancer. **2007**, 23, 524 1
- 175 Anti-Epidermal Growth Factor Receptor Strategies for Advanced Breast Cancer. **2007**, 213-234
- 174 Epidermal Growth Factor Receptor Inhibition in NonSmall Cell Lung Cancer. **2007**, 81-96
- 173 Signal Transduction Inhibitors, HER Family, EGFR Inhibition and Clinical Achievements. **2007**, 19-44
- 172 What is cancer?. **2007**, 1-16 0
- 171 Molecular Basis of Radiation Therapy. **2008**, 593-604 1
- 170 Therapeutic Targeting of Apoptosis in Cancer. **2008**, 263-278
- 169 Head and Neck Malignancies: Chemotherapy and Radiation Perspective. **2008**, 425-430
- 168 Effects of Exercise Training and Selenium on MCT1 and MCT4 Protein Levels in Skeletal Muscles of Diabetic Goto-Kakizaki Rats. **2008**, 18, 1-8
- 167 EGFR signaling in invasion, angiogenesis and metastasis. **2008**, 245-264 1
- 166 Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. **2008**, 317-365
- 165 HER-2/neu Protein Expression in Canine Mammary Adenocarcinoma. **2008**, 18, 16-22
- 164 Constitutive activation of truncated EGF receptors in glioblastoma. **2008**, 265-280
- 163 Genes and metastasis: experimental advances and clinical implications. **2008**, 33-58
- 162 Natural Agents That Can Sensitize Tumor Cells to Chemotherapy and Radiation Therapy. **2008**, 211-240 3
- 161 [Antiangiogenic therapy for gastrointestinal tumors]. **2008**, 149, 2317-24
- 160 Integration of Target-Based Agents in Current Protocols of Breast Cancer Therapy. **2009**, 203-224
- 159 Signal Transduction Inhibitors in the Treatment of Breast Cancer. **2009**, 177-201

- 158 The Role of Gangliosides in Renal Cell Carcinoma. **2009**, 405-423
- 157 Kutane Nebenwirkungen unter Therapie mit EGFR-Inhibitoren. **2009**, 248-251
- 156 Inherent Resistance to Epidermal Growth Factor Receptor Antibodies in Refractory Metastatic Colorectal Cancer. **2009**, 9, 165-174 1
- 155 Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. **2009**, 2, 251-60 1
- 154 EGFR-Directed Monoclonal Antibodies. **2010**, 407-436
- 153 Molecular Carcinogenesis. **2010**, 975-1003
- 152 Biologisch zielgerichtete medikamentöse Therapie. **2010**, 265-275
- 151 The Role of Oncogene Activation in Tumor Progression. **2010**, 19-41
- 150 Protein Kinase Inhibitors in Drug Discovery. 1
- 149 Epidermal Growth Factor Receptor-Targeted Therapies. **2011**, 305-333
- 148 JNK-Mediated FOXO Expression Plays a Critical Role in EGFR Tyrosine Kinase Inhibitor-Induced BIM Expression and Apoptosis. **2012**, 03, 424-434
- 147 Molecular Imaging of Ovarian Carcinoma. **2013**, 479-496
- 146 CHAPTER 13. Hsp90 Inhibitors in Clinic. **2013**, 336-378
- 145 TYPES OF DNA DAMAGE. **2013**, 115-118
- 144 Signal Transduction Inhibitors of the HER Family. **2013**, 17-50
- 143 Polymorphisms in Genes of Drug Targets and Metabolism. **2014**, 289-332
- 142 Monoclonal Antibodies. **2014**, 585-624
- 141 The Human Epidermal Growth Factor Receptor (HER) Family: Structure and Function. **2014**, 7-17

- 140 Insulin-Like Growth Factor-1 Receptors in Head and Neck Cancer. **2014**, 113-130 1
- 139 ErbB Receptors and ErbB Targeted Therapies in Endometrial Cancer. **2014**, 05, 483-492 0
- 138 Intracellular Antibodies as Tools to Study ErbB Receptor Tyrosine Kinases. **1998**, 61-74
- 137 Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway. **2015**, 381-412
- 136 Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications. **2016**, 1-13
- 135 Frequency and Clinical Impact of KRAS Mutations in Patients with Colorectal Cancer from the Middle East. **2016**, 5, 67-74 0
- 134 Physiologic and Molecular Basis of PET in Cancer Imaging. **2017**, 399-427 0
- 133 Biological Principles and Clinical Application of EGFR Inhibitors in Cancer. **2017**, 709-726
- 132 Production of Specific Anti-EGFR Single Chain Antibodies: A Promising Strategy in the Immunotherapy of EGFR Expressing Tumor Tissues. **2017**, In Press, 1
- 131 Targeting epidermal growth factor receptor: An important strategy in oncology. **2017**, 8,
- 130 Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non-Small Cell Lung Cancer. **2017**, 8, 196-201 0
- 129 Phosphorylation of iRhom2 Is Essential for Stimulated Proteolytic Shedding by the Metalloprotease ADAM17/TACE. *SSRN Electronic Journal*, 1
- 128 Beta-Catenin Downregulation Contributes to Epidermal Growth Factor-induced Migration and Invasion of MDAMB231 Cells. **2018**, 43, 161-169
- 127 Effect of tamoxifen treatment on the epidermal growth factor receptor expression in the mouse ovarian tissue.
- 126 Clinical Strategies for Developing Next-Generation Cancer Precision Medicines. **2019**, 105-117
- 125 Trophoblast proliferation, migration, and invasion is regulated by the miR-195/EGFR signaling pathway in recurrent spontaneous abortion patients. 0
- 124 Biological rationale for a patient-specific approach in the treatment of breast cancer. Clinical value of novel biomarkers of breast cancer. **2019**, 15, 10-29 2
- 123 RSGSA: a Robust and Stable Gene Selection Algorithm.

- 122 Ascofuranone inhibits epidermal growth factor-induced cell migration by blocking epithelial-mesenchymal transition in lung cancer cells. **2020**, 880, 173199 0
- 121 In vitro Study of Radiosensitivity Effects of Galbanic Acid on Ovarian Tumor Cells (OVCAR-3 Cell Line). **2021**, 16, 1934578X2110460
- 120 Radiolabeled Peptide Probes for Liver Cancer Imaging. **2020**, 27, 6968-6986 2
- 119 Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous delivery of tyrosine kinase inhibitors and kinase activity biosensors. **2021**, 13, 18520-18535 0
- 118 Evaluation of anti-epithelial-mesenchymal transition property of Garcinia mangostana rind extract. **2021**, 7,
- 117 Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. **2021**, 21, 1333-1353 4
- 116 Interplay between Mitochondrial Metabolism and Cellular Redox State Dictates Cancer Cell Survival. **2021**, 2021, 1341604 5
- 115 Interleukin-2 and its Receptors in Human Solid Tumours: Immunobiology and Clinical Significance. **2001**, 27-50
- 114 Immunophenotypic Characterization of Infiltrating Poly- and Mononuclear Cells in Childhood Brain Tumors. **2005**, 13-161
- 113 Management of Cerebral Metastasis in Patients with Non-Small-Cell Lung Cancer. **2006**, 335-342
- 112 Chemoprevention of Lung Cancer. **2006**, 609-626
- 111 Applications in Lung Cancer. **2006**, 231-250
- 110 Chemosensitization. **2005**, 335-348
- 109 Signaling Modules in Glial Tumors and Implications for Molecular Therapy. **2006**, 389-417
- 108 Cancer Chemotherapy. **2006**, 543-557
- 107 The Advancement of Epidermal Growth Factor Receptor Inhibitors in Cancer Therapy. **2007**, 335-357
- 106 The Cell Cycle. **2008**, 3-32
- 105 Targeted Therapy For Breast Cancer. **2008**, 309-342

104	Molecular Targeting of Colorectal Cancer. 2008 , 133-163	
103	Targeted Drug Therapy in Pancreatic Cancer. 2008 , 271-287	
102	Prevention of Breast Cancer. 2006 , 63-94	
101	Ductal Carcinoma In Situ: Systemic Treatment. 2006 , 137-156	
100	Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. 2001 , 3, 245-54	13
99	Assays for complexed prostate-specific antigen and other advances in the diagnosis of prostate cancer. 2003 , 5 Suppl 6, S10-6	4
98	Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. 1997 , 151, 1523-30	545
97	Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. 2006 , 13, 99-107	40
96	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. 2009 , 3, 215-24	24
95	Lung cancer cytology: potential pitfalls and mimics - a review. 2010 , 3, 367-85	47
94	Non-small cell lung carcinoma therapy using mTOR-siRNA. 2012 , 5, 119-25	8
93	Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. 2013 , 25, 90-4	12
92	Profiling serum HER-2/NEU in prostate cancer. 2013 , 17, 108-12	4
91	Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. 2010 , 30, 319-25	74
90	The effect of 5'untranslated region polymorphism in EGF gene, rs4444903, on colorectal cancer. 2013 , 6, 129-35	5
89	Potential roles of Centipede Scolopendra extracts as a strategy against EGFR-dependent cancers. 2015 , 7, 39-52	10
88	Overexpression of BRCA1 attenuates the sensitivity of PC9 cells to gefitinib. 2015 , 8, 12869-76	1
87	Antibody Therapeutics in Oncology. 2016 , 2,	9

86	Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options. 2016 , 13, 77-86		7
85	Drug resistance in lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2010 , 1, 23-36	2.9	54
84	[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650]. <i>Chinese Journal of Lung Cancer</i> , 2012 , 15, 689-93	0.6	1
83	[Effect and mechanism of gefitinib inhibition on non-small cell lung cancer radiosensitivity of HCC827 and H358 cell lines]. <i>Chinese Journal of Lung Cancer</i> , 2012 , 15, 324-31	0.6	
82	Differential Expression of RAGE, EGFR and Ki-67 in Primary Tumors and Lymph Node Deposits of Breast Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018 , 19, 2269-2277	1.7	0
81	Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	1
80	A robust and stable gene selection algorithm based on graph theory and machine learning. <i>Human Genomics</i> , 2021 , 15, 66	6.8	0
79	The Epithelial-Mesenchymal Transition Influences the Resistance of Oral Squamous Cell Carcinoma to Monoclonal Antibodies via Its Effect on Energy Homeostasis and the Tumor Microenvironment. <i>Cancers</i> , 2021 , 13,	6.6	2
78	Trastuzumab (Herceptin) in the treatment of breast cancer with HER2 overexpression. 2001 , 3, 172-182		1
77	ErbB tyrosine kinase receptor inhibitors in breast cancer treatment. 2004 , 6, 12-21		1
76	SYNTHESIS AND EVALUATION OF NOVEL CHEMICAL ENTITIES AS ANTI-BREAST CANCER AGENTS. <i>Indian Drugs</i> , 2019 , 56, 28-31	0.2	
75	Active Humoral Response Reverts Tumorigenicity through Disruption of Key Signaling Pathway.. <i>Vaccines</i> , 2022 , 10,	5.3	0
74	Paradoxical role of interleukin-33/suppressor of tumorigenicity 2 in colorectal carcinogenesis: Progress and therapeutic potential.. <i>World Journal of Clinical Cases</i> , 2022 , 10, 23-34	1.6	
73	Development of Radiohalogenated Osimertinib Derivatives as Imaging Probes for Companion Diagnostics of Osimertinib.. <i>Journal of Medicinal Chemistry</i> , 2022 ,	8.3	1
72	Analysis of Factors Affecting 5-ALA Fluorescence Intensity in Visualizing Glial Tumor Cells-Literature Review.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	2
71	Basic Principles and Recent Advances in Magnetic Cell Separation. <i>Magnetochemistry</i> , 2022 , 8, 11	3.1	3
70	Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment.. <i>Cancers</i> , 2022 , 14,	6.6	1
69	Discovery of EGFR-Targeted Environment-Sensitive fluorescent probes for cell imaging and efficient tumor detection.. <i>Bioorganic Chemistry</i> , 2022 , 121, 105585	5.1	

68	Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway.. <i>Cancer Cell International</i> , 2022 , 22, 7	6.4	0
67	Downregulation of metallothionein 2A reduces migration, invasion and proliferation activities in human squamous cell carcinoma cells.. <i>Molecular Biology Reports</i> , 2022 , 1	2.8	1
66	Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2009 , 11, 737-47	3.6	3
65	Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications. 2022 , 1-17		
64	Positive Aspects of Oxidative Stress at Different Levels of the Human Body: A Review.. <i>Antioxidants</i> , 2022 , 11,	7.1	3
63	Near-Infrared Fluorescence Tumor-Targeted Imaging in Lung Cancer: A Systematic Review.. <i>Life</i> , 2022 , 12,	3	0
62	Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation. <i>The Cochrane Library</i> , 2022 , 2022,	5.2	
61	Tumor spheroid invasion in epidermal growth factor gradients revealed by a 3D microfluidic device.. <i>Physical Biology</i> , 2022 ,	3	0
60	Medicina de precisión en cáncer colorrectal y gastroesofágico avanzado. <i>Revista Médica Clínica Las Condes</i> , 2022 , 33, 125-139	0.2	
59	O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2107453119	11.5	1
58	In silico approach to probe the binding affinity between OMVs harboring the Z affibody and the EGF receptor.. <i>Journal of Molecular Modeling</i> , 2022 , 28, 113	2	
57	Screening of Marine Compounds as an Emerging and Promising Approach against Estrogen Receptor Alpha-Positive Breast Cancer.. <i>BioMed Research International</i> , 2021 , 2021, 9734279	3	1
56	Small-Molecule Receptor Tyrosine Kinase Inhibitors in Targeted Cancer Therapy. 2005 , 531-552		
55	Table_1.DOC. 2018 ,		
54	Table_2.doc. 2018 ,		
53	Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor. 2005 , 11, 397-405		34
52	Broad reactivity and enhanced potency of recombinant anti-EGFR Anti-CD3 bispecific antibody-armed activated T cells against solid tumours. <i>Annals of Medicine</i> , 2022 , 54, 1047-1057	1.5	
51	Thietanes and derivatives thereof in medicinal chemistry.. <i>Current Topics in Medicinal Chemistry</i> , 2022 ,	3	

50	Disentangling ERBB Signaling in Breast Cancer Subtypes A Model-Based Analysis. <i>Cancers</i> , 2022 , 14, 2379	6.6	0
49	New pyrimidine-5-carbonitrile derivatives as EGFR inhibitors with anticancer and apoptotic activity: Design, molecular modeling and synthesis. <i>New Journal of Chemistry</i> ,	3.6	
48	Epidermal Growth Factor Modulates Tyrosine Phosphorylation of a Novel Tensin Family Member, Tensin3. <i>Molecular Cancer Research</i> , 2004 , 2, 225-232	6.6	43
47	Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma. <i>Frontiers in Oncology</i> , 2022 , 12,	5.3	
46	Downregulation of Thymidine Phosphorylase Expression by 17-AAG Potentiates the Cytotoxic Effect of Tamoxifen and Erlotinib in Human Squamous Cell Carcinoma Cells. <i>SSRN Electronic Journal</i>	1	
45	Biological impediments to monoclonal antibodyBased cancer immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1493-1501	6.1	40
44	Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications. 2022 , 1-17		
43	Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1,4]diazepine derivatives as potent EGFR/CDK2 inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022 , 37, 1884-1902	5.6	6
42	Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor. <i>Clinical Cancer Research</i> , 2005 , 11, 1268-1276	12.9	11
41	Epidermal growth factor receptorRelated peptide inhibits growth of PC-3 prostate cancer cells. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1615-1621	6.1	10
40	The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer. 2005 , 11, 795-805		50
39	CD109 Is a Critical Determinant of EGFR Expression and Signaling, and Tumorigenicity in Squamous Cell Carcinoma Cells. 2022 , 14, 3672		
38	Ultraviolet Radiation Exposure and its Impacts on Cutaneous Phosphorylation Signaling in Carcinogenesis: Focusing on Protein Tyrosine Phosphatases		
37	Heat shock protein 90 inhibitor 17-AAG down-regulates thymidine phosphorylase expression and potentiates the cytotoxic effect of tamoxifen and erlotinib in human lung squamous carcinoma cells. 2022 , 115207		
36	Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. 2004 , 3, 21-27		5
35	The Evolution of Antibodies into Versatile Tumor-Targeting Agents. 2005 , 11, 129-138		7
34	Control of cell metabolism by the epidermal growth factor receptor. 2022 , 1869, 119359		1
33	Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications. 2022 , 151-167		0

32	Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates. 2022 , 14, 1917	0
31	Survival of Lung Cancer Patients by Histopathology in Taiwan from 2010 to 2016: A Nationwide Study. 2022 , 11, 5503	0
30	Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways. 2022 , 27, 5889	1
29	Benzimidazole-linked pyrazolo[1,5-a]pyrimidine conjugates: synthesis and detail evaluation as potential anticancer agents.	0
28	Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. 12,	2
27	Near-infrared (NIR) fluorescence-emitting small organic molecules for cancer imaging and therapy. 2022 , 51, 8957-9008	0
26	Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies. 2022 , 14, 5160	1
25	Postoperative Prognostic Predictors of Bile Duct Cancers: Clinical Analysis and Immunoassays of Tissue Microarrays. 2022 ,	1
24	Targeted therapy and molecular genetics. 2023 , 464-488.e11	0
23	Mechanism Underlying Metformin Action and Its Potential to Reduce Gastric Cancer Risk. 2022 , 23, 14163	0
22	Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR. 2023 , 38, 239-245	1
21	Biochemical Basis of Selective Accumulation and Targeted Delivery of Photosensitizers to Tumor Tissues. 2022 , 87, 1226-1242	1
20	Immunotherapy and Targeted Therapy in the Management of Oral Cancers. 2022 ,	0
19	Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights. 2022 , 27, 8901	0
18	Lectin-based phototherapy targeting cell surface glycans for pancreatic cancer.	1
17	Synthesis of New Bioactive Indolyl-1,2,4-Triazole Hybrids As Dual Inhibitors for EGFR/PARP-1 Targeting Breast and Liver Cancer Cells. 2022 , 7, 45665-45677	0
16	Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma. 2023 , 30, 1363-1380	0
15	Synthesis, antiproliferative and enzymatic inhibition activities of quinazolines incorporating benzenesulfonamide: Cell cycle analysis and molecular modeling study. 2023 , 1278, 134928	1

- 14 New developments in targeted therapy for metastatic colorectal cancer. **2023**, 15, 175883592211485 ○
- 13 Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action. **2023**, 18, ○
- 12 Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations. **2023**, 11, 6 ○
- 11 Fluorescence molecular optomic signatures improve identification of tumors in head and neck specimens. 5, ○
- 10 Advances in NK cell therapy for brain tumors. **2023**, 7, ○
- 9 Nanomedicine in therapeutic warfront against estrogen receptor β positive breast cancer. ○
- 8 Protein kinase D1 overexpression potentiates epidermal growth factor signaling pathway in MCF-7 cells. **2023**, 50, 3641-3651 ○
- 7 A hybrid deep forest-based method for predicting synergistic drug combinations. **2023**, 3, 100411 ○
- 6 Identifying novel and potent inhibitors of EGFR protein for the drug development against the breast cancer. 1-13 ○
- 5 Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. 29, 1395-1426 ○
- 4 Correlation of fluorescence optomics method classification performance to varying expression level of epidermal growth factor receptor. **2023**, ○
- 3 Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study. **2023**, 15, 2188 ○
- 2 A new paradigm for epidermal growth factor receptor expression exists in PTC and NIFTP regulated by microRNAs. 13, ○
- 1 Vitamin D analog calcitriol for breast cancer therapy; an integrated drug discovery approach. 1-27 ○